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Abstract
Molecular recognition refers to the interaction between two or more molecules through
complementary noncovalent bonding, for example, via hydrogen bonding, electrostatic
interactions, van der Waals forces or hydrophobic forces. Molecular recognition plays
an important role in biology and mediates interactions between receptors and ligands,
antigens and antibodies, nucleic acids and proteins, proteins and proteins, enzymes and
substrates, and nucleic acids with each other.
Many cellular processes are governed by a group of proteins acting in a coordinated
manner; such complicated mechanisms are closely regulated: changes in the populations
of particular complexes or changes in concentrations of the products of protein mediated
reactions can switch cells from one state to another (from replication to apoptosis, for
example). These small variations in molecular populations are caused by very delicate
differences in the thermodynamics or kinetics of reactions. This implies that in order to
understand not only biological systems in terms of their molecular components, but also to
be able to predict and model system response to stimuli (whether it is a natural substrate
or a drug), characterisation of the thermodynamic and kinetic components of the binding
process is of paramount importance.
This combined computational-experimental project was focused on the development of
new computational approaches able to predict the enthalpic component of ligand binding,
using quantum mechanics. A concept of ‘theoceptors’ was developed, which are theoretical
receptors constructed by computing the optimal geometry of ligands binding in the receptor.
This project was supported by AstraZeneca, and it included an industrial placement in
the Structural and Biophysical Sciences area, where the experimental data was generated
to characterise the thermodynamics and kinetics of binding of a range of ligands to two
biological targets, using two experimental techniques, isothermal titration calorimetry and
surface plasmon resonance.
The findings contribute greatly to the process currently underway of expanding our
understanding of the relevance of both of these aspects of biochemistry to drug discovery.
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Part I
Theoretical background and literature
review
Chapter 1
Protein-ligand interactions
1.1 Introduction
In protein ligand complexes, complementarity of shape and chemical groups between
the binding partners is usually observed: apolar groups come together, hydrogen bond
donors match hydrogen bond acceptors and charged groups of the ligand orient so that
they are neutralised by the oppositely charged groups of the protein. However, this image
is only complete when changes in the interactions of both the binding partners with the
surrounding environment are taken into consideration. Protein-ligand binding affinities
are driven by the balance between a large number of factors, many of which cannot be
accounted for by a simple analysis of a crystal structure. In solution, both water and ions
can dramatically affect the electrostatics and change the environment found within certain
binding sites.
Several types of non-covalent bonds are critical in both maintaining the shape of
biological macromolecules and enabling one molecule to bind specifically but transiently
to another (Figure 1.1). Although the energy released in formation of non-covalent
interactions is low, when acting together, they lead to stable association between either
different parts of a large molecule, or two different binding partners. Formulating the
rules for molecular interactions is only possible within certain boundaries. Molecular
interactions are non-additive and the same apparent interaction might result different
amounts of observed energy in different contexts [1].
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Fig. 1.1 Noncovalent interactions.
1.2 Non-covalent interactions
1.2.1 Hydrogen bonds
Hydrogen bonds are attractive interactions between a hydrogen atom from a molecule or a
fragment X-H, where X is more electronegative than H, and another electronegative atom
or a group of atoms, such as nitrogen or oxygen.
An important feature of hydrogen bonds is directionality: these interactions are the
strongest when the angle X-H····Y is closest to 180°. Contribution of hydrogen bonds to an
overall affinity is context dependent and may vary substantially in different environments.
The spectrum of hydrogen bond strengths extends from 0.2-4 kcal/mol for weak bonds to
4-15 kcal/mol for moderate bonds and 15-40 kcal/mol for strong bonds [2]. In the protein
apo state, almost all of its medium strength donor or acceptor groups will make hydrogen
bonds with either other parts of the protein or the surrounding solvent. For a hydrogen
bond to form, the desolvation of both the donor and acceptor has to occur. Because the
effects of hydration and bond formation cancel out, these interactions do not necessarily
add much binding free energy [3]. There is some evidence that energetic consequences
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for not satisfying the hydrogen bond donor have more drastic effects than not satisfying
the acceptor: the penalty for burying a donor in a desolvated state has been reported to
be 4.3-5.3 kcal/mol for a hydroxyl group binding in a hydrophobic pocket [4]. Therefore,
directionality and the energetic penalty for not forming hydrogen bonds makes hydrogen
bonds a large source of specificity in biomolecular recognition.
An example of where an addition of hydrogen bonding moiety caused a dramatic
effect on potency (so called ‘activity cliff’) are the two cyclin-dependent kinase 2 (CDK2)
inhibitors in Figure 1.2. These two molecules are only distinguished by charged hydrogen
bond interaction between a sulfonamide group in one of the purine- based inhibitors and
residue Asp86 of the enzyme, causing a 166-fold potency increase [5].
Fig. 1.2 Affinity data for two CDK2 purine-based inhibitors (PDB codes are 1H1Q and
1H1S).
1.2.2 Electrostatic interactions
Electrostatic interactions are attractive forces between opposite charges and can be ap-
proximately classified into three types: charge-charge, charge-dipole and dipole-dipole.
Typical charge-charge (Coulombic) interactions are those between oppositely charged
atoms, such as ligand functional groups and positively or negatively charged amino acid
side chains. A dipole-induced dipole interaction is caused when a molecule with a perma-
nent dipole approaches another molecule, causing it to become temporarily polarised. The
two molecules are then attracted to interact with each other (Debye force); this is known
as induction. Dipole-dipole interactions (Keesom forces) are electrostatic interactions
between permanent dipoles in molecules.
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1.2.3 Van der Waals interactions
A collective term to describe the non-Coulombic interactions is van der Waals interactions.
These interactions have two components. Attractive force (London dispersion) is an
interaction between two induced dipoles that dominates at longer distances, typically at
0.4-0.7 nm. Repulsive interaction, on the other hand, occurs at shorter distances as a result
of the Pauli exclusion principle that prevents the collapse of the molecules (Figure 1.3).
Van der Waals interactions are very weak, but because a large number of such interactions
occur during the binding event, they contribute to the free energy significantly.
Fig. 1.3 Interatomic distances. Van der Waals attraction occurs at short range, and rapidly
reduces as the interacting atoms move apart by a few Angstroms. Repulsion occurs when
the distance between interacting atoms becomes even slightly less than the sum of their
contact radii. These effects are often modeled using a 6-12 equation, as shown in the figure.
r is the distance of separation between both particles, A is 4εσ6, B is εσ12, ε is the a
measure of how strongly the two particles attract each other and σ is van der Waals radius.
1.2.4 Hydrophobic interactions and structural water
Hydrophobic interactions refer to the association or folding of non-polar molecules in
aqueous solution. Interactions between ligands and hydrophobic amino acid side chains
contribute significantly to the binding free energy. Hydrophobic interactions quantified
by the amount of hydrophobic surface buried upon ligand binding have been shown to
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correlate well with the binding free energy [6, 7]. However, a lot of this affinity is gained
because of the sub-optimal solvation of the binding site in the apo state. The strength of
hydrophobic interactions is not caused by an attractive direct force between non-polar
molecules. Rather, it results from the system achieving greatest thermodynamic stability
by minimising the number of ordered water molecules required to surround hydrophobic
portions of the solute molecules. This is the concept of the classical hydrophobic effect
(Figure 1.4). The classical hydrophobic effect may be overestimated as hydrogen bonds at
hydrophobic surfaces are weaker [8] and water molecules retain a significant amount of
residual mobility [9].
Fig. 1.4 Classic hydrophobic effect. While separate, both protein and ligand force neigh-
bouring water molecules into an ordered shell. Binding of ligand to a protein releases
some of the ordered water, and water then forms one larger "cage" structure around the
complex. This maximises the amount of free water and causes an increase in entropy. If
this mechanism was the only force driving the formation of the complex, all binding events
involving hydrophobic ligands would be entropy-driven.
Therefore, it appears that there is no single hydrophobic effect. There is a fine balance
between enthalpic and entropic contributions arising from the interactions with the solvent.
These effects have different structural and thermodynamic origins in different molecular
contexts, and can be classified as non classical hydrophobic effects [10].
An illustrative example where large gains in binding free energy were achieved when
a lipophilic pocket was optimally occupied by nonpolar ligand atoms is optimisiation
of the interactions in the S1 pocket of serine protease DPP-IV [11]. In this example, a
400-fold increase in binding affinity was achieved by substituting a meta-phenyl hydrogen
atom with a -CH2F group. The -CH2F group forms five short hydrophobic contacts with
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the residues in the S1 pocket. This subsituent had a 9-fold higher interaction strength
compared to the methyl substituent, which can be explained by the slightly larger volume
of the -CH2F group that enables a tighter fit and better shape complementarity (Figure 1.5).
Fig. 1.5 Human DDP-IV with an aminobenzoquinolizone inhibitor (PDB code 3KWJ).
Affinity data for the three related inhibitors.
Every ligand binding event displaces water molecules from the binding site. Most of
these water molecules are highly disordered and are rarely crystallographically observed.
Those that are observed need to be assessed as to whether they can be replaced or whether
they are structural and therefore should be considered a part of the complex. Displacement
of water molecules from the binding site may affect the resulting thermodynamic signature
in a dramatic way. However, the direction of the influence cannot be predicted by simple
rules because it is heavily dependent on the context: some proteins become more rigid
[12], while others become more dynamic upon water binding [13] and displaced water
molecules do not necessarily result in favourable entropy, particularly if they were less
ordered in the bound state than they are in the bulk solvent.
In the design of inhibitors of Scytalone Dehydratase, a key target against the pathogenic
fungus, Magnaporthe grisea, the causative agent of blast disease in rice crops, the inhibitory
potency was increased by synthesising compounds where a nitrile moiety was directed into
the space occupied by one of the crystallographic water molecules. Replacement of the
nitrile with a hydrogen atom lowered binding affinity 18000-fold (Figure 1.6) [14]. Nitrile
functionality displaces the water molecule while maintaining the hydrogen bond with the
nearby Tyr50 residue.
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Fig. 1.6 An overlay of the two crystal structures of Scytalone Dehydratase inhibitors, 1STD
and 3STD. Replacement of the nitrile with a hydrogen atom decreases binding affinity.
1.2.5 Interactions involving π systems
Aromatic rings can interact by a combination of electrostatic and dispersive interactions
[15]. Interactions between the ligands and aromatic protein sidechains (Phe, Trp and Tyr)
are very common in protein-ligand complexes. These interactions are strongly orientation
dependent, and two arrangements are favoured: one where two rings are parallel to each
other, and a perpendicular (T-shaped) arrangement. Quantum mechanical calculations of
the dimerisation energy of benzene predict these two arrangements to be isoenergetic (De
= -2.5 kcal/mol) [16], which is in good agreement with the experimental results (De=-1.6
to -2.4 kcal/mol) [17, 18]. An introduction of heteroatoms into the aromatic rings, as well
as adding functional substituents affects the alignment of positive and negative charges,
modulating π interactions [19]. Aromatic interactions are not limited only to π−π systems:
cation-π interactions have been extensively studied in protein structures [20] and it has
been shown that these are rarely buried, contributing -0.8 to -0.5 kcal/mol to the overall
binding free energy. This energy drops significantly with increased solvent exposure [21].
With the exception of cation-π interactions, energetic contribution interactions involving π
systems make to the overall binding energy is low, but they are important in orientating
and positioning the ligand within the binding site.
An interesting example is the S4 binding pocket of serine protease factor Xa, comprised
of Tyr, Phe and Trp residues. Introducing a carbonyl group causes a polarisation of the
ring CH2 on top of Trp, increasing the CH2-π interaction and causing a planarization of
the morpholinone ring, bringing it into a perpendicular arrangement to the aryl ring. This
effect is reflected by the 60-fold increase in potency (Figure 1.7) [22].
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Fig. 1.7 Structures of Xa inhibitors. Introducing a carbonyl group causes a polarisation of
the ring CH2 on top of Trp (PDB code 2W26).
1.2.6 Halogen bonds
The concept of halogen bonds is similar to hydrogen bonds. Both interactions involve
a relationship between an electron donor and electron acceptor. In a halogen bond, the
halogen atom acts as a donor. Although widely present in protein-ligand complexes, the
importance of these interactions in molecular recognition has not been recognised for a
long time. This is because halogens were predominantly seen as hydrophobic moieties
used to fill apolar protein cavities [23, 24]. The nature of halogens allows for a patch of
negative charge to be formed around the central region of the halogen-carbon bond, leaving
the outer region positively charged. This partial positive charge is known as the σ -hole
[25, 26]. Halogens involved in bond formation are Cl, Br, and I, with the strength of the
interaction increasing with the size of halogen electron donor. This type of interaction is
mostly electrostatic in nature, and the strength is affected by the electronegativity of the
binding partner [27]. Fluorine’s small size and extremely high electronegativity prevents
it from forming halogen bonds. Instead, it forms the so called ’fluorine bonds’ [28]. In
general, halogen bonds are fairly weak interactions, but they are specific and can lead to
clear gains in binding affinity [3].
A case study of PDE5 and its inhibitors compared the corresponding H, F, Cl, Br and
I analogues binding to the catalytic domain of PDE5 [29]. Comparison of the activities
shows iodo being the most potent and fluoro the least active, actually worse than hydrogen
(Figure 1.8). ITC studies reveal that binding strength of the halogen bonding between
chlorine, bromine, and iodine of inhibitor and the protein is -1.57, -3.09, and -5.59 kJ/mol,
respectively.
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Fig. 1.8 Structures of five inhibitors and their complexes with the catalytic domain of
PDE5. Chemical structures of the five inhibitors. PDB codes are 4OEX, 3SHY, 3SHZ,
3SIE, 4OEW.)
1.3 Protein-ligand structure determination
The two most commonly used methods for obtaining structural information on protein-
ligand complexes are x-ray crystallography and NMR-spectroscopy. Currently, x-ray
crystallography is a superior approach when it comes to providing a detailed picture of
the complex at the atomic level. However, the two approaches should be considered as
complementary, where the limitations of one technique can be overcome by use of the
other.
1.3.1 Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR spectroscopy can provide detailed information about protein-ligand interactions,
inaccessible to other techniques. It can be used to study different aspects of biomolecular
recognition, such as screening libraries of small molecules, determining 3D structure of the
complex, or to determine thermodynamic and kinetic parameters [30]. NMR detects ligand
binding through changes in the resonant frequencies called chemical shifts. These changes
are highly sensitive to the atom environment, making it possible to determine where the
ligand binds and which parts of the molecule are contributing to the binding. The advantage
NMR has over other methods is that it quickly delivers information about the binding
event, even when the structure of the receptor can not be determined at high resolution [31].
Unlike x-ray crystallography, it allows protein structures to be determined in conditions that
are very close to the physiological state (i.e. in solution). The main disadvantages of NMR
are that the sample preparation can be much more expensive and that data interpretation is
much more complex and time-consuming than x-ray crystallography.
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1.3.2 Protein-ligand crystal structures
The primary source of structural information for protein-ligand complexes is x-ray crystal-
lography, which captures static snapshots of (sometimes highly) dynamic complexes. Once
protein crystals have been obtained, x-ray diffraction measurements can be carried out.
This is done either by using in-house equipment or at a synchrotron radiation source. The
three-dimensional structure is initially obtained in the form of an experimental electron
density map. The map is then interpreted, resulting in an atomic model for the protein
structure. Once an atomic model is known, crystal structures of the protein of interest with
ligand bound can be prepared and analyzed in a straightforward fashion [32, 33].
X-ray structures are an irreplaceable tool not only in biochemistry, chemistry and
related disciplines, but also in computer based methods where they are largely used as
starting points on which simple or more complicated calculations are applied. When these
structures are used for compound design, a number of assumptions have to be made: 1) the
protein structure is correct and known with high accuracy, 2) the experimental conditions
under which the crystal was obtained are relevant to the binding event, 3) the ligand
structure is accurate and that interactions between the binding partners are correct and
well understood [34]. What is often forgotten is that an x-ray structure is a subjective
interpretation of an observed electron density map, and as such involves assumptions and
sometimes even mistakes [35]. Users who misunderstand this can be misled, especially
when studying highly mobile regions of the structure, such as active sites and ligands
[36]. Validation of protein structures is relatively straightforward, but small molecules
have almost unlimited conformational freedom and chemical variability which are difficult
to parameterize, and can be particular to each ligand. This becomes problematic when
the structure of the protein is secondary and the real interest is in the ligand. Problems
can include: erroneous ligand structures (missing atoms, connectivity issues and incorrect
bond orders), geometric constraints (incorrect bond orders and angles), steric clashes
between protein and the ligand, conformational errors (cis- or twisted amides, distorted
rings, non-planar aromatic groups, etc.), incorrect orientations relative to the binding site,
and problems with assigning protonation states and charges [37]. Resolution is a global
indicator of quality, but it does not provide any information about the local quality of the
protein-ligand model. Another common metric used to measure the overall quality of a
model is the R-value, a linear residual measuring the difference between the observed
and calculated diffraction data. These two metrics are coupled: a low resolution structure
will have higher residuals than a similar well-defined, higher resolution structure [38].
This implies that to assess which parts of the model are strongly supported by the data
and which are not, relying exclusively on statistical parameters is not enough. To avoid
basing experiments on wrong structural data, users should examine electron density maps
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in regions of functional interest. One of the most common metrics for assessing the fit
of a model to the local density is the real space-correlation coefficient (RSCC). It ranges
from 0 (‘bad’, electron density is effectively missing) to 1 (‘good’, model fits the density
perfectly) [39].
1.3.2.1 Ligand strain
Potent inhibitors are expected to bind in a relatively low energy conformation [40]. An
important question regarding biomolecular recognition is what is the energy price paid by
the ligand to adopt this bioactive conformation? The simplest approach to answering this
question would be to estimate strain energies using molecular mechanics (MM) via force
fields and then calculate the energy difference between the bioactive conformation (the
one present in the protein-bound state) and the global energy minimum of the unbound,
free ligand. This approach makes an assumption that the crystallographically observed
ligand conformation is correct and accurately represented. X-ray derived conformations
can be a valid approximation of the bioactive ones, however, what is often overlooked
(albeit unintentionally) is that protein-ligand crystal models are interpretations that are
several steps removed from the experimental measurements, and as such have lot of
uncertainties (the most simple ones regarding bond lengths and angles) introduced during
the refinement process, usually dependent on the force field used. The energy of the lowest
energy structure (global minimum) can never be verified with absolute accuracy, however,
a well-chosen one allows a lower boundary to be placed on the strain energy, because
any lower energy structure must increase it. A study by Perola et al. [40] suggested
that approximately 60% of the ligands in a set of 150 medicinally relevant complexes
bind with strain energies lower than 5 kcal/mol, while 10% of the strain energies were
above 9 kcal/mol. A more recent quantum mechanical (QM) study [41] on more than
1200 structures reports this range to be from 0-25 kcal/mol. Several QM/MM [42], and
QM [43] methods describing and quantifying ligand strain provide additional evidence
about this ubiquitous problem. It has also been pointed out that current force fields do not
assess the relative energies of different sized molecules evenly [44]. Different force fields
used during structure refinement have different optimal values for bond lengths, which
may result in artificially large strain energies. An estimated 25% of recently determined
protein-inhibitor complexes have errors that could be removed during crystallographic
refinement. These errors are large enough to potentially lead to a wrong interpretation of
the binding interactions [45].
Chapter 2
Thermodynamics of drug binding
2.1 Introduction
Understanding the nature of molecular recognition phenomena requires a detailed descrip-
tion of the forces that drive formation of complexes. Since biomolecular recognition is
governed by thermodynamics, a quantitative description of the forces that govern molecular
associations requires determination of changes of all thermodynamic parameters. Correlat-
ing these parameters with the structures of the interacting partners is of great interest to
medicinal chemistry since it contributes significantly to structure-based molecular design
strategies [7]. Improvements in instrumentation capable of full thermodynamic profiling
such as ITC (isothermal titration calorimetry), a technique which has become cheaper and
more widely applied in the last decade, have enabled the use of individual thermodynamic
binding terms. These provide a useful guide for compound optimisation because they help
pinpoint the forces that need optimisation [46].
2.2 Theoretical background
If we consider a simple, reversible binding event
P+L⇄ PL
where P is a protein and L a small molecule (ligand), then the change in Gibbs free
energy (∆G) under arbitrary conditions, for PL complex formation is related to standard
Gibbs free energy change (∆G◦), under standard conditions (for example, 1M of P, 1M
of L at pH 7 and 25 C◦ ) by the following equation which is based on the second law of
thermodynamics:
∆G = ∆G◦+RT ln
[PL]
[P][L]
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At equilibrium and under standard conditions where ∆G=0, this equation becomes
∆G◦ =−RT ln [PL]
[P][L]
=−RT lnKa = RT lnKd
where R is the gas constant, T is the absolute temperature, Ka is the equilibrium
association constant and Kd is the equilibrium dissociation constant. It is more appropriate
to write Kd/Cref than Kd. Cref is a standard or reference concentration expressed in the
same units as Kd. Therefore, ∆G◦ depends on the reference concentration. A common
value used is 1 molL-1. From now on, Cref is implicit, unless otherwise stated.
Strength of the interactions between the protein and the ligand is usually represented
by Kd, Ka or Ki (inhibition constant, the concentration required to produce half maxi-
mum inhibition). These values are often referred to interchangeably. Sometimes the IC50
(half-maximal inhibitory concentration) value is used instead of the binding constant. This
value is defined as the concentration of the ligand required to produce 50% inhibition of
protein activity. Unlike Ki, IC50 values depend on the concentrations of the enzyme and
the substrate used in the enzymatic reaction. In principle, IC50 values can be transformed
into binding constants using the Cheng–Prusoff equation [47]. As shown above, at equi-
librium and under constant pressure and standard conditions, the binding constant can be
transformed into Gibbs free energy of binding, ∆G. ∆G is a sum of two energetic terms:
the change of enthalpy ∆H and the change of entropy ∆S such that:
∆G = ∆H−T∆S
where T is the absolute temperature. In principle, many combinations of ∆H and
∆S can give rise to the same ∆G value and, therefore, to the same binding affinity to a
given target. However, compounds with equal affinities but optimised enthalpically or
entropically are not equivalent because the interactions that give rise to favourable binding
enthalpies or entropies are different [48].
In a simplified view, the enthalpic contribution to the free energy of binding is related
to the specificity and strength of the interactions formed between the protein and the ligand.
The entropic contribution to the free energy reflects the dynamics of the whole system. A
favourable enthalpic term is obtained through good geometric complementarity between
the binding partners. Interactions like hydrogen bonds are stereo specific which implies
that favourable enthalpy change is contributing not only to affinity but also to selectivity
[49]. Two major terms define entropic contribution: a favourable, but non specific force
that is associated with the burial of hydrophobic groups and usually an unfavourable
conformational entropy term that reflects the loss of conformational degrees of freedom in
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both drug-like molecule and protein. Both the enthalpy and entropy change are dependent
on the heat capacity change (∆Cp):
∆H =
∫ T2
T1
∆CpdT
∆S =
∫ T2
T1
∆Cp
T
dT
A negative value for ∆Cp indicates that the complex has a lower heat capacity. A
favourable entropic component is often associated with the release of water molecules
from a binding interface, and coupled with a decrease in ∆Cp, it can be used as an indicator
of hydrophobic interactions [50, 51].
To achieve high binding affinity (that is, low dissociation constant Kd) both enthalpy
and entropy have to contribute constructively. Although simultaneous optimisation of both
enthalpy and entropy is desired, in practice this is notoriously difficult to achieve. Even if
enthalpic optimisation is achieved, it is often compensated by restriction of mobility of the
interacting molecules, which manifests as entropy loss. This phenomenon is referred to as
enthalpy-entropy compensation [52].
2.3 Enthalpic considerations
The enthalpic term is a measure of a net change in the number and strength of the protein-
ligand interactions on going from the apo to bound state. Therefore, increasing an enthalpic
contribution to ∆G seems a sensible strategy for improving affinity and selectivity during
the ligand optimisation process. However, when comparing the thermodynamic signatures
of the compounds synthesised in medicinal chemistry programs to thermodynamic signa-
tures of the biological ligands, it can be noted that the former have on average a greater
favourable entropic component [53]. This is because introducing lipophilic interactions
that lack directionality is much easier than controlling the geometries of individual polar
groups. Furthermore, attempting to ‘build-in’ enthalpy by introducing additional polar
groups is extremely challenging to achieve, as the breakage of the interactions that water
makes causes an energetic penalty that might be hard to overcome. There is also a penalty
for desolvating polar groups that is often not compensated by enthalpically favourable
bond formation. Even when all these obstacles are overcome, structuring of protein regions
induced by newly formed interactions can lead to loss in conformational entropy, resulting
in no affinity gains. Although this suggests that a focus on good enthalpic starting points
is justified, the examples in the medicinal chemistry literature where the progress from
first-in-class to the best-in-class is achieved by improving the enthalpic contribution are
anecdotal rather than factual. Even though the thermodynamic profiles of HIV protease,
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and HMG-CoA reductase inhibitors show the improvement in the enthalpic contribution
from first-in-class (Fluvastatin; Indinavir) to best-in-class (Rosuvastatin; Darunavir) (Fig-
ure 2.1), this is no different to detecting a biased coin: flipping a coin 5 times is not enough
to enable us to detect bias at 95% confidence level; a coin needs to land the same way
at least 8 times out of 9 before we can confidently declare bias (this is further discussed
in Section 3). In other words, it is not clear if such entropically or enthalpically driven
thermodynamic profiles can be rationally designed.
Fig. 2.1 Enthalpic optimisation towards best-in-class compound: thermodynamic profile of
HMG-CoA reductase inhibitors; thermodynamic profile of HIV protease inhibitors [54].
2.4 Measuring binding thermodynamics
2.4.1 Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) is a technique capable of directly measuring enthalpy
change upon binding. In most ITC instruments, a reference cell is filled with buffer, and a
sample cell is filled with the protein into which the ligand is titrated (Figure 2.2). Each
injection of the ligand causes heat change that arises from four sources: binding interaction,
dilution of both ligand and the macromolecule and a heat effect caused by mixing. The
extent of binding is determined by directly measuring heat exchange, whether the heat is
being generated or absorbed upon binding: the temperature difference between reference
and sample cell is detected by the instrument, triggering a change in the feedback power
applied to the sample cell. The heat change is calculated by integrating the heater power
over time of the measurement and parameter values (stoichiometry n, Ka and ∆H) estimated
by non-linear regression analysis, enabling determination of Kb, ∆G and ∆S [46].
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Fig. 2.2 Basic configuration of an ITC instrument. Raw data measured in a typical ITC
experiment.
An adequate model has to be applied to fit the titration curve and the results extracted
from the ITC experiments should be interpreted carefully. There are four most common
models used for fitting ITC data [55, 56]:
• Ligand binding to one molecule with n identical and independent sites
This is the simplest binding model. It assumes a single independent binding site and
a formation of a 1:1 ligand/macromolecule complex. The best fit will generate n, K
and ∆H.
• Ligand binding to one macromolecule with m different and independent classes of
sites
This model makes the assumption that there are two binding events that occur with
independent thermodynamics and the statistical saturation of each site is dictated by
the magnitude of the individual K values. In this case, the best fit will generate n, K
and ∆H for each site.
• Ligand binding by the displacement of another ligand in the single binding site of a
macromolecule (competitive binding)
Competitive binding experiments are carried out when for example solubility is
an issue, or binding affinities exceede the detection limit of the ITC instrument.
Competitive binding studies are carried out using the strong-binding ligand A as the
injectant, with the solution in the cell containing the second competitive ligand B as
well as the binding protein (or other target molecule). In order to do curve-fitting
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on results from a competitive binding experiment, a non-competitive experiment
must first be carried out in the conventional way to determine the binding parameters
for ligand B (nB, KB and ∆HB) itself. These three parameters are used as input
which then allows nA, KA and ∆HA to be determined from results of the competitive
experiment.
• Ligand binding to a macromolecule with two dependent (cooperative) binding sites
Model assumes that the binding of one ligand influences the binding of the second.
Association constants will differ by a cooperativity constant α .
By performing the titration experiment at a range of different temperatures, ∆Cp can
be determined [57]:
∆Cp =
∆HT2 −∆HT1
T2−T1
Each of these parameters reflects the characteristics of the complex minus that of free
partners. In other words, negative ∆G◦ indicates that the complex is in a lower free energy
state than it is in the sum of the free binding partners, therefore binding is favoured.
2.4.1.1 Protonation effect
All interactions between the ligand and the macromolecule occur in a solvent or buffer
environment and include rearrangement of bonds between the interacting partners as well
as surrounding solvent molecules. A common interaction that takes place in such an
environment is proton transfer between the complex and the bulk solvent. Therefore, calori-
metric experiments result in enthalpies composed of two contributors: reaction enthalpies
and enthalpies of ionisation of buffer. Protein-ligand interactions can be expressed as:
P+L+nH+⇄ PL(nH+;∆H)
where n represents the number of protons taken up during the process of complex formation.
If the reaction is conducted in a buffer solution, the protons to be taken up are released
from the buffer:
BH+⇄ B+H+;∆Hi)
thus, in an actual calorimetric measurements the observed enthalpy change is given as:
∆Hobs = ∆H +n∆Hi
This means that to correctly determine the net enthalpy change ∆H, a contribution from the
buffer side on the observed heat effects has to be subtracted from the observed enthalpy
change. To calculate the appropriate correction it is necessary to perform a calorimetric
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Fig. 2.3 ∆Hobs vs ∆Hi:variation of observed binding enthalpy with various buffers
measurement with at least two buffers of different ∆Hi at the same pH. The ∆Hobs is then
plotted against the ∆Hi, enabling the determination of n and ∆H (the slope and the intercept
respectively), the actual binding enthalpy (Figure 2.3) [58, 59].
If protonation changes occur uniformly across the congeneric ligand series, or the
protonation state is relatively distant to the site where ligands are modified, relative
differences between the thermodynamic signatures can still be interpreted conclusively.
For example, compensating effects arising from deprotonation of His and protonation of the
primary amino function of the ligand were observed in the ITC study of a congeneric series
of thrombin inhibitors, so similar behaviour for the analogous inhibitors was assumed [60].
ITC experimental setup, interpretation of thermodynamic signatures, and the assess-
ment of the protonation effect will be discussed in chapters 7 and 8.
2.4.2 Estimation of thermodynamic parameters from changes in pro-
tein stability
Binding of a ligand to a protein occurs only if it represents an energetically favourable
process, that is, if it leads to the release of free energy. Therefore, the protein-ligand
complex has to be more stable than the free partners, with the extent of stabilisation
dependent on the magnitude of the binding energy. Therefore, it is possible to estimate the
free energy of binding by comparing the differences in stability of the complex and free
partners.
The simplest model of protein denaturation is:
P
k2−−⇀↽−
k−2
U
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where P is folded protein in apo form, U is the unfolded protein, k2 and k-2 are the
rate constants for folding and unfolding. The Gibbs free energy change for the reversible
unfolding without the presence of the intermediates is then given by
∆GU−P = GU −GP
.
In the presence of the ligand, the unfolding scheme becomes:
P′L′
k−1−−⇀↽−
k1
P+L
k2−−⇀↽−
k−2
U
and the observed Gibbs free energy change is now
∆Gobs = ∆GU−P−∆G,
from which it is then easy to determine ∆G.
Thermodynamic characterisation of protein stability is usually performed by thermal
denaturation. Differential Scanning Calorimetry (DSC) [61] is the method in which the
heat capacity of the system is monitored as function of temperature. This method can
be used to determine the melting temperature, Tm, change in heat capacity, ∆Cp, and the
enthalpy of unfolding, ∆H. In an equilibrium state, the change in these parameters can be
used to estimate binding affinity.
2.4.3 Indirect thermodynamic measurements
ITC measures enthalpy change upon binding directly. When performing this measurement
is not possible or practical (solubility issues, reagents or instrument availability, etc.), this
parameter can be accessed indirectly, by determining van’t Hoff enthalpy ( ∆HvH) through
the temperature dependence of Kd as defined by the van’t Hoff relationship
ln
Kdre f
Kd
=
∆HvHre f −Tre f∆Cp
R
(
1
Tre f
− 1
T
)+
∆Cp
R
ln
T
Tre f
where Kd is the dissociation constant and ref refers to any arbitrary reference temper-
ature. The potential problem with this approach is the inclusion of the ∆Cp term which
allows for the temperature dependence of ∆H. This term is often difficult to estimate in the
absence of calorimetric data. Values of ∆Cp and ∆H are correlated and the magnitude of
the changes in ∆G with temperature are usually relatively small, leading to discrepancies
between calorimetric and van’t Hoff enthalpies [46].
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2.5 Ligand efficiency metrics-LEMs
For any small molecule to be considered a likely drug candidate, it must satisfy a number
of different properties such as size, lipophilicity, shape, number of hydrogen bond donors
or acceptors, polarity, toxicological profile etc [62, 63]. It has been observed that these
properties for orally bioavailable drug candidates occupy a relatively narrow range known
as ’drug-like’ space [64]. Ligand efficiency metrics are used to quantify the link between
physicochemical properties and potency. They account for the contribution of a risk factor
such as molecular weight or lipophilicity to activity [65, 66]. The rationale is that this
would allow for a more relevant comparison of compounds than would be possible just by
using affinity or potency measures [67]. LEMs are typically defined by scaling or offsetting
measured activity by the value of the physicochemical property that is considered to be a
risk factor. For example, it is assumed that an increased lipophilicity or molecular size can
lead to poor physical properties and compound promiscuity. Affinity scaled by molecular
size gives Ligand Efficiency (LE), a metric that aims to compare molecules according to
their average binding energy per atom [68]: LE = ∆G◦/HA where ∆G◦ is standard Gibbs
energy and HA number of heavy atoms. Offsetting potency or affinity by lipophilicity
gives Ligand Lipophilic Efficiency (LLE) [69]. LLE quantifies the moving of a compound
from octanol to its binding site: LLE = pIC50− (c)logP. In other words, it describes the
contribution of lipophilicity to potency.
LEMs are widely accepted and used by the drug discovery community, often ignoring
underlying assumptions [70–72]. Both scaling and offsetting assume that the relationship
between the activity or potency and the physicochemical property is linear. In the case of
offsetting, it is assumed that the relevant line has a unit slope, whereas scaling implies that
the relevant line passes through the origin, which suggests that affinity or potency values
in all assays are zero for ligands with zero atoms. It is important to remember that values
of zero for ∆G◦ or IC50 do not indicate an absence of interactions between protein and the
ligand [73]. A zero value simply is a statement that affinity or potency is equal to standard
or reference concentration:
∆G◦ = RT ln(
Kd
C◦
)
pIC50 =−log(IC50M )
In both of these expressions Kd and pIC50 have been divided by a concentration
because the log function is defined only for dimensionless units. Therefore, it is important
to remember that molarity is built into both of these definitions and that the choice of 1 M
as a reference concentration is arbitrary and historical in nature. Consequences of this are
best illustrated using the example given in table 2.1:
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Table 2.1 Effect of standard concentration on ligand efficiency
NHA Kd/M C◦/M LE
10 10-3 1 0.40
20 10-6 1 0.40
30 10-9 1 0.40
10 10-3 0.1 0.27
20 10-6 0.1 0.33
30 10-9 0.1 0.36
10 10-3 10 0.54
20 10-6 10 0.47
30 10-9 10 0.45
This example shows how the perception of efficiency changes when the concentration
unit with which affinity or potency is specified varies. When a reference concentration of
1 M is used, the three compounds are all equally ligand efficient. If standard C is 0.1 M,
the compounds appear to become more ligand efficient as molecular size increases but the
opposite behaviour is observed when standard C is 10 M.
Even though LLE is invariant with the choice of reference state (unlike standard
concentration, reference concentration has no thermodynamic significance), the unit slope
is arbitrary in the same way. It is valid to question whether slope=1 is a better metric
than slope=0.7, for example. There is no reason that normalisation of activity should be
restricted to any of these functional forms. Rather than imposing constraints to make
assumptions about the trends in the data, the relevant line should be fit to establish the
actual trend. This way, LEM can be thought of as an attempt to quantify the extent to
which compounds beat (or are beaten by) the actual trend in the activity data, or, in other
words, which compounds have higher (or lower) activity than it would be expected given
the physicochemical property. Residuals give the difference between observed value and
value predicted by the model and do not change with the choice of concentration units and
are independent of molecular size.
The driving forces in ligand binding and the relation to LLE will be further explored in
chapter 5, where it will be explained how and why this property can be used in computa-
tional modelling.
Chapter 3
Kinetics of drug binding
3.1 Introduction
At the beginning of the twentieth century, Paul Ehrlich coined a phrase that soon became
a postulate of modern pharmacology and molecular medicine: corpora non agunt nisi
fixate (“a substance will not work unless it is bound”) [74]. In other words, a drug is
efficacious as long it remains bound and modulates the activity of its receptor. Target
affinity is considered to be a proxy for an in vivo efficacy, focusing much of an early stage
drug discovery efforts on optimising the selectivity and affinity of the binary complex.
Fighting disease or its symptoms using drugs can be described as a continuous kinetic
process, easily divided into two parts: pharmacokinetics (PK) which determines how the
concentration of drug changes over time (sometimes described as what the body does to
the drug) and pharmacodynamics (PD), a term that describes what the drug does to the
body [75].
Binding kinetics (BK) represent how quickly a drug-target complex forms (described
by a rate constant of ligand association-kon) and dissociates (described by a rate constant
of ligand dissociation-ko f f ). The affinity of interaction is represented by the equilibrium
dissociation constant Kd, a value that is dependent on both rate constants, according to the
equation:
Kd =
ko f f
kon
The steps that determine how quickly the complex will form, like diffusion or desolva-
tion, are difficult to affect, making optimisation of the association rate a difficult task. The
rate at which the protein-ligand complex forms also depends on the concentration of the
ligand. On the other hand, the dissociation rate constant is not affected by pharmacological
factors or ligand concentration and is only dependent on the specific interactions between
the binding partners. From this equation it can easily be seen that different combinations
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of ko f f and kon can result in the same affinity. In most situations, the duration of biological
effect induced by formation of the drug-target complex is related to the lifetime of the
complex: the longer the ligand is bound to its receptor, the longer the biological effect lasts
[76]. Given a comparable Kd, a ligand’s efficacy (ability to produce biological response
upon binding) is determined by ko f f , a constant that is concentration-independent, but
is dependent on specific interactions between ligand and protein. This implies that it
is the lifetime of the receptor-ligand complex that determines the effect in the cellular
context; when the residence time (reciprocal of the dissociation rate constant; 1/ko f f ) of
the complex is long, a significant level of receptor occupancy can be preserved even when
the concentration of the ligand in the system is reduced. A good real life example is given
by Copeland et al. [77]; they compare residence time to ones residence time at a hotel.
The price for a hotel stay is not influenced by how long it takes for the guest to arrive at
the hotel but by the time between check in (analogous to the bound state) and check out
(analogous to dissociation).
3.2 General binding mechanisms
There are three general binding mechanism that can lead to long residence times. The
simplest mechanism is a formation of PL binary complex
in which k1 is equivalent to kon and k2 is equivalent to ko f f . In the second mechanism,
the protein exists in an ensemble of conformations, some of which are capable of binding
the ligand. Presence of the ligand will shift the equilibrium between the conformations,
favouring the formation of the conformation capable of binding the ligand:
In this model, the rate-limiting step is the interconversion of the two forms of the
protein, P and P*. Once the P* forms, the ligand binds rapidly. k1 represents the rate
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constant of this interconversion and k2 is the constant for the reverse process. As only the
P* conformation can bind the ligand, Kd* is defined as the ratio of k4 and k3.
In the third mechanism, the protein exists in a single conformational state with subopti-
mal complementarity to the ligand, but is still capable of ligand binding. Upon the initial
encounter with the ligand, the protein undergoes a conformational readjustment:
In this model, the rate limiting step is the slow isomerisation from the PL state to P*L.
The binding affinity in this model reflects the affinity of the final P*L state and is defined
as Kd*=Kd/(1+(k3/k4)).
3.3 Long or short residence time
General binding mechanisms can sometimes be hard to distinguish experimentally. Most
drug-like molecules bind to their targets through the induced-fit mechanism (third model)
[78]. Regardless of what the association pathway is, the definition of residence time is the
same:
τ =
1
ko f f
The time it takes for 50% of the protein-ligand complex to decay is the half-life of the
complex:
t1/2 =
ln2
ko f f
Both residence times and half-lives are measures of the lifetime of the protein-ligand
complex.
One of the crucial considerations during early-stage drug discovery is whether to aim
for long or short residence times, mainly because a long residence time can have both
beneficial and detrimental outcomes. As a general rule, short residence time is required
when a ligand needs to perform routine physiological functions. A prominent example
is Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, which is an open
channel blocker, capable of fast dissociation from the receptor, thus enabling the receptor
to quickly return to its resting state [79]. Other examples include Dopamine-2 receptor
antagonists, such as Risperidone, a typical antipsychotic, for which it has been estab-
lished that mechanism-based toxicity can be avoided by means of rapid and competitive
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dissociation rates and cyclooxygenase inhibitors Ibuprofen and Naproxen, often used as
anti-inflammatory agents. Ibuprofen and Naproxen are rapid reversible inhibitors, whereas
their analogue, acetylsalycilic acid (Aspirin) has an irreversible binding profile with con-
comitant increased risk of bleeding [80]. The majority of the marketed drugs have a long
residence time, as this is considered to be more efficient. Long residence time is the best
strategy when therapies require long lasting target occupancy (maintaining high blood
levels for a long time is the alternative). The foremost example is probably Darunavir - the
HIV protease inhibitor most recently approved by the FDA. What differentiates Darunavir
from its analogues is an extremely long residence time and this property has been linked
to the higher antiviral activity and higher genetic barrier to development of resistance
[81, 82]. Darunavir also has the highest enthalpic contribution to the overall free energy of
binding and it is intuitive to think that the specific interactions that contribute to enthalpy
also contribute to the long residence time: ligand dissociation requires increased mobility
for both the protein and ligand and will thus be associated with a favourable entropy
component. Therefore, the energy barrier is likely to be almost exclusively enthalpic [83].
Until recently, routine use of kinetic data in drug discovery processes has not been
common. However, the measurement of accurate kinetic data for protein-ligand interactions
has been enhanced in recent years by the use of sensitive, high-throughput label free
instrumentation, making drug-target residence times a valuable parameter in the drug
discovery process [84] (Figure 3.1).
Fig. 3.1 Association rate constant kon plotted against dissociation rate constant ko f f .
Diagonal lines in the plot represent equilibrium dissociation constant (Kd) values.
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3.4 Measuring binding kinetics
The increased interest in optimising binding kinetics has been accompanied by an im-
provement in the related instrumentation capable of providing binding rates. In theory,
any technique capable of measuring and differentiating between the amount of bound and
free ligand can be used to determine on and off rates. In practice, measuring binding
kinetics accurately and reproducibly can be very challenging. The most widely used
techniques include label-free methods such as surface plasmon resonance and techniques
using labelling and fluorescence.
3.4.1 Surface plasmon resonance
Kinetic characterisation using surface plasmon resonance (SPR) is one of the most estab-
lished methods for measuring real-time quantitative binding affinities and kinetics. In this
label-free technique, a protein of interest is immobilised to the sensor surface while analyte
is free in solution and passed over the surface. Binding of an analyte to an immobilised
protein induces a change in the refractive index on the sensor surface: this change is linear
to the number of molecules bound. A sensorgram depicts changes in SPR angle in real
time, with responses measured in resonance units (RU). When the pulse of analyte (drug)
is long enough, steady state can be reached (flat part of the sensorgram curve). At the end
of the injection, the analyte is replaced by a continuous buffer flow, and the corresponding
decrease in signal now reflects dissociation of analyte from the surface-bound protein
(Figure 3.2 ) [85].
Kd is determined by plotting the response units (RU) at equilibrium against the ligand
concentration. Rate constants ko f f and kon are estimated by regression of association
and dissociation gradients measured at different analyte concentrations. The simplest 1:1
binding mechanism is applicable in the vast majority of cases. In this model, one analyte
molecule from solution binds to immobilised protein. Analysis of the sensorgram curve in
the association phase, in which binding is measured while the analyte solution flows over
the ligand surface, allows the determination of the rate of complex formation. Rt and Rmax
correspond to the observed response at time t and to the theoretical maximal response that
would be observed if an infinite concentration of analyte A was injected [86, 87]:
d[R]
dt
= kon[A](Rmax−Rt)− ko f f Rt
Rt =
Rmax[A]
ko f f +[A]︸ ︷︷ ︸
Determines the equilibrium level
× [1− e−(kon[A]+ko f f )t ]︸ ︷︷ ︸
Determines the time to reach the equilibrium
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Fig. 3.2 Surface plasmon resonance detects changes in the refractive index in the immediate
vicinity of the surface layer of a sensor chip. A typical SPR sensorgram. Kd is determined
by plotting the response units (RU) at equilibrium against the ligand concentration.
In the dissociation phase, the concentration of analyte in the flow is suddenly reduced
to zero by the injection of the running buffer. The rate of complex dissociation follows
simple exponential decay, or first-order kinetics:
Rt = R0× e−(kdt)
where R0 is the signal level at the beginning of dissociation.
When a poor fit is obtained to the data using the simple 1:1 binding model the binding
kinetics are considered complex. Because all complex binding models generate equations
with two or more exponential terms, it is usually impossible to distinguish between
different models by curve fitting alone and additional experiments have to be performed
[88]. There are four complex binding models for analysing non-Langmuir interactions: the
heterogeneous analyte, heterogeneous ligand, two-state, and bivalent analyte models.
It is necessary to provide a biological justification for the use of other models, and
conclusions based on analyses with these complex models should be confirmed with
additional experiments [89].
3.4 Measuring binding kinetics 29
SPR has a short assay development time, low material consumption and can be used
to determine kinetic parameters in parallel mode. However, the immobilisation of the
receptor could have an effect on the binding properties. The method also has relatively
low throughput due to the slow regeneration step. The dynamic range for rate constants
determined by SPR is limited: the limits for kon are between 103 and 107 M-1s-1, and for
ko f f between 10-6 and 10-1 s-1. It is almost impossible to determine the rate constants for
very weak interactions where quick association is caused by high analyte concentration.
These complexes usually have ko f f below the limit that can be determined.
The experimental setup, interpretation of kinetic signatures, and the assessment of the
residence time will be discussed in chapters 7 and 8.
3.4.2 Radioligand binding
Radioligand binding is a preferred technique for measuring binding kinetics of G-protein
coupled receptors [90, 91]. There are two main approaches to measure kinetics using this
method. The first approach is direct radiolabeling where receptors are pre-incubated with
the radiolabeled ligand to reach equillibrium. Further binding of the radioligand to receptor
is then blocked by adding an excess amount of assay buffer or saturating concentration of
unlabeled ligand to prevent reassociation. After initiating dissociation, o f f rate is measured
to determine how rapidly the ligand dissociates from the receptors. The association
is determined in a separate experiment at different radioligand concentrations, or by
performing an experiment at single a concentration when ko f f is known. The second
approach is indirect. The kinetic properties of a compound are determined through
competition displacement by a radioligand of known affinity [92]. The high-throughput
variant is a dual-point competition association assay which measures radioligand binding
at two different time points in the absence or presence of unlabeled competitors. If the
unlabeled competitor dissociates faster than the radioligand, the competition curve will
monotonically reach its equilibrium. If however, the radioligand dissociates faster, the
association curve will have two phases [91].
Even though radioligand binding assays are capable of determining kinetic rate con-
stants, the experiment is expensive and generates radioactive waste. Alternative approaches
are fluorescence methods, such as time resolved fluorescence resonance energy transfer
(TR-FRET) [93] or fluorescence anisotropy [94].
Chapter 4
Computational approaches to molecular
recognition
4.1 Introduction
Computational chemistry can be described as chemistry performed using computers rather
than chemicals. It is usually used when a mathematical method is sufficiently well
developed that it can be automated for implementation on a computer. Much like the
experiment, calculations can be applied in order to collect the data or simply as a way of
looking at the unusual.
Although performing calculations is a lot cheaper than experiment, the cost of cal-
culations rapidly increases with the molecular size. Based on the underlying theory and
applicability domain, computational chemistry can be divided into three main approaches,
as summarised in table 4.1.
Over the last two decades powerful molecular modelling tools have been developed
which are capable of accurately predicting structures, energetics, reactivities and other
properties of molecules. These developments are largely due to the dramatic increase
in computer speed and the design of efficient algorithms. Accurate calculations are still
computationally very demanding and it is often advantageous to calculate the differences
in binding energies throughout the ligand series, rather than absolute values [33, 95].
This information can then be used to guide molecular design and synthesis. Ideally, the
computational approaches would be as accurate as experiment, with binding energies
correct to within 1 kcal/mol. This goal has not yet been achieved. There are many reasons
why accurate prediction of free energy of binding is difficult. These estimates are small
differences between large numbers and the interactions between binding partners depend
on the details of molecular conformation and both ligand and protein have many degrees
of freedom, which makes exploration of conformational space a challenging task [96].
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Table 4.1 Computational chemistry methods
Method Advantages Disadvantages
Molecular
Mechanics
• relies on force-field with em-
bedded empirical parameters
• applicable for large systems
computationally least inten-
sive
• force-field dependent
• requires experimental data
• restricted to equilibrium struc-
tures
Semi empirical • requires experimentally de-
rived empirical parameters
• less demanding than ab initio
methods
• suitable for studying transition
states
• computationally expensive
• less rigorous than ab initio
methods
• requires experimental data
Ab initio • does not require experimental
data
• suitable for studying transition
states
• useful for determination of
properties that are inaccessi-
ble experimentally
• computationally very expen-
sive
• applicable only for smaller
systems
Furthermore, contributions from both enthalpic and entropic changes to the overall binding
free energy are global parameters that reflect the overall heat effect caused by energy
exchange between all the species in the reaction mixture [97]. To deconvolute these
contributions to individual terms is a very challenging task. Despite all the difficulties,
computational modelling has a significant potential to make accurate predictions and guide
molecular design.
4.2 Approaches to calculating affinity
4.2.1 Docking and scoring
Docking methods aim to identify the predominant binding mode(s) of a ligand with a
protein of known three-dimensional structure. This conformation is then used to assign
a binding energy or a binding score. The method must be computationally rapid so
thousands of molecules can be docked and ranked per hour. Scoring functions are used to
rank different binding modes and can be empirical, force field based, or knowledge based
[98, 99]. In an empirical scoring function, binding energy is decomposed into several
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terms, such as hydrogen bonds, ionic interactions, hydrophobic effect and binding entropy,
which are then summed up to give a final score. The force-field-based scoring functions
calculate the sum of van der Waals and electrostatic energy terms. Knowledge-based
scoring functions use the assumption that the more favourable an interaction is, the more
frequently they will appear in the available structures of protein-ligand complexes. The
score is calculated by rewarding preferred contacts and penalising repulsive interactions
between each atom in the ligand and protein within a given cutoff.
Table 4.2 Examples of Docking and Scoring approaches
Scoring Function
Description Examples
Empirical sum of individual contributions to binding
energy
LUDI [100],
ChemScore
[101],
GlideScore
[102]
Force field based sum of van der Waals and electrostatic energy
term
Dock [103],
Gold [104],
Autodock [105]
Knowledge based derived from crystal-structure data PMF [106],
DrugScore [98]
Ligand Conformational Space Search
Systematic uniform sampling of search space
Stochastic random changes to a single ligand or a population of ligands
• Monte Carlo Prodock [107], ICM [108], MCDOCK [109], DockVision [110]
• Genetic Algorithm GOLD [104], AutoDock [105], DIVALI [111], DARWIN [112]
In theory, search space for protein-ligand binding should consist of all possible unbound
ligand and protein conformations, all possible ligand conformations within a given protein
conformation, and all possible protein conformations with all possible ligand conforma-
tions. In practice, it is impossible to exhaustively explore this search space with the current
technology. Therefore, to satisfy both speed and search space coverage criteria, two major
approaches have been developed: systematic and stochastic. Systematic searching is deter-
ministic and includes sampling at predefined intervals, while stochastic searching samples
the conformational space by performing random changes to a single ligand or a population
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of ligands. There are two basic types of methods based on random algorithms: Monte
Carlo methods and Genetic Algorithm methods [113, 114]. In Monte Carlo methods, an
initial configuration is refined by taking random steps which are accepted or rejected, based
on a Boltzmann probability function, until a certain number of steps have been tried. The
genetic algorithm approach is inspired by biological evolution. This approach starts from
an initial population of different conformations of the ligand with respect to the protein.
The score of each pose acts as the fitness function used to select individuals for the next
iteration, until the final population is reached. Most common examples of docking and
scoring approaches are given in table 4.2
Based on how broadly the method explores the search space, the approaches fall into
two categories: local or global. Local search methods aim to find the nearest or local
energy minimum to the starting conformation, whereas global methods search for the best
or global energy minimum within the defined search space. Hybrid global–local search
methods have been shown to perform even better than global methods alone, being more
efficient and able to find lower energies [115].
4.2.2 Molecular mechanics
There are several methods for computing the potential energy of an isolated molecule or
a complex in a given conformation. Empirical methods substitute fitted parameters of
electronic structures in a few energy terms that are easily calculated. This is molecular
mechanics or force field approach and the underlying principle here is that cumulative
physical forces can be used to describe molecular geometries and energies. The building
blocks are atoms and electrons are not considered as individual particles. A molecule
is thought of as a collection of masses centered around the nuclei (atoms) connected by
springs (bonds). A potential energy is constructed as a function of atomic positions, using
a large body of experimentally determined, parameterised data. The most commonly used
examples include CHARMM [116], AMBER [117], GROMOS [118] and OPLS [119].
Force field energy can be written as a sum of terms, each describing the energy required
for distorting a molecule in a specific fashion:
EFF = Estr +Ebend +Etors+EvdW +Eel +Ecross
The first two terms treat bond stretching and angle bending, the third term is the energy
for rotation around a bond, EvdW and Eel describe the non-bonded interactions. Ecross
describes the coupling between the first three terms (Figure 4.1) [120].
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Fig. 4.1 Force field energy terms
4.2.3 Endpoint methods
End-point methods involve sampling of the ligand and protein in bound and free (unbound)
state and then taking the difference between the absolute energies of the two states to
estimate the binding free energy [121].
The simplest example is the Linear Interaction Energy (LIE) approach [122, 123]. LIE
involves running two molecular dynamics simulations: one for the ligand in solution and
the other for the ligand in the protein binding site. The binding free energy is estimated
based on the difference in the energetics of the interactions between ligand and receptor in
the “bound” versus “free” states (i.e. the endpoints):
∆Gbind ≈ β (⟨Eboundelec ⟩−⟨E f reeelec ⟩)+α(⟨EboundvdW ⟩−⟨E f reevdW ⟩)+ γ
The main assumption, deriving from linear response considerations, is that only (conver-
gent) averages of the interaction energies between the ligand and its surroundings need to
be evaluated [124]. The angle brackets indicate ensemble averages and their superscripts
indicate from which simulation the average is computed. α , β and γ are the coefficients
that account for the internal energy of the solvent and the protein and are dependent upon
the force field, polarity of the small molecule, and the hydrophobicity of the binding pocket
[125].
In second end-point approach, molecular mechanics energies are combined with the
Poisson–Boltzmann (MM-PBSA) or generalized Born (MM-GBSA) and surface area
continuum solvation to calculate binding free energies. Three molecular dynamics simula-
tions are carried out: free ligand, apo protein and their complex [126, 127]. Binding free
energy is then calculated as a difference between the complex, free ligand and the unbound
receptor:
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∆Gbind = ⟨GPL⟩−⟨GP⟩−⟨GL⟩,
The free energy of each state is approximated from the sum of six terms:
G = Ebnd +Eelec+EvdW +Gpol +Gnp−T SMM
where the first three terms are the molecular mechanics energy (bonded interactions,
electrostatic and van der Waals interactions), Gpol is polar solvation energy from PB or
GB, Gnp is nonpolar continuum-solvation energy contributions and TSMM is the solute
entropic contribution.
LIE and MM/PBSA have been compared several times, but the performance varied
strongly with the tested system [128–131]. MM/PBSA often overestimates differences in
binding affinities, giving a favourable correlation coefficient, but a poor median absolute
deviation, MAD [132].
4.2.4 Pathway methods
In pathway methods the ligand is gradually separated from the protein. The initial and final
states are linked by a pathway of small steps for which the difference in free energy can be
calculated. This class includes methods in which the ligand/protein interactions are gradu-
ally switched off, such as thermodynamic integration (TI) and free-energy perturbation
(FEP). Both techniques use thermodynamic cycles to estimate free energy changes, ∆∆G,
between two ligands. One ligand is perturbed into another with the help of a coupling pa-
rameter in both the solvent and protein environment. This method is termed computational
alchemy [133]. A free energy cycle shows that the difference between the free energies
of binding ∆GbindA and ∆GbindB equals the difference between the binding free energies
of the two ligands, ∆G2 and ∆G1 (Figure 4.2). Calculating ∆GbindA and ∆GbindB involves
simulation on a physical pathway (horizontal lines) and can be very difficult, as it involves
defining a reaction coordinate. Since the free energy depends only on the state and not the
pathway, this difference can be calculated along the non-physical pathway (vertical lines).
Ligand A is transformed to ligand B, both in the solution and in the context of the protein.
∆G1 results from transforming ligand A to ligand B in solution, while ∆G2 results from
the same transformation, this time in the binding site. Thus, relative change in free energy
of binding between two related ligands can be calculated
∆∆Gbind = ∆GbindB−∆GbindA = ∆G2−∆G1
.
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Fig. 4.2 Thermodynamic cycle
A widely used approach to calculating free energy changes associated with an alchemi-
cal transformation is thermodynamic integration, TI. In this approach, the energy of the
system is a function of a parameter λ . λ varies from 0 in the initial state to 1 in the
final state. Usual procedure includes simulations at several λ values and computing the
numerical integral at the each step. At each intermediate step λi, a short "equilibration"
run is first performed (since the point of equilibrium has changed) and then a “production”
run where the integral is computed. The number of windows between λ=0 and λ=1 has to
be decided in advance, but the data can then be divided into equilibration and production
parts later. It is possible to accumulate runs so no data are wasted.
In another approach, free energy perturbation (FEP) simulation of the system is per-
formed at λ and λ +∆ steps. This way, an energy change associated with each step is
obtained, and the small free energy difference between the two states can be determined.
The number of windows and the equilibration time have to be decided in advance. The
windows are created serially, so if the equilibration time is insufficient, the simulation has
to be repeated. Both approaches are conceptually shown in figure 4.3
The double decoupling method involves simulation of two alchemical processes [134].
In the first one, the interactions between the protein and the ligand are switched off, while
the ligand is restrained in the binding site. In the second step, the restraint is removed.
All of these methods are widely used to evaluate the differences in the free energy
of binding between a series of closely related ligands [135–140]. However, all of these
techniques suffer from the same drawbacks. Insufficient sampling, limited accuracy of
the current force fields and the fact that these methods do still require vast computational
resources are the main factors that hamper routine use of these approaches. The most
common parameter used to test validity of the force field description of the protein is the
structural conformational preference, which may not be sufficiently accurate for the use in
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Fig. 4.3 Left: FEP, the difference in free energy is estimated from the relative probability
of sampling a configuration appropriate to state B in state A. Right: TI, the free energy
difference is determined by integrating along a reversible path from A to B.
binding calculations. Another possible source of errors is ligand parameterisation, as only
a few force fields have tools for determining compatible functional groups [141].
Many approaches have been developed to overcome the sampling problem. Molecular
dynamics are most often applied with enhanced sampling techniques that allow for rare
events to be observed on a feasible timescale. Steered molecular dynamics (SMD) [142],
umbrella sampling [143] and metadynamics [144] are techniques where the ligand and
the protein are physically separated from each other. In SMD, the ligand is dragged out
from the protein using a moving restraining potential, and umbrella sampling includes
independent sampling of a a finite number of windows along the path from the bound to
the unbound state. In metadynamics, an external history-dependent potential is added in
a few degrees of freedom (collective variables) that prevents the system from sampling
already observed events.
These methods have been successfully applied to estimating free energies of ligand
binding [145–147], however, they do require knowing the binding mode in advance which
may limit their applicability.
4.3 Computational methods for binding kinetics
Most of the computational approaches to describing molecular recognition have been
focused on calculating affinities and free energies. Unlike free energy calculations, where
valuable insights can be obtained by studying only reaction endpoints, estimation of bind-
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ing kinetics relies on the reconstruction of the binding pathway. Two main approaches have
been developed [148]. Brownian dynamics is a technique in which the solvent molecules
are coarse-grained, which enables sampling rare events on reasonable timescales. This
technique has recently been used to provide quantitative estimates. In particular, the resi-
dence time of HSP90 and MDM2 inhibitors was computed along with the characterisation
of the drug-receptor encounter complexes [149].
The approximations and assumptions (rigid body dynamics, reduced point-charge
interactions, implicit solvent, and a relatively large timestep) made when using Brownian
dynamics to simulate molecular binding can also introduce inaccuracies. Therefore, to
accurately recover experimental observables related to a binding process, additional models
to approximate physical effects due to solvation shells and polarisation, solvent entropic
effects, and solute internal degrees of freedom are often needed [150].
The second approach involves molecular dynamics. Ligand binding and unbinding
occurs on millisecond time scales, which can hardly be achieved in a reasonable computer
time. Enhanced-sampling methods are generally used to address this shortcoming and
in some recent applications it has been possible to reconstruct the kinetics of binding by
combining them with other theoretical approaches [151, 152].
All these approaches modify the system by applying forces that might alter the dynam-
ics of the system. The advances in software algorithms, parallelisation of codes enabling
high performance computing and the development of specialised hardware infrastructures
has enabled the use of unbiased brute force simulations. In 2008, a special-purpose ma-
chine for molecular dynamics simulation (ANTON)[153] was developed by D.E.Shaw
Research that enables 1 millisecond scales to be reached [154].
4.4 The basics of quantum mechanics
4.4.1 Introduction
Classical mechanics, built upon Newton’s second law (F = ma) accurately describe most
systems that can be easily observed: movements of the objects of "normal" size (larger than
an atom, smaller than a planet), at a "normal" temperature (close to room temperature),
moving through space at a "normal" speed (anything significantly less than the speed of
light). In other words, classical physics is deterministic, meaning that it is possible to
predict the trajectory of a particle and therefore location of the particle at a certain time.
When the velocity of a particle is comparable to the speed of light, relativistic effects
become important. Small light particles do not behave in a way that is consistent with
the Newton’s equations: it is common to think of the particle as being distributed through
space like a wave, and it is then possible to calculate the probability of a particle being at a
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certain place at a certain time. The interpretation is no longer deterministic, it becomes
probabilistic, and the mathematical representation that replaces the classical concept of
trajectory is called a wavefunction ψ . Atoms and molecules behave essentially as classic
particles, while electrons can only be described by quantum mechanics.
The following sections briefly describe the basics of quantum mechanics and approxi-
mations that have to be made in order to develop these concepts into techniques that can
be used to study physical, chemical and biological phenomena, and is based on different
molecular modelling and computational chemistry textbooks [120, 155].
4.4.2 Atomic units
Quantum mechanics is concerned with electrons, protons and neutrons. The atomic units
have been chosen such that the fundamental electron properties are all equal to one atomic
unit. Mass, charge, etc. can then be expressed as multiples of these constants. The atomic
units of mass, charge, length and energy are given below:
1 mass unit equals rest mass of electron, me =9.1094×10-31 kg
1 unit of charge equals the elementary charge on an electron, e =1.6022×10-19 C
1 unit of length (1 Bohr) is a0 = 4π h¯ε0/mee2=5.2918×10-11 m
1 unit of energy (1 Hartree) is Eh = h¯/meao2=4.3597×10-18 J
4.5 Schrödinger equation
In 1926, the Austrian physicist Erwin Schrödinger proposed the equation that describes
how the wavefunction of a physical system evolves over time. The time-independent form
of this equation for a particle of mass m, under the influence of an external field V is:
{− h¯
2
2m
∇2+V}ψ(r) = Eψ(r)
where h¯2 is a modification of Planck’s constant h¯ = h2π = 1.05457×10−34Js, E is energy
and ∇2 (‘del squared’) is
∇2 =
∂ 2
∂x2
+
∂ 2
∂y2
+
∂ 2
∂ z2
In the general case, the Schrödinger equation is written
Hˆψ = Eψ
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where Hˆ is the Hamiltonian operator, which describes the kinetic and potential energy of
the system:
Hˆ =− h¯
2
2m
∇2+V
or,
Hˆ =−
electrons
∑
i=1
∇2i
2︸ ︷︷ ︸
Te
−
nuclei
∑
A=1
∇2A
2mA︸ ︷︷ ︸
Tn
−
electrons
∑
i=1
nuclei
∑
A=1
ZA
riA︸ ︷︷ ︸
Ven
+
electrons
∑
i=1
electrons
∑
j>1
1
ri j︸ ︷︷ ︸
Vee
+
nuclei
∑
A=1
nuclei
∑
B>A
ZAZB
RAB︸ ︷︷ ︸
Vnn
where Te is the operator for the kinetic energy of the electrons, Tn is the operator for the
kinetic energy of the nuclei, Vee is the operator for the Coulomb attraction between electrons
and nuclei, Vee is electron repulsion and Vnn is repulsion between nuclei. Schematic
representation of two atoms with the electrons whose coordinates are given by the vectors
ri and rj is given in figure 4.4.
Fig. 4.4 Schematic representation of two atoms with the electrons whose coordinates are
given by the vectors ri and rj.
4.6 Born-Oppenheimer approximation
It is a general principle of quantum mechanics that there is an operator for every physical
observable. If the wavefunction that describes a system is an eigenfunction of an operator,
then the value of the associated observable is extracted from the eigenfunction by operating
on the eigenfunction with the appropriate operator1. To solve the Schrödinger equation,
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it is necessary to find values of E and the function ψ such that when the wavefunction is
operated upon by the Hamiltonian, it returns the wavefunction multiplied by the energy. ψ
is an eigenfunction and E the eigenvalue.
Because the mass of the nuclei is much greater than the mass of electrons, only the
electrons are considered as independent variables of Hˆ, and the position of the nuclei is
assumed to be stationary. The movement of electrons and nuclei are therefore separated.
This is called the Born-Oppenheimer approximation, and can be written in the following
form:
ψmolecule = ψelectronsψnuclei
The Hamiltonian for a molecule with stationary nuclei (Tn = 0, Vnn = constant) is thus :
Hˆ =−
electrons
∑
i=1
∇2i
2
−
electrons
∑
i=1
nuclei
∑
A=1
ZA
riA
+
electrons
∑
i=1
electrons
∑
j>i
1
ri j
The first term is the kinetic energy of the electrons, the second term is the attraction of
the electrons to nuclei and the third term represents repulsion between electrons. Because
of the large mass difference between electrons and nuclei, nuclei are stationary from the
electronic point of view. The expression therefore ignores the coupling between the nuclear
and electronic velocities but provides the potential energy surface on which the nuclei
moves. In other words, upon invoking the Born-Oppenheimer approximation, the wave
equation describes the probability of finding the electrons, given the positions of the nuclei.
A quantum mechanics treatment requires no experimental information as input, and,
in theory, it should be the tool of choice for the reliable description of complex chemical
processes. The first step in solving the Schrödinger equation for an arbitrary molecule is to
set the specific Hamiltonian Hˆ of the target system. To do that, parts of the Hamiltonian
that are specific for the system in hand need to be known: number of the electrons in the
system and the external potential that is completely determined through the positions and
charges of the nuclei. All the other operators are independent of the particular molecule.
The next step is to find the eigenfunction ψ and the corresponding eigenvalue E. Once ψ is
determined, all properties of interest can be obtained by applying the appropriate operators
to the wavefunction. In practice, the Schrödinger equation can only accurately be solved
for the hydrogen atom, meaning that a range of approximations have to be applied, which
in turn reduce the accuracy of the obtained results.
Two basic QM approaches are used in practice and they both rely on the Born-
Oppenheimer approximation in which the electrons move in the field of the fixed nuclei,
1An eigenfunction of an operator Aˆ is a function f such that the application of Aˆ on f gives f again,
times a constant.
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but differ based on the different types of approximations they use: semi-empirical and ab
initio.
4.7 Ab initio methods
Ab initio is a Latin term meaning "from the beginning", or "from first principles" which
implies that this approach requires no empirical parameters as an input. These methods do
still rely on experimental data, but in a more subtle fashion, by guiding the selection of
the model. Many different models exist and which one will be used is chosen by running
calibration studies and comparing the performance against experimental data.
4.7.1 Hartree-Fock approximation
The Schrödinger equation can exactly be solved for only a few problems (one being
the hydrogen atom) and the full quantum solution of a system of any nontrivial size is
very difficult. The simplest type of ab initio electronic calculation is Hartree-Fock. The
basic idea behind this approach is that electrons behave as independent particles: each
electron interacts with the average field of all the other electrons and the many-electron
wavefunction takes the form of a determinant of single-electron wavefunctions (Slater
determinant). This approximation gives an average effect of repulsion, but not the explicit
repulsion interaction and the resulting energies tend to be too high. In case a complete
basis of single-electron wavefunctions is found, it is possible (in principle) to express the
exact many-electron wavefunction as a linear combination of all possible determinants
made of these wavefunctions (convergence to ground state).
The Hartree-Fock method starts with an initial guess for the orbital coefficients. This
function is then used to calculate energy and a new set of orbital coefficients, which can
then be used to obtain a new set, and so on. The procedure continues iteratively until
the energies and orbital coefficients remain constant from one iteration to the next. This
procedure is called the Self-Consistent Field procedure (SCF).
The most significant drawback of Hartree-Fock theory is that it fails to account for
electron-electron correlation. The simplest way to tackle this problem is Møller-Plesset
Perturbation Theory, usually of second (MP2), third (MP3) or fourth (MP4) order. The
Hamiltonian operator H is expressed as sum of a ’zeroth order’ Hamiltonian H0 and a
perturbation V : H = H0+λV , where V is the small perturbation and λ is a dimensionless
parameter.
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4.7.2 Basis set
In ab initio methods, molecular orbitals are approximated by a linear combination of
atomic orbitals. A basis set is a mathematical description of the orbitals within a system
used to perform the theoretical calculation. Larger basis sets approximate more accurately
the orbitals by imposing fewer restrictions on the locations of the electrons in space. An
infinite basis set would lead to the calculation of the exact molecular energy, but this
calculation would take an infinite amount of time. In practice, a calculation has converged
to the exact solution when all the approximations are sufficiently small in magnitude so that
the finite set of basis functions tends toward the limit of a complete set. The convergence
is usually not monotonic, and sometimes the smallest calculation gives the best result for
some properties.
There are two types of basis functions commonly used in electronic structure cal-
culations: Slater type orbitals (STO) and Gaussian type orbitals (GTO). STOs decay
exponentially with the distance from nuclei, while accurately describing the long-range
overlap between the atoms. Unfortunately, some of the integrals in STOs are difficult
or even impossible to solve. It is therefore common to approximate STOs with a linear
combination of Gaussian orbitals, which leads to a 4-5 orders of magnitude more rapid
calculations and huge computational savings. This is due to "Gaussian Product Theorem"
which states that the product of two GTOs on two different atoms is a finite sum of Gaus-
sians centered on a point along the axis connecting them. There are many levels of basis
sets comprised of GTOs and they differ depending upon how many basis functions are
used to characterise a given electron in an atom in the molecule. The smallest of these is
called the minimal basis set and it describes only the most basic aspects of the orbitals. It
contains the minimal number of functions that are required to represent all the electrons on
each atom.
4.7.2.1 Split-valence
It is common to represent bonding orbitals by more than one basis function, and since the
inner-shell electrons are not as vital to the calculation, they are described with a single
orbital. A basis set that doubles the number of functions in a minimal basis set is called
a double zeta basis (triple if it triples, quadruple if it quadruples and so on). These are
so called "split-valence" basis sets. The notation is of form X−Y Zg, where X represents
the number of primitive Gaussians in the inner shell, Y and Z indicate that the valence
orbitals are composed of two basis functions, one for contracted, other for extended valence
orbitals. Unlike the minimal basis sets, where the density is fixed and unable to adjust to
different molecular environments, split-valence basis sets allow the density to adjust in
space appropriate to the particular molecular environment.
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4.7.2.2 Polarised sets
The most common addition to minimal basis set is the addition of polarisation functions.
For example, using the minimal basis set, the only basis function located on a hydrogen
atom would be the one approximating the 1s orbital. The electron cloud in an isolated
hydrogen atom is symmetrical, but when the hydrogen atom is present in a molecule,
electrons are attracted towards the other nuclei. When polarisation is added, a p-function
is also added to the basis set, allowing molecular orbitals involving hydrogen atoms to be
more asymmetric about the nucleus, leading to more accurate representations of bonding
between atoms. In a similar fashion, d-type functions can be added to a basis set with
valence p orbital, and f functions to a basis set with d-type orbitals. The use of polarisation
functions is denoted by an asterisk (*). One asterisk (*) indicates that a polarisation
function has been added on the heavy (non-hydrogen) atoms, while two asterisks (**)
indicate the use of a polarisation function on hydrogen and helium atoms as well.
4.7.2.3 Diffuse sets
Another addition to the basis set which is useful for describing anions, molecules with
lone pairs, transition states, excited states, or any other molecule that have a significant
electron density at the distances further from the nuclei than the most ground state neutral
molecules, is a diffuse function, which is denoted by a plus (+) sign. These are very
shallow Gaussian basis functions, which more accurately represent the "tail" portion of
the atomic orbitals, far from the atomic nuclei. Two plus signs (++) indicate that diffuse
functions have been added to light atoms as well.
For example, the 6-31+G* basis set uses a single STO composed of 6 Gaussians for
inner shell electrons, and two STOs for valence electrons: the contracted (inner) STO is
composed of three GTOs, the extended (outer) STO is composed of a single GTO, a set
of d orbitals is added on the heavy atoms (denoted by *) and an additional set of diffuse
Gaussians is added on the heavy atoms (denoted by +).
The horizontal axes of the diagram in figure 4.5 relates to the extent to which the
motions of electrons are independent from one another. At the extreme right are the models
where there is no separation of electron motions, i.e., electron motions are fully correlated.
At the extreme left are the Hartree-Fock models that do not take correlation energy into
account and practical correlated models are somewhere in the middle.
The vertical axis relates to the basis set. At the top is the complete basis set that
involves all possible functions, while at the bottom is the basis set containing the fewest
possible functions. The region at the top right (fully correlated and complete basis set)
corresponds to solving the exact Schrödinger equation.
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Fig. 4.5 Pople diagram describing the convergence of the quantum-mechanical nonrela-
tivistic electronic energy with the size of the basis set and the level of electron correlation.
4.7.3 Density functional theory (DFT)
Density functional theory (DFT), a variant of ab initio is not based on solving the
Schrödinger equation. In this approach, the many-electron wavefunction is completely by-
passed in favour of the electron density, which is a function of three Cartesian cooridnates.
Unlike the wavefunction which becomes more complicated as the number of electrons
increases, the determination of electron density is independent of the number of electrons.
According to the the Hohenberg-Kohn Theorems, the ground state energy of the system
depends uniquely on the electron density, i.e. the total energy is a functional of the electron
density that depends on only 3 spatial coordinates. Electron density is expressed as a linear
combination of basis functions similar in mathematical form to Hartree-Fock orbitals. A
determinant is then formed from these functions and it is used to compute energy. The
correct ground state density for a system is the one that minimizes the total energy through
the functional E[n(x,y,z)], so it is possible to apply the variational principle to minimise
the energy with respect to the electron density. The problem with this technique is that no
one knows what the exact energy functional is. The simplest approximation is the local-
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density approximation (LDA), that assumes that the density of the molecule is uniform
throughout the molecule - the functional depends only on the (local) density at a given
point. Modern methods using generalised gradient approximations (GGAs) account for the
non-uniformity of the electron density by taking into account the gradient of the density
to produce a more accurate functional. An extension of GGAs is Meta-GGAs, where the
functional depends on density, its gradient, and its second derivative, such as functionals
from the Minnesota family , and Hybrid DFT functional that mix in Hartree-Fock exchange.
Most popular examples are B3LYP (hybrid GGA) [156–158] and M06 [159], which is a
hybrid meta-GGA functional and the dominant method of choice in this work.
4.7.4 Semi-empirical methods
Semi-empirical methods are applicable to larger molecules and may give accurate results
when applied to study molecules that are similar to ones used for parameterisation. In the
approach, some integrals are either omitted or parameterised based on experimental data,
such as ionisation energies of atoms or dipole moments.
Existing semi-empirical methods differ based on the approximations made when
evaluating one- and two- electron integrals and by the parameterisation approach. The
most frequently used methods (MNDO [160], AM1 [161], PM3 [162]) are all based on
the Neglect of Differential Diatomic Overlap (NDDO) [163] integral approximation. This
is a class of Zero Differential Overlap (ZDO) methods, in which all two-electron integrals
involving two-centre charge distributions are neglected [164].
4.7.5 Quantum mechanical approaches to calculating binding affin-
ity
A systematic approach in which ab initio methods improve the accuracy with which
molecular recognition is described presents an appealing complementary approach to
existing MM based methods [165–167]. Advances in parallel computing and sophisticated
QM algorithms in conjunction with plunging prices of CPU time have led to diversification
in the evolution of computational methods: with an end of Moore’s law approaching
(according to Intel, number crunching power is now doubling only every 2.5 years), the
future of computing is driven by the progress in new algorithms, cloud computing services
that enable harvesting of additional computing and storage resources for a fraction of
the cost to purchase new computers, and new computing architectures- specialised chips
optimised for specific jobs (one example being Anton, a supercomputer built for molecular
dynamics simulations). These impressive improvements enable QM to progress from being
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a sidekick to less computationally demanding (but also less accurate methods), to a more
central role in in silico compound design.
In recent years, significant progress has been made in approaches that use mainly QM
to estimate binding (or decompose binding affinity). So far, QM calculations of binding
affinities that include only the portion of the protein that is directly involved in binding
have been performed with a range of methods, including semi-empirical, HF and DFT,
with basis sets up to 6-31G**. Most of the examples have been mentioned in a recent
comprehensive review by Ryde and Söderhjelm [167] and prominent examples together
with some additional ones are discussed here.
One of the earliest examples is Peräklyä and Pakannen’s work in 1994, where the
authors looked at binding energies of L-arabinose, D-fucose and D-galactose to L-arabinose
binding protein [168]. Three contributions were taken into account: direct ligand active site
energy calculated at the HF/6-31G* level of theory, solvation of the ligand and long-range
electrostatic interactions both calculated at MM level, using a distance dependent dielectric
constant. The system included ligand and nine surrounding residues and the correlation to
experimental data, R2, was 0.37. In 1995, they used a similar approach to study binding
of seven ligands by p-hydroxybenzoate hydroxylase (PHBH). The calculations included
ligand and six surrounding residues and the complex was optimised at the HF/3-21G level,
resulting in R2=0.7 [169].
In 2004, Nikitina et al. used semi-empirical QM on eight protein-ligand complexes to
estimate the enthalpic contributions to binding free energy. In their approach they included
all the residues with at least one heavy atom within 5 Å of the ligand and performed
optimisation at the PM3 level of theory, with fixed backbone atoms. This study also looked
at two different approaches to including water molecules that were bonded to both protein
and the ligand [170]. This work was followed up by a study in which mixed implicit and
explicit solvation models were included. Water molecules were added to all potential
hydrogen bonding sites in both the protein and the ligand. The calculated enthalpies agreed
with the experimental enthalpies within 2 kcal/mol [171].
In 2005, Raha and Merz used semiempirical QM to design a scoring function capable
of calculating electrostatic interactions and solvation free energy expected during protein-
ligand complexation. This approach was successful in replicating the binding free energy
trends in a diverse set consisting of 165 protein-ligand complexes and also had a predictive
power in calculating the binding free energy both from the experimentally solved structures
and from docked poses. For 165 noncovalent complexes, the interaction energies were
within 2.5 kcal/mol without any fitting [172].
In the same year Villar et al. looked at how AM1 and PM3 derived interaction energies
and geometries between small molecules that simulate typical ligand-protein interactions
compare to higher level techniques MP2 and B3LYP. AM1 gave much better agreement
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with higher level techniques than PM3 and was further tested on the 5 ligand-protein
complexes from the PDB. All protein residues within 5 Å from the ligand were treated
with AM1. This gave reasonable geometries but no comparison with experimental energies
was performed [173].
Leach et al. studied two series of compounds that inhibit dimerisation of iNOS.
Their system included backbone atoms of six residues forming the binding site, the Cys
interacting with the iron, and iron porphyrin with the various sidechains on the heme
porphyrin ligand removed. The systems were treated with the range of QM methods, with
M06HF performing the best (R2 of 0.94 for LLE) [174]. Svensson et al. used DFT to
explore the relationship between the measured and predicted affinities between a set of
positively charged amidine and guanidine cores binding to the β - site of APP cleaving
enzyme (BACE-1) [175]. Using a similar approach, Roos et al. looked at the relative
binding affinities of a matched series of mineralocorticoid receptor (MR) agonists, using a
range of DFT methods, with M062X performing the best (R2 of 0.76 for LLE) [176].
A lot of work has been done with the ab inito fragment molecular orbital (FMO)
approach. In this approach, a system is divided into fragments which are then treated with
QM. By summing up the pair interaction energies (PIE) calculated for individual fragments,
it is possible to get estimates of Ki. FMO has been used to predict the inhibitor potency of
28 CDK2 inhibitors [177] where the fragments were evaluated at the MP2/6-31G * level of
theory, to assess binding energies of the FK506-binding protein and 10 ligand molecules
[178], for lead optimisation of interleukin-2 Inducible T-Cell Kinase (ITK) inhibitors [179],
combined with hierarchical GPCR modelling protocol (HGMP) to investigate 18 class A
GPCR-ligand x-ray structures [180] and to explore the interactions and selectivity of the
human orexin-2 receptor and its nonpeptidic agonist [181].
Research aims of this project
Predicting the potency of a compound remains an unsolved problem. For any compound to
become a likely drug candidate, it needs to satisfy a number of different ADMET properties
and have a good toxicological profile. Above all, the compound needs to bind tightly and
selectively to a specific location on the target, and elicit the desired functional response of
the target molecule.
Many compounds are synthesised and tested, most of which turn out to be inactive
against the desired target, failing thus at the very first hurdle. Computational approaches
to predicting many of the properties of the compounds are improving and provide a
benefit by avoiding the expenses of making and testing compounds that are unlikely
to become drugs. In parallel with these computational advances, what is understood
by potency as measured by experimentalists has evolved. Drug action begins with the
interaction between the compound and its target. This molecular recognition triggers a
series of molecular events that ultimately result in a useful pharmacological response that
corrects the pathophysiology. The molecular details of this response are dependent on the
thermodynamics and binding kinetics. Therefore, addressing both thermodynamics and
kinetics aspects of ligand binding can potentially reduce the numbers of compounds that
need to be evaluated, and provide new opportunities for rational lead optimisation.
An overall aim of this project is to propose new ideas that contribute beneficially to the
development of computational methods for interpreting potency in terms of thermodynamic
or kinetic parameters.
The work described in this thesis presents a novel approach in which quantum me-
chanics is used to predict the enthalpic component of ligand binding, by constructing
‘theoceptors’- theoretical receptors constructed by computing the optimal geometry of
the ligand and the binding site. The introductory chapters 1 to 4 describe the theoretical
background and give an overview of the state-of-the-art, while chapter 5 describes how
this approach can be used to provide useful insights into interactions between proteins and
ligands and turn these insights into new ideas for fragment series (see example of lactate
dehydrogenase A inhibitors).
During the course of the project, an opportunity arose for expanding the application
domain of the theoceptor approach. To test whether the method is also suitable for
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correctly selecting preferred protein conformations and ligand positions where there
is some movement of the protein backbone, a series of multiconformational structural
refinements with the theoceptor derived geometries was performed. The results present
compelling case to support the broader use of the methodology. Chapter 6 details this work.
This work was supported by EPSRC UK National Service for Computational Chemistry
Software (NSCCS) at Imperial College London.
This project included an industrial placement in the AstraZeneca’s Structural and Bio-
physical Sciences area, where thermodynamic and kinetic signatures of 3-phosphoglycerate
dehydrogenase and Mycobacterium tuberculosis Enoyl-ACP reductase inhibitors were
generated. These results together with some of the issues and uncertainties associated with
the two biophysical techniques used (surface plasmon resonance and isothermal titration
calorimetry) are discussed in chapters 7 and 8.
In addition to this, an ongoing collaboration with MedChemica Limited (a local start-
up company) was established. In chapter 9, some probabilistic insights into the field of
matched molecular pair analysis are provided. This work was awarded a CINF Scholarship
for Scientific Excellence at the 2016 American Chemical Society meeting in San Diego.
Part II
Experimental section
Chapter 5
Theoceptors for Lactate dehydrogenase
A (LDHA)
5.1 Introduction
In most normal cells, ATP is generated by oxidative phosphorylation, while cancer cells
predominantly produce energy by converting glucose into lactate through glycolysis, a
phenomenon first discovered by Otto Warburg [182]. One molecular target in the glycolytic
pathway is lactate dehydrogenase A (LDHA), an enzyme that catalyses the reversible
conversion of pyruvate to lactate, with the concomitant conversion of NADH to NAD+
(Figure 5.1). Several classes of cancers are characterised by elevated levels of lactate, and
the enzyme itself is overexpressed in human tumours, making LDHA a promising target
for cancer chemotherapies [183–187].
Fig. 5.1 Reaction catalysed by lactate dehydrogenase
Binding calculations can be very computationally demanding. The first principles
nature of QM calculations enables systematic improvements to the accuracy with which
biomolecular recognition is described. This methodical approach to solving chemical and
biological problems is quite appealing, but practical use is hindered by the computational
cost of these calculations. In this chapter, an alternative structurally “exclusive” approach
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that includes only the parts of the protein that are involved in ligand recognition and
neglects the remainder is proposed.
The proposed approach is reductionist and begins with the notion that a necessary first
step to identifying interacting partners is to understand the interactions between molecules
at an atomic level. By using ab initio methods, new discoveries require only the protein
geometry. The computational method (steps 1 to 5) is presented in Figure 5.2. The steps
involved are: 1) A binding site in a known protein structure (from x-ray crystallographic
or NMR experiments) is selected 2) The protein residues immediately flanking the binding
site are identified. The remainder of the protein is deleted. Tautomeric and protonation
states of the protein must be assigned. 3) The Cα and Cβ atoms are identified. These will
be fixed in space during the quantum mechanical calculations. 4) Quantum mechanical
geometry optimisation causes small changes to both the ligand and protein geometry. Large
changes indicate an inappropriate structure or protonation state. Structural water molecules
can be constrained or allowed to move. 5) The ligand is optimised in isolation. Solution
phase quantum mechanical optimisation is performed.
Fig. 5.2 Steps involved in constructing the theoceptor. Binding site in the crystal structure
is selected. Residues directly involved in binding are identified. The Cα and Cβ atoms are
identified and fixed in space to mimic the scaffolding effect of the remainder of the protein.
Geometry of the complex is optimised. Ligand is optimised in isolation
This chapter details the efforts in computational modelling of different series of LDHA
inhibitors and shows how quantum mechanical calculations can provide useful insights
into interactions between protein and ligands, with the ultimate goal of suggesting a new
fragment series with the more favourable predicted potency.
5.2 Compound selection
The set of compounds included in this computational study included 3,6-disubstituted
dihydropyrones, 3-hydroxycyclohex-2-enones, 2-thio-6-oxo-1,6- dihydropyrimidines, and
amino-pyrazines from a high-throughput screen (HTS) of the Genentech/Roche corporate
compound collection [188–192]; small, negatively charged pyridine derivative [193]; and
three compounds sharing malonate as a common substituent originating from AstraZeneca
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fragment screening campaigns [194] (Table 5.1). The compounds were selected based on
the availability of structural and bioactivity data.
Table 5.1 Compounds selected for computational studies. For structures 1-7, LLE was
calculated as pIC50- clogP, and for structures 8-11 as pKd –clogP, logP was calculated
using ChemAxon logP predictor [195]
pIC50
pKd
(SPR)
pKd
(NMR)
LLE
1 5.76 5.46 NC 1.98
2 6.06 5.74 NC 0.41
3 6.44 NC NC 1.96
4 8.22 NC NC 0.64
5 7.22 NC NC 2.13
6 5.3 5.3 NC 1.49
7 6.12 5.29 NC 3.16
5.2 Compound selection 55
8 <3.3 3.67 3.33 1.52
9 <3.3 2.96 3.63 1.98
10 <3.3 3.55 3 1.53
11 <2.7 2.63 NC 0.19
* NC=not calculated
5.2.1 Crystal structure evaluation
Crystal structures of 8 and 9 are available in complex with rat LDHA (PDB codes 4AJE
and 4AJI), as attempts to generate a soakable crystal system using human LDHA were
unsuccessful [194], and structure of 11 is available in complex with rabbit LDHA (PDB
code 4I8X), as that system gave well-diffracting crystals [193]. Structures 1-7 are all
available in complex with human LDHA [188–192].
RSCC values for the 10 ligands selected are given in table 5.2. Density maps contoured
at 1 σ of the ligands with lower RSCC values (ligands 3, 6 and 7) are shown in figure 5.3.
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Table 5.2 RSCC values of ligands 1-8,10-11.
PDB Chain (µM) RSCC ligand
1 4QO7 A 0.958
2 4QO8 A 0.921
3 4RLS D 0.883
4 4R68 B 0.979
5 4R69 D 0.943
6 4M49 A 0.816
7 4JNK D 0.911
8 4AJE B 0.988
10 4AJI B 0.963
11 4I8X B 0.913
Fig. 5.3 Density maps 2mFo-DFc of ligands 3,7 (first row) and 6, 5 (second row) contoured
at 1 σ .
5.3 Docking
The set of structures was studied using AutoDockVina [196]. Docking was performed into
a representative structure from each rat, rabbit and human system. Three structures (6,
11 and 8) were processed with Schrödinger’s protein preparation wizard [197] to ensure
reasonable starting points for docking: hydrogen atoms were added after deleting any
original ones, followed by adjustment of bond orders for amino acid residues and the ligand.
The protonation and tautomeric states of Asp, Glu, Arg, Lys and His were adjusted to match
a pH of 7.4. All water molecules and cofactors were removed. Structures were overlaid
and a user-defined docking search space, which is explored for possible ligand binding
conformations (grid box), was centred on the 2-aminopyrazine-based ligand from 4M49
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and extended 30 grid points in each direction. Ligands were extracted from the crystal
structures of the complexes and polar ligand hydrogens were added with AutoDock Tools
(ADT 1.5.4) [198]. Two types of ligand geometries were provided as input: geometries
extracted from protein crystal structures and geometries generated by application of Corina
[199] to 2D structures. Correct bond orders and protonation states were assigned upon
visual inspection.
The geometries obtained for compounds 1-8 and 10-11 by AutoDock Vina were
compared to their crystal structures and results are summarised in Table 5.3. The entries
coloured red are the ones where the native binding mode was not correctly reproduced
(rmsd<=1.5 Å).
Table 5.3 Docking scores for the highest ranking pose obtained for docking each compound
into each protein structure. RMSDs for ligands in the best ranked docking pose when
superimposed to those in crystal structures. For structures 1-7, LLE was calculated as
pIC50- clogP, and for structures 8-11 as pKd –clogP.
Human Rat Rabbit Corina
pIC50 pKd LLE Score RMSD Score RMSD Score RMSD Score RMSD
1 5.76 5.46 1.98 -6.5 0.54 -6.0 1.08 -7.1 1.14 -7.5 4.31
2 6.06 5.74 0.41 -6.7 0.33 -7.6 2.08 -6.9 2.06 -7.0 5.14
3 6.44 NC 1.96 -7.4 0.54 -8.6 2.04 -7.5 2.05 -7.8 3.75
4 8.22 NC 0.64 -7.3 1.17 -6.5 2.50 -7.8 1.23 -7.3 4.89
5 7.22 NC 2.13 -8.0 2.36 -7.8 0.49 -7.5 0.37 -8.1 5.54
6 5.3 5.3 1.49 -8.2 2.50 -7.6 2.04 -7.8 1.80 -7.5 5.26
7 6.12 5.29 3.16 -7.5 1.69 -8.1 3.10 -8.4 3.73 -8.0 6.8
8 <3.3 3.32 1.52 -5.2 1.54 -5.9 1.18 -5.7 1.44 -5.4 2.43
10 <3.3 3 1.98 -5.7 2.14 -5.8 0.86 -5.8 1.05 -5.6 4.18
11 <3.3 2.63 1.53 -6.3 1.14 -6.2 0.44 -6.6 0.46 -6.2 1.66
The ligands come from very different series and do not share a common substructure
hence, the distances between the centre of mass of each ligand, Arg168 Cβ and Asn137
Cγ , (two residues participating in hydrogen bond formation), were assessed (Table 5.4,
Figure 5.4). It is interesting to note that none of the dockings ranked the most potent and
one of the weakest binding ligands, ligands 4 and 8 correctly.
The geometric parameters in Table 5.4 show that poses Vina ranks the best are not
the native ones. In most of the cases, the native binding pose was found but it was not
ranked the best. In terms of orientation of the ligand, redocking of the native conformation
or docking of Corina-generated conformations into the human structure outperformed
docking into rabbit or rat crystal systems.
Surprisingly, the best correlation between the docking score and potency or binding
affinity is achieved when docking Corina generated structures into the human receptor
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Fig. 5.4 The centre of the docking grid box was placed on the centre of ligand 6. Geometry
assessment: distance between centre of the mass of the ligand and Arg168 Cζ and Asn137
Cγ . In case of the ligand 6, both of these centres coincide and are shown as black ball.
(R2 of 0.6), even though it performed the worst on both RMSD and geometry assessment
(Table 5.5).
As it has been discussed previously (Chapter 2, Ligand efficiency metrics-LEMs), it
has been observed throughout the years that general partitioning effect caused by increased
lipophilicity is linked to poor physical-chemical and ADME1 properties. It is a common
practice to examine ligand lipophilic efficiency (LLE, defined as pIC50- clogP for structures
1-7, and for structures 8-11 as pKd –clogP ), a metric that accounts for these effects [65].
Therefore, LLE is a useful property to improve during a lead optimisation process, and it is
of value to examine if any of structure-activity relationship (SAR) modelling affects LLE.
Docking results were compared to LLE and no correlation was observed - correlation
coefficients range from 0.08 for redocking into human crystal system, to 0.21 for docking
of Corina-generated ligands (Table 5.5).
1absorption, distribution, metabolism, and excretion
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Table 5.4 Distances from the centre of mass of the ligand in the crystal structure and the
best ranking poses to Cζ Arg168 and Cγ Asn137. Entries coloured green are within 1 Å
relative to crystal structure.
1 2 3 4 5 6 7 8 10 11
Crystal
Arg168 Cζ 6.0 6.8 5.2 7.9 7.3 9.7 11.9 7.1 7.4 7.9
Asn137 Cγ 6.1 5.7 6.1 4.9 7.3 6.7 4.1 4.9 5.2 5.1
Human
Arg168 Cζ 8.8 9.6 9.0 9.8 12.7 18.1 9.0 7.2 8.6 24.6
Asn137 Cγ 4.9 6.2 6.0 5.3 8.3 11.9 5.4 5.7 4.3 16.3
Rat
Arg168 Cζ 6.3 5.2 5.0 9.5 6.1 5.4 5.8 9.6 9.0 5.8
Asn137 Cγ 16.2 15.3 15.2 5.5 16.0 15.5 15.8 4.7 4.5 15.8
Rabbit
Arg168 Cζ 8.2 13.6 5.4 9.5 11.4 9.9 15.5 9.0 7.3 7.8
Asn137 Cγ 5.5 7.8 15.6 5.5 6.6 3.6 9.3 4.8 4.8 4.7
Corina
Arg168 Cζ 10.7 10.0 20.5 9.8 17.1 10.2 15.5 7.2 8.5 24.5
Asn137 Cγ 5.2 6.6 14.6 5.0 10.9 3.4 9.6 4.6 4.5 16.2
Table 5.5 Summary statistics describing the relationship between docking scores and
pIC50/Kd or LLE. For structures 1-7, LLE was calculated as pIC50- clogP, and for structures
8-11 as pKd -clogP
pIC50/Kd LLE
R2 RMSE R2 RMSE
Human 0.48 0.89 0.08 3.01
Rat 0.27 1.57 0.16 2.3
Rabbit 0.48 0.77 0.15 1.94
Corina 0.6 0.69 0.21 1.75
5.4 Structure processing and QM optimisation
Ten crystal structures (the complexes of 1-8, 10 and 11) were split into their constituent
chains and superimposed. Noticeable differences in binding site residues were present
for: 1) Arg105 - this highly mobile residue was observed protruding into binding sites in
rat and rabbit structures, as well as human structures in chains where there is no ligand
present. In human structures with the ligand present, this residue is pointing away towards
Glu191 2) Tyr238 - sidechain points away from the binding site in chains where there is
no ligand present (Figure 5.5).
No cofactor was present in crystal structures of 8, 10 and 11 and no electron density
corresponding to cofactor structure could be observed. Crystal structures of remaining
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Fig. 5.5 Arg105 and Tyr238 were observed protruding into binding sites in rat and rabbit
structures and human structures in chains where there is no ligand present. Human structure
is shown in purple, rat in grey.
complexes (1- 7) had cofactor modelled into well defined corresponding electron density.
Selected structures are given in Table 5.2. The structure of 9 was obtained by analogy to
that of 10. All the ligands ionise at physiological pH.
Residues that were identified as the ones directly involved in ligand binding were
selected as a part of the theoceptor: Arg168, His192, Val234, Asp165, Asp194, Tyr238,
and Asn137. Protonation states were assigned manually and the net charge of the residues
was 0. Asp165 forms a hydrogen bond with His192 and is stabilised by an additional
hydrogen bond with one water molecule. Preliminary studies in which the theoceptor
did not include this water molecule showed that this hydrogen bond is highly dependent
on the starting Asp165 conformation. When the water molecule is present, Asp165
forms a hydrogen bond with water oxygen, which keeps the sidechain conformation in
optimal position to interact with positively charged His192 sidechain. Therefore, this water
molecule is considered structural as it is necessary for plasticity of the binding site and it
was kept as a part of the theoceptor. All interactions with the ligand are through protein
sidechains: backbone, cofactor and the remainder of the protein were deleted. To account
for the scaffolding effect of the rest of the protein, Cα , Cβ and water oxygen atoms were
fixed in space using the fixed Cartesian redundant coordinate feature in Gaussian09, as
shown in Figure 5.6.
The process of ligand binding to its protein target can be seen as a partition problem
where ligand is transferred from one medium (free in water) to another (binding site).
Dielectric constant (ε) value for the interior of the protein is relatively low (about 6-7)
[200], compared to dielectric constant of water, which is 80 at 20 C◦. Therefore, the interior
of the protein resembles the gas phase more than it resembles water (Figure 5.7). LLE
can be interpreted as proportional to free energy of binding for an inhibitor partitioning
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Fig. 5.6 Theoceptor 1. Cα and Cβ were fixed during the QM optimisation
between 1-octanol and the enzyme, rather than between water and the enzyme. Dielectric
constant of 1-octanol is 10.3 [201], making it more similar to gas phase than water. From
a computational perspective, this has removed the aqueous environment, which is hard
to model, and suggests LLE values may be better reproduced using this approach than
potency or affinity.
Fig. 5.7 For proteins in aqueous solutions, hydrophobic pockets inside the protein have
a lower dielectric constant than an outer solvent. LLE can be interpreted as proportional
to free energy of binding for an inhibitor partitioning between 1-octanol and the enzyme,
rather than between water and the enzyme
The geometries were optimised in vacuo at the M06 level of theory with the 6-31+G**
basis set. To include the effect aqueous environment has on a small molecules, free ligand
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Table 5.6 LDHA theoceptor complexation energies
Predicted
affinity
(kcal/mol)
LLE
1 -23.2 1.99
2 -13.6 0.41
3 -13.8 1.96
4 -15.0 0.64
5 -17.7 2.13
6 -10.3 1.48
7 -24.9 3.16
8 -15.6 1.53
9 -18.9 1.99
10 -19.7 1.53
11 -10.4 0.19
11m -6.4 0.19
malonate -39.5 2.63
oxamate -62.6 5.66
structures were optimised with solvation incorporated, using the PCM water model, at the
same level of theory.
The affinity was defined as the energy difference between lowest energy of the complex,
free ligand and the apo structure: ΔE=Ecomplex-Eligand-Eapo. The calculated values are
given in table 5.6. LLE plotted against computed complexation energies for all the
compounds is show in figure 5.8.
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Fig. 5.8 LLE plotted against computed complexation energies for compounds 1-11, oxam-
ate and malonate
5.5 Beyond electron density maps - conformational, struc-
tural and stereochemical preferences
The tetrahydropyran ring of ligand 5 is crystallographically modelled in a boat conforma-
tion, a conformation that has torsional and steric strain and is usually of higher energy
than the chair conformation. When this tetrahydropyran ring was modelled as a chair,
the free conformation was 9 kcal/mol lower than the boat. The RSCC of the ligand was
0.94, which implies that the ligand fits the density well- however looking at the density
contoured at 1σ (Figure 5.3), it is clear that both chair and boat would fit equally well. It is
interesting to note that the conformation has not been changed after a short minimisation
using the OPLS_2005 force field. Optimising the theoceptor with ligand 5 in a chair
conformation resulted in more than -10 kcal/mol energy lowering compared to the starting
crystal-derived structure (Figure 5.9).
A RSCC for ligand 3 of 0.833 suggests that the ligand does not fit the density map
accurately, which was confirmed after visual inspection of the emap- the density around
the indane moiety is missing (Figure 5.3). The first step to model this compound was to
determine the preferred position of the oxygen atom in the dihydropyrone ring, because this
can easily be misplaced when interpreting electron density maps. Changing the position
of oxygen atom inverts the configuration of the stereocentre. The energy difference
of the theoceptor optimised with the ligand stereocentre in (S) configuration (as it was
crystallographically interpreted) and the one where the ligand stereocentre was in (R)
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Fig. 5.9 Geometry optimisation of theoceptors with compound 5. The tetrahydropyran ring
was crystallographically modelled in boat conformation. Modelling it as chair resulted in
more than -10 kcal/mol energy gain. Hydrogen atoms are omitted for clarity.
configuration was less than 0.2 kcal/mol, indicating that the dihydropyrone oxygen is not
interacting with the theoceptor (Figure 5.10).
Fig. 5.10 Exploring stereochemical preferences of ligand 3.
The missing electron density around the indane moiety suggests that the phenyl sub-
stituent can adopt pseudo-axial or pseudo-equatorial orientation, relative to the dihydropy-
rone ring. Pseudo-axial conformation with the ligand (R) stereocentre configuration had
-8 kcal/mol lower energy than the starting crystallographically observed structure. This
energy gain is originating from additional edge to face stacking between the ligand and
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tyrosine, as well as the intramolecular interactions between the two terminal rings. (Figure
5.10).
Similar to 3, we next looked at the position of nitrogen in the pyridine carboxylic acid
moiety of ligand 11 (Figure 5.11). The energy difference between the ligand with nitrogen
oriented as in the crystal structure and the mirror structure in which the pyridine is rotated
through ~180°(11m) was 4 kcal/mol. This 4 kcal/mol gain preference for 11 is due to
an interaction of the pyridine nitrogen with a positively charged environment formed by
the sidechains of His192 and Asn137. In 11m this nitrogen is pointing away from the
theoceptor.
Fig. 5.11 Theoceptor 11m and 11. There is a 4 kcal/mol energy preference for ligand 11,
caused by pyridin nitrogen interacting with the positively charged portion of the theoceptor.
The phenyl substituent in ligand 1 was observed crystallographically in an axial position
relative to the 3-hydroxycyclohexenone ring. Somewhat surprisingly, axial and equatorial
ligand conformations were computed to be energetically indistinguishable in the unbound
state. Substituents larger than hydrogen generally suffer greater steric crowding when
they are oriented axial rather than equatorial. Consequently, substituted cyclohexanes
will preferentially adopt conformations in which large substituents assume equatorial
orientation. In 3-hydroxycyclohexenone ring there are no axial hydrogens located on the
same side of the ring, and, consequently, no steric crowding. However, there is a clear
preference in the bound state: the theoceptor with the ligand in an equatorial conformation
is 4 kcal/mol higher in energy. This difference originates from protein-ligand edge to face
stacking present when the ligand is in an axial conformation (Figure 5.12).
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Fig. 5.12 Axial and equatorial orientations of ligand 1. When the ligand is in an axial
orientation, there is an energy contribution originating from protein-ligand edge to face
stacking.
5.6 Finding the ligand global minimum energy conforma-
tion
Although the ligands are often expected to bind to the protein in a low energy conforma-
tional form, this is not always the case [40, 202]. Apart from the protein induced strain,
additional complicating factors are inaccuracies in interpreting electron density maps
that end up with the ligand conformations far from the global energy minimum, such as
was the case with ligand 5. To overcome this limitation, additional ligand conformations
were generated using a stochastic search, as implemented in MOE (Molecular Operating
Environment) [203] and these conformations were then optimised in solution.
One of the strong indicators of how far away the ligand is from the global minimum
is the complexation energy: due to the relationship ΔE=Ecomplex-Eligand-Eapo, deviation
from the line of the best fit can be caused if the geometry of the complex or the ligand
are deviating from their lowest energy structure. Which one of these two parameters is
not optimal is indicated by the direction of the offset. The initial complexation energy of
theoceptor with ligand 4 was -20.0 kcal/mol, causing an offset from the line of the best
fit. The direction of the offset indicated that the ligand conformation is in fact trapped in
one of its local minima. This was confirmed by optimising MOE derived structures: QM
optimisation energies of almost all additionally generated structures were lower in energy
and the structure determined to be the likely global minimum (at this level of theory) was
5 kcal/mol lower than the energy of the optimised PDB extracted structure (Figure 5.13).
Initial optimisation of the theoceptor with ligand 7 resulted in a complexation energy of
-16.5 kcal/mol, causing an offset from the line of the best fit that implies that the complex
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Fig. 5.13 Schematic representation of structure 4 conformational search. Each point
represents a local minimum. The lowest energy structure (global minimum) is 5 kcal/mol
lower in energy than the starting one.
geometry is not in its lowest conformational form. Ligand 7 forms some of its interactions
with the protein through its sulfonamide moiety and residues Asp140, Glu191 and Arg105,
that were not included as the part of the theoceptor. The lack of these additional interactions
was first believed to be the origin of the positioning away from the line of the best fit
(Figure 5.14).
Fig. 5.14 Left: ligand 7 forms some of its interactions with the protein through its sulfon-
amide moiety and residues Asp140, Glu191 and Arg105, that were not included as the part
of the theoceptor. Right: there is a 9 kcal/mol energy difference between the theoceptor
optimised with the crystallographically observed ligand conformation and theoceptor with
global minimum.
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However, all generated ligand 7 conformations were lower energy states, with the
lowest energy conformation being -3.9 kcal/mol away from the crystal derived one (Figure
5.15).
Fig. 5.15 All additionally generated ligand 7 conformations were lower in energy than the
crystallographically observed one (top left, shown as black sticks). The angle between the
two ring planes is shown.
In this conformation, the dichlorophenyl group is stacking with the sulfonamide substi-
tuted terminal phenyl group and the amide is pointing towards the aromatic ring, which
was not observed in the crystal structure. This rotation is supported by the observed
electron density map (Figure 5.3). Optimising the complex with this ligand conformation
resulted in a complexation energy -9 kcal/mol lower than the theoceptor optimised with the
crystallographically observed ligand conformation, minimising the offset and suggesting
that the energetic contribution sulfonamide moiety makes with the residues that are missing
in the theoceptor description is not as high.
Crystallographically observed structures of ligands 2 and 6 were already close to
conformational global minimum: conformational search did not result in lower energy
structures. For example, all additionally generated ligand 6 conformations were up to 5
kcal/mol higher in energy than crystal-derived one, and up to 8.4 kcal higher in case of
ligand 2.
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5.7 Malonate derivatives - assessing protonation state and
tautomeric preferences
Initial positioning of the malonate derivatives was carried out by superimposing the
malonate moiety on the 3-hydroxy cyclohexenone ring of ligand 1, so that it was in a
close proximity to the basic side chain of Arg168. The correct protonation state and
conformation had to be determined. The malonate moiety of compound 9 was first
modelled in its dianionic form, with the resulting complex energy of +44 kcal/mol. This
arises due to the loss of solvation energy that is not compensated by sufficient interactions
in the receptor. These findings suggest that the malonate moiety may bind in a mono
deprotonated form.
To assess the effect that the malonate moiety conformation has on the overall theoceptor
energy, we tested three different ligand conformations for malonate derivative 9 in the
theoceptor (Figure 5.16 ).
Fig. 5.16 Positioning of ligand 9. The lowest energy is achieved when malonate forms 4
hydrogen bonds with the surrounding residues.
The lowest energy theoceptor was the one where the malonate moiety made four
hydrogen bonds with the nearby sidechains (-18.9 kcal/mol). The energy difference of 15
kcal/mol between the highest and lowest energy theoceptors emphasises the effect subtle
conformational changes of the interacting groups can have on the overall binding energy,
particularly when strongly interacting groups such as anions are involved. Ligands 8 and
10 were initially positioned based on theoceptor 9, so that malonate forms four hydrogen
bonds with the theoceptor sidechains. Optimised structures are shown in Figure 5.17.
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Fig. 5.17 Theoceptors for compounds 8, 9 and 10. The malonate moiety forms four
hydrogen bonds with the protein sidechains.
5.8 Malonate and oxamate - binding in the presence of
cofactor
A total of 8 different malonate tautomeric monoanions were optimised in solution and
all were found to be energetically indistinguishable (within 0.5 kcal/mol range). The
correct orientation of malonate in the binding cavity could not be confidently determined:
optimisation of 8 different theoceptors, each with a different malonate starting position
resulted in complexes with energies ranging from -8 to +16 kcal/mol (Figure 5.18).
These findings, in conjunction with ambiguity concerning the state of the protein during
the experimental measurements2, suggested that malonate may bind in the presence of
cofactor NADH. Calculations employed the oxidised and reduced form of nicotinamide
with the ribose present but with the phosphate moiety truncated to a methyl group3 (Figure
5.19).
The binding energy to the theoceptor with co-factor in its reduced form was 5.4
kcal/mol, suggesting that it is not the correct form. The binding energy to the theoceptor
with co-factor in its oxidized form is almost -40 kcal/mol (Table 5.8), which is consistent
with the high ligand efficiency observed for this simple compound (Table 5.7).
The optimisation of the malonate theoceptor with the oxidised form of the theoceptor
was then repeated, this time with cofactor reduced to just nicotinamide with a methyl group
attached and the theoceptor binding energy was found to be approximately -47 kcal/mol.
These calculations achieved energies that were not changing substantially but which
did not formally satisfy the optimisation criteria in Gaussian09. In such situations the
2R. Ward, personal communication
3To compute the energy of binding required an updated receptor energy, which involved the normal
theoceptor with the co-factor also present. All the Cα and Cβ , and water oxygen atoms were fixed in space,
together with the N-C bond between nicotinamide and ribose again reflecting the scaffolding effect of the
remainder of the co-factor molecule in the bound state.
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Fig. 5.18 Malonate theoceptors. Findings suggest cofactor is necessary for binding.
potential energy surface was expected to be quite “flat” and the geometry and energy were
simply oscillating in a trivial fashion .
The next step was to assess binding of oxamate, a molecule that is isoelectronic and
isosteric to pyruvate and as such is an excellent substrate mimic. As was the case with
malonate, binding is facilitated by the presence of a positively charged portion of co-factor:
the energy difference between the theoceptor with and without co-factor bound was more
than 50 kcal/mol (Figure 5.20).
These findings are very interesting from the drug designer’s point of view: small
negatively charged molecules that mimic the substrate and bind in the presence of cofactor
(rather than competing with it) have the tendency to be more ligand lipophilic efficient.
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Fig. 5.19 Malonate theoceptors were first optimised in the presence of the oxidized
and reduced forms of nicotinamide with the phosphate truncated to a methyl group.
Optimisation was then performed with cofactor reduced only to nicotinamide with a
methyl group attached.
Table 5.7 Chemical structure of malonate and oxamate. LLE was calculated as pKd- clogP
malonate oxamate
pKd 2.3 4.58
clogP -0.33 -1.07
LLE 2.63 5.66
Table 5.8 Complexation energies for malonate and oxamate in the presence of oxidised
and reduced portion of cofactor.
Nicotinamide-ribose Nicotinamide
Reduced
(kcal/mol)
Oxidised
(kcal/mol)
Reduced
(kcal/mol)
malonate 5.4 -39.5 -46.9
oxamate -62.6
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Fig. 5.20 Theoceptor for oxamate without cofactor and with truncated cofactor present.
Complexation energies were -5.0 kcal/mol and -62.6 kcal/mol respectively.
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5.8.1 Suggested compounds
With these findings in mind, the next step was to design compounds that would bind in
the presence of cofactor and be more ligand lipophilic efficient. To test the hypothesis
that small, negatively charged compounds are more efficient, the first compound was a
fragment that is neutral at physiological pH. This fragment was positioned by modifying
the malonate bound structure (Figure 5.21). Complexation energy of the theoceptor with
compound 1 was -7.3 kcal/mol, which resulted in relatively low predicted LLE of 0.68.
LLE was calculated from the equation of the line of the best fit in figure 5.8, and pKd was
then calculated from the LLE=pKd-clogP relationship. When the theoceptor was optimised
with the negatively charged fragment 2, the predicted LLE was 5.04, which is in line with
what would be expected given the oxamate/malonate binding. In compound 2_Me, the
methyl substituent is moved to position 5 of the isoxazolone ring, in order to explore if
this exit vector could be used for fragment growing. Predicted LLE was 5.68, slightly
better than predicted LLE for fragment 2, where the methyl substituent is at position 4.
Compound 3 is an oxadiazole ring with methyl substituent at position 3. This exit vector is
slightly less supported, with predicted LLE of 5.39.
Fig. 5.21 Structure, binding mode and predicted LLE of suggested compounds 1-3. Com-
pound 1 is shown with malonate superimosed.
Finally, the fragment was grown through addition of benzene to compound 2 (Figure
5.22).
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Fig. 5.22 Structure, binding mode and predicted LLE of suggested compound 4
The predicted LLE of this compound (compound 4) was 6.56, which would be ex-
pected given the hypothesis that the smaller compounds that are negatively charged at
the physiological pH and bind in the presence of the cofactor would experience higher
LLE. The isoxazolone O acts as a hydrogen bond acceptor to Asn137 sidechain NH2,
while the oxo substituent forms a forked hydrogen bond with the sidechain of Arg168.
The positively charged portion of the cofactor and the negatively charged portion of the
fragment are within 4 Å of each other, contributing to the overall complexation energy.
5.8.2 Conclusions
This chapter details the efforts in computational modelling of different series of LDHA
inhibitors and shows how quantum mechanical calculations can provide useful insight into
interactions between protein and ligands. It demonstrates how this deeper understanding
of nature of interactions between the binding partners can inspire new ideas- new frag-
ment series is suggested based on the insights gathered from systematic analysis of the
interactions between protein and ligands originating from a distinct fragment series.
It also shows how QM calculations can be used for determining conformational,
tautomeric and stereochemical preferences and help elucidate uncertainties caused by poor
crystallographical models.
Unfortunately, there was no opportunity to test these compounds experimentally, and
the hope is that once they are published, our predictions will be verified (or disputed) by
one of the interested parties.
Chapter 6
Binding of a homologous series of
alkylbenzenes with lysozyme
6.1 Introduction
Synthesising the congeneric series of ligands is a standard process in ligand optimisation.
The underlying assumption is that any minor change in the ligand would be accommodated
with equivalently small, smooth amino acid sidechain movement. A fascinating recent
study by Merski et al. showed that a homologous series of ligands bind to lysozyme with
surprising changes in the protein structure and the positioning of the constant part of the
ligands [204]. The F-helix adopts different discrete states in the same crystal: closed,
intermediate and open, with proportions of each of the three conformations varying with
the ligand. This suggests that even small ligand changes such as an addition of methyl
group can cause conformational shifts between an ensemble of low-energy states, making
prediction of the preferred geometry for proteins binding small molecules a significant
challenge. A large number of such easily accessible states is available to most binding
sites, so finding ways of distinguishing them from one another is important.
The problem has recently been studied using the FEP/REST1 approach [205]. It
was shown that even while using enhanced sampling techniques, the predicted relative
binding free energies are sensitive to the initial protein conformational state. This work
also highlights the importance of sufficient sampling of protein conformational changes
and demonstrates how inclusion of three key protein residues in the “hot” region of the
FEP/REST simulation improves the sampling and resolves this sensitivity, given enough
simulation time.
1free energy perturbation/replica exchange with solute tempering, REST is an enhanced sampling
approach
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This chapter aims to investigate whether quantum mechanical calculations are able to
correctly identify which ligands would bind preferentially to which protein conformations
and therefore provide a solution (of the “approaches that sample among precalculated
states” class) to the computational challenge posed by Merski et al.
6.2 Discrete protein conformational states
Structures of lysozyme in complex with benzene, ethylbenzene, n-propylbenzene, sec-
butylbenzene, n-butylbenzene, n-pentylbenzene and n-hexylbenzene were determined at
high resolution (1.60-1.80 Å) and refined as a multiconformer model (PDB codes: 4W52 –
4W59) [204]. n-propylbenzene, sec-butylbenzene, n-butylbenzene, n-pentylbenzene and
n-hexylbenzene were observed in two major conformations, based on the orientation of the
flexible F-helix loop, between the residues 107 and 115 (Figure 6.1). In the apo and benzene
bound structure, the closed conformation was the dominant one. This conformation
occupied approximately 90% of the observed electron density, while the remaining 10%
was unassigned. In the toluene bound structure, the binding cavity starts to open to
the bulk solvent. This is the intermediate conformation and it occupies approximately
20% of the observed density. This conformation becomes more dominant as the alkyl
sidechain of the ligand grows through the series. In ethyl-, n-propyl- and sec-butylbenzene
structures the closed and intermediate conformations appear in about equal proportions.
In the n-butylbenzene bound complex, a third, open conformation starts to appear. This
conformation coexists with closed and intermediate, occupying different proportions of the
observed density. The three discrete states are characterised by a hydrogen-bonding pattern
between the backbone residues of the F-helix. This pattern changes as the binding cavity
expands, with the open conformation having the lowest number of these intramolecular
bonds.
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Fig. 6.1 Three protein conformations observed in the binding of congeneric ligands to
lysozyme. The residues that undergo the largest changes are highlighted in the red box.
The preferred binding conformation of the ethylbenzene (PDB code 4W54) is shown for
the closed and intermediate protein conformations (A and B). Open protein conformation
(C) is shown with n-hexylbenzene bound (PDB code 4W59). All three conformations
overlayed (D). Proportions of each of the three conformations varying with the ligand (E).
Full congeneric series (F).
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6.3 Theoceptor approach
6.3.1 Theoceptor construction
Eight crystal structures were split into their constituent chains and superimposed. Residues
that were within 5 Å of the n-hexylbenzene in 4W59 were selected as a part of the
theoceptor: Ile78, Leu84, Val87, Tyr88, Leu91, Ala99, Met102, Val103, Met106, Vall11,
Ala112, Phe114, Leu121, Leu133, Phe153. The shape of the binding cavity was well
captured with these fifteen residues (228 atoms in total). Therefore, the two residues that
were also within the 5 Å of the ligand (Gly107 and Leu118) were excluded from the
selection to decrease the number of degrees of freedom and speed up the calculations.
Protonation states were assigned manually and the net charge of the theoceptor was
0. Backbone atoms and the remainder of the protein were deleted. To account for the
scaffolding effect of the rest of the protein, Cα and Cβ atoms were fixed in space using
the fixed Cartesian redundant coordinate feature in Gaussian09. The geometries were
optimised in vacuo at the M06 level of theory with the 6-31+G* basis set. The free ligand
structures were optimised at the same level of theory but with solvation incorporated, using
the polarisable continuum (PCM) water model.
Vibrational corrections, solvation of the receptor and the complex are essentially the
same across all the structures, and they were treated as a constant. The affinity was then
defined as the energy difference between the lowest energy of the complex, free ligand and
a constant:
∆G = ∆Eelec+(∆Evib+∆Esolv)
= ∆Eelec+∆Evib−Esolvcomplex −Esolvreceptor︸ ︷︷ ︸
constant
−Esolvligand
= ∆Eelec−Esolvligand − const
Constants were determined for open, closed and intermediate conformation. Benzene
closed conformation was then set to zero. Calculated complexation energies are reported
relative to benzene closed conformation.
6.3.2 Complexation energies
For the smallest ligand (benzene), the calculations accurately predict the most stable
conformation to be the closed one (Figure 6.2). The energy of this conformation is the
lowest of the three, which is in agreement with the refinement. This value is set to
zero and all the other energies are relative to this one. For toluene, calculations show
ambiguous results- all three conformations seem to be energetically equal, even though the
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Table 6.1 The calculated complexation energies, relative to the benzene closed conforma-
tion. Energies are in units kcal/mol.
closed intermediate open
benzene 0.0 2.3 3.6
toluene -1.2 -1.2 -1.0
ethylbenzene -4.0 -3.7 -3.3
n-propylbenzene -6.7 -5.6 -4.8
sec-butylbenzene -5.6 -7.7 -4.7
n-butylbenzene -3.9 -7.0 -6.7
n-pentylbenzene -11.1 -7.9 -9.9
n-hexylbenzene -12.4 -9.2 -12.9
Fig. 6.2 The calculated complexation energies.
crystallographical refinement suggests that the closed conformation is much more abundant
than the intermediate, while the open should not be present at all. Ethylbenzene is refined
as a mixture of closed and intermediate conformations in equal proportions: this is partially
captured in the theoceptor calculations where the conformations are correctly ranked
(closed -4.0 kcal/mol, intermediate -3.7 kcal/mol), but the open conformation that is not
present according to the original refinement is only 0.4 kcal/mol higher in energy than the
intermediate one. n-propylbenzene calculations correctly predict the closed conformation
to be the dominant one, followed by the intermediate. sec-butylbenzene is also calculated
to be a mixture of the intermediate and closed, but this time the intermediate conformation
is energetically more stable. n-butylbenzene is a mixture of all three conformations with
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intermediate being the dominant. For n-pentylbenzene, QM calculations predict the closed
conformation to be the lowest energy one, which is in disagreement with the structural
refinement that suggests the open conformation should be prevalent. This is somewhat
surprising, given that the QM model accurately pinpoints the open n-hexylbenzene as the
most stable one.
n-pentyl- and n-hexylbenzene were crystallographically modelled in two conformations
(open and closed) with the occupancies rounded to the nearest 10%. In these two structures,
the closed conformation was modelled without the ligand and is considered to be in fact
in an apo state. n-butylbenzene, a structure where all three loops are present was also
modelled without the ligand in the closed state. However, calculations suggest that the
ligand binds in the closed conformation as well and occupies a low energy state. This is
further investigated in the following section.
6.4 Multiconformational refinement
Given that the optimised theoceptor structures give the coordinates of the preferred protein
conformations and ligand positions, the structures of the complexes were refined with
these additional ligand and F-loop conformations. Because the work of Merski et.al used
an earlier version of the software, the available PDB structures were first refined in the
1.10.1 version of PHENIX [206], and ligand parameters were generated using eLBOW
(PHENIX package) [207] to ensure that the refinement statistics can be compared with
the new models. Structures refined with the newer version of the software were in perfect
agreement with the original ones, with the Rwork to Rfree ratios for original and re-refined
structures within ±0.05, as shown in table 6.2. The absolute differences in R-factors
between the refinements in the two versions of the software is most likely caused by the
changes in the bulk solvent corrections between the two versions [208].
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Table 6.2 Refinement parameters. Rwork and Rfree from the work of Merski et al, ’re-
refinement’ are the same structures refined with the newer version of the software, ’theo-
ceptor’ denotes the refinement based on the theoceptor calculations.
Merski et.al re-refinement theoceptor
PDB Rwork Rfree Rwork Rfree Rwork Rfree
apo 4W51 0.175 0.191 0.160 0.168 0.160 0.168
benzene 4W52 0.165 0.182 0.155 0.179 0.155 0.179
toluene 4W53 0.174 0.205 0.148 0.166 0.149 0.164
ethylbenzene 4W54 0.165 0.198 0.138 0.173 0.138 0.173
n-propylbenzene 4W55 0.166 0.187 0.140 0.160 0.140 0.160
sec-butylbenzene 4W56 0.171 0.188 0.141 0.158 0.141 0.158
n-butylbenzene 4W57 0.170 0.185 0.143 0.164 0.144 0.164
n-pentylbenzene 4W58 0.161 0.184 0.146 0.168 0.141 0.162
n-hexylbenzene 4W59 0.176 0.187 0.145 0.148 0.144 0.148
6.4.1 Apo and benzene bound structure
Both theoceptor calculations and structural refinement suggest that the closed conformation
is the dominant one in apo and benzene bound structures. Looking at the electron density
maps of the structures refined with the F loop as a single, closed conformation, no patches
of positive or negative electron density are observed (Figure 6.3, left hand-side). When
the structures are refined with all three loop conformations, patches of positive (green)
and negative (red) electron density around the protein can be observed, indicating atom
misplacement. This is accompanied with higher Rfree values (Rfree increased to 0.173).
The patches grow as the occupancy of the alternative loops is increased. Therefore, as it
was in the Merski et al. refinement, the closed conformation occupies roughly 90% of the
observed electron density, while 10% remains unmodelled.
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Fig. 6.3 Electron density maps for structural refinement of apo and benzene bound struc-
tures. On the left are the re-refined structures where the F loop is in a closed conformation
and on the right are the structures with all three loop conformations. Negative electron
density (red mesh, mFo-DFc,±σ ) suggest that it is highly unlikely that any conformation
other than closed is present in a proportions that can be confidently determined.
6.4.2 Toluene, ethyl- and n-propylbenzene bound structures
In the work of Merski et al., toluene was modelled with the closed conformation occupying
roughly 80% of the observed density, while the remaining 20% was assigned to the inter-
mediate conformation. QM calculations suggest closed and intermediate conformations
are energetically equal, and open to be only slightly less favourable (+ 0.2 kcal/mol). When
refined with all three loops, no additional patches of negative or positive electron density
appear (Figure 6.4). The presence of a third loop is also supported by the refinement
statistics: Rfree slightly decreases from 0.166 to 0.164. The proportions of conformations
are assigned as follows: 70% open, 20% intermediate and remaining 10% open.
Ethyl- and n-propylbenzene bound structures were observed as a mixture of closed
and intermediate conformations. In the work of Merski et al., a 10% occupancy cutoff for
modelling alternative conformations was applied. Looking at the electron density maps of
6.4 Multiconformational refinement 84
the structures with the two F loop conformations (Figure 6.4, left hand-side), small patches
of positive (green) electron density can be observed. These structures were refined with the
F loop in all possible conformations applying 5% occupancy cutoff criterion. The addition
of the third, open loop did not affect the Rfree value in the case of the n-propylbenzene
bound structures. In the ethylbenzene bound structure, there was a small increase (from
0.173 to 0.178). Looking at the electron densities of these newly refined structures (Figure
6.4 right hand-side), it can be observed that there are no patches of negative (red mesh)
electron density around the protein sidechain that would suggest that the atoms have been
modelled in the wrong place. However, the occupancy of this additional loop seems to be
below 10%. In the case of the n-propylbenzene bound structure, the closed conformation
remains at 60%. The intermediate conformation occupies 30% when the third loop is
present and the 10% difference is assigned to the open conformation.
The closed conformation as the dominant one is also confirmed by the theoceptor
energies. Theoceptors in closed conformation were lowest in energy, followed by the
intermediate conformation. This difference is not as prominent in the ethylbenzene bound
structure, but becomes more obvious as the ligand increases in size: intermediate and
open conformation can hardly be energetically distinguished from one another in the
ethylbenzene complex, while in the n-propylbenzene complex, there is a 1 kcal/mol
difference between the states.
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Fig. 6.4 Electron density maps for structural refinement of toluene, ethyl- and n-
propylbenzene bound structures. On the left are the re-refined structures where the F
loop is in the closed and intermediate conformation and on the right are the structures
with all three loop conformations. Positive electron density (green mesh, mFo-DFc, ±1σ )
indicates areas where the current model fails to place sufficient electrons. Negative electron
density (red mesh, mFo-DFc, ±1σ ) indicates areas where the current model places too
many electrons.
6.4 Multiconformational refinement 86
6.4.3 sec-butylbenzene bound structures
sec-butylbenzene was crystallographically modelled by Merski et al as the R-isomer with
the F loop in intermediate and closed conformations in a 60 to 40 ratio. Looking at the
electron density map in Figure 6.5, two small patches of negative electron density can be
observed around the ligand aromatic ring and alkyl sidechain.
Fig. 6.5 Left: sec-butylbenzene was modelled as R-isomer with the F loop in intermediate
and closed conformations in a 60 to 40 ratio. Right: sec-butylbenzene refined with all three
loops and both R and S ligands.
When the theoceptor was optimised with the ligand structures extracted from the PDB
files, the closed conformation was calculated to be the most stable one (-5.6 kcal/mol,
intermediate -4.6 kcal/mol and open -4.7 kcal/mol). All three complexes were again
optimised, this time with R-isomers. In closed and open conformations, there is a preference
for the R-isomer (R closed -5.6 kcal/mol, S closed -3.9 kcal/mol; R open -4.7 kcal/mol, S
open -1.3 kcal/mol ). This preference is even more prominent in intermediate structures:
theoceptor with the S-isomer was 5 kcal/mol higher in energy than the one optimised with
the R-isomer (+1.1 kcal/mol compared to -4.6 kcal/mol).
Looking at the electron density around the ligand, it can be observed that is it not
as sharp and well defined as it is for other members of the series, especially around the
aromatic ring, a portion of the ligand present in each member. This suggests that the ligand
can occupy different conformations in the binding cavity. This was further investigated
using QM (Figure 6.6).
Additional calculations were first performed for the intermediate structures, as based
on refinement, this one would be expected to represent the most stable state. A structure
optimised with the ligand as observed in the open state was 2 kcal/mol higher in energy
than the starting intermediate (-2.6 kcal/mol compared to -4.6 kcal/mol) while several
other attempts where the starting ligand conformation was created by comparison to the
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density performed even worse-these structures were 9.7 kcal/mol and 9.3 kcal/mol and 2
kcal/mol higher in energy than the one extracted from the PDB.
Fig. 6.6 The intermediate complex of sec-butylbenzene was optimised with different ligand
conformations. Top left: the theoceptor with ligand R-isomer ligand structure as deposited
in the PDB (purple), the S-isomer (violet) was 5 kcal/mol higher in energy compared to R
. Second row: additional ligand structures that resulted in higher complexation energies.
Structure shown in grey is 2 kcal/mol higher, and structure shown in green is 9.7 kcal/mol
higher in energy than the one with R-isomer ligand structure as deposited in the PDB
(shown in purple).
The lowest energy structure was determined to be -3.1 kcal/mol lower than the PDB
one (-7.7 kcal/mol compared to -4.6 kcal/mol). Somewhat surprisingly, no stereochemical
preference could be observed- the S-isomer was only 0.3 kcal/mol higher in energy (-7.4
kcal/mol) (Figure 6.7).
When the structure was refined with all three loops and both R and S ligands from the
lowest energy structures (Figure 6.5 right hand side), patches of both negative and positive
electron density around the ligand indicating atom misplacement can be observed. This
is accompanied by the increase in Rfree value, from 0.158 to 0.165. The occupancies are
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Fig. 6.7 R and S sec-butylbenzene isomers. These complexes are -3.1 (R-isomer, shown in
blue) and -2.8 kcal/mol (S-isomer, shown in red) lower in energy than the theoceptor with
the PDB ligand structure.
assigned as follows: 20% to both S and R intermediate and closed, and 20% to R and 0%
S open.
The S ligand in the open conformation was then excluded from the refinement and the
resulting occupancies were set to 25% for S and R intermediate, 20% S closed, 10% R
closed and 20% R open. Rfree increased to 0.164. Again, the model was a poor fit to the
observed electron density.
When refined with just the two loops (closed and intermediate) with the ligands in
R and S conformation, Rfree slightly increases to 0.161. More importantly, there are no
additional patches of negative electron density present (Figure 6.8). The occupancies
were assigned as follows: S intermediate 30%, R intermediate 25%, R closed 45% and
S closed 0%. What is interesting here is that the stereochemical preference is present
in closed conformation, but not in intermediate, which was suggested by the theoceptor
calculations. Different ligand conformations that are supported by the density and the fact
that stereochemical preference seems to exist in one of the protein conformations but not
in the other makes this refinement the most interesting and challenging one.
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Fig. 6.8 sec-butylbenzene refined with closed and intermediate loop and R and S ligand
isomers.
6.4.4 n-butyl- n-pentyl- and n-hexylbenzene bound structures
All three loop conformations are present in n-butylbenzene. In the work of Merski et al.,
the ligand was modelled in intermediate and closed protein conformation, but not in the
open.
Fig. 6.9 Electron density maps for structural refinement of n-butylbenzene bound structure.
Left is the structure where F loop is in all three conformations, with the ligand modelled in
intermediate and open conformation, as it was in the work of Merski et al. On the right is
the structures with all three loop conformations, as well as all three ligand conformations.
Added closed ligand conformation is shown in orange.
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When the refinement was repeated, this time with all three ligand structures, no change
in the refinement statistics was observed. Visual inspection of the electron density maps
showed that this third ligand conformation can be tolerated, as no patches of negative
electron density appeared (Figure 6.9).
In the work of Merski et al, the n-pentyl bound structure was modelled as a mixture
of open (70%) and closed (30%) conformation. Ligand was modelled in open, but not in
the closed conformation. When looking at the density of this refinement (Figure 6.10), it
can be seen that when the F loop is in closed conformation, it protrudes in what is ligand
density in open conformation. No alternative ligand conformation is suggested.
Fig. 6.10 The n-pentylbenzene bound structure was refined as 70% open (left) and 30%
closed conformation, as it was in the work of Merski et al. The closed conformation is
considered to be unoccupied by the ligand (right).
When refined as three loops and using theoceptor derived ligand geometries, there is a
slight decrease in Rfree from 0.168 to 0.166 when occupancies are set to 60%, 30% and
10% for open, closed and intermediate conformations. Looking at the electron density for
this refinement (Figure 6.11), small patches of negative electron density around the ligand
alkyl chain and benzene ring can be observed.
When the intermediate conformation was excluded from the refinement, Rfree decreased
to 0.162, however, some negative electron density around the benzene ring can still be
observed (Figure 6.12), as the ring is not fitting the density well.
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Fig. 6.11 When n-pentylbenzene was refined as three loops and using theoceptor derived
ligand geometries, occupancies were set to 60%, 30% and 10% for open, closed and
intermediate conformations. There is a patch of negative electron density around the
ligand.
Fig. 6.12 Deletion of the intermediate loop ligand conformation resulted in an improvement
in the refinement statistics. The proportion of open and closed conformations changed to
65% for open and 35% for closed. Patches of negative electron density are present around
the benzene ring.
Similarly, the n-hexyl bound structure was modelled as a mixture of open (70%) and
closed (30%) conformations. The ligand was modelled in open, but not in the closed
conformation. When looking at the density of this refinement (Figure 6.13), it can be seen
that when the F loop is in closed conformation, it protrudes in the ligand density. Again,
no alternative ligand conformation is suggested.
Addition of the intermediate loop and theoceptor derived closed and intermediate
ligand conformations resulted in no change in the refinement statistics, Rfree remained the
same, and the proportion of open and closed conformations was 60% open, 35% closed
and the small remaining portion was assigned to the intermediate conformation. Like in
the n-pentylbenzene refinement, patches of negative electron density are present around
the ligand (Figure 6.14).
6.4 Multiconformational refinement 92
Fig. 6.13 The n-hexylbenzene bound structure was refined as 70% open (left) and 30%
closed conformation, as it was in the work of Merski et al. The closed conformation is
considered to be unoccupied by ligand (right).
Fig. 6.14 Deletion of the intermediate loop ligand conformation resulted in no change in
the refinement statistics. The proportion of open and closed conformations changed to
65% for open and 35% for closed. Patches of negative electron density are not present.
When the intermediate conformation is removed from the refinement, the patches
disappear (Figure 6.15), not affecting the refinement statistics. This implies that the
n-hexylbenzene complex is indeed in open and closed conformation, but also that the
ligand can be present in the closed conformation. The proportion of open and closed
conformations was 65% and 35%.
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Fig. 6.15 Addition of the intermediate loop and theoceptor derived closed and intermediate
ligand conformations resulted in no change in the refinement statistics. The proportion of
open and closed conformations changed to 60% for open, 35% for closed and the small
remaining portion was assigned to the intermediate conformation.
6.4.4.1 Is the closed conformation an apo state?
Whether or not the ligand is actually present in the closed conformation, or these are in
fact apo states is not clear from the refinement. QM calculations imply ligand not only
can be present in the closed conformation, but can also occupy a low energy state. Some
small patches of electron density indicating atom misplacement do appear when alternative
ligand conformations are added to the n-pentylbenzene refinement, which suggest that the
ligand conformation might not be optimal. It is interesting to note that in the FEP/REST
study [205], simulations with the ligands in the closed structures were successfully run. All
this indicates that at this point, it can not be excluded that the ligand is present in the closed
conformation. In the case of n-butyl and n-hexylbenzene structures, the conformation of
the ligand that binds to the closed theoceptor suggested by the QM calculations seem to fit
the density well. However, in the case of the n-pentylbenzene, this conformation is not
optimal. It is tempting to speculate whether the correct conformation can be found by
optimising the complex with different ligand starting structures.
6.4.5 Partial occupancies of theoceptor derived structures
To examine how these energies are distributed over the three possible conformations2,
energies were converted to Boltzmann populations:
ni
N
=
e(−Ei/kT )
∑
n= j
e(−E j/kT )
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where ni is number of molecules in the ith energy state, N is the total number of
molecules, Ei is the energy of the ith energy state (open, closed and intermediate in this
case), k is the Boltzmann constant and T is temperature (298 K).
The previous section showed that the theoceptor approach performs well when it comes
to selecting the most stable of the three possible conformations. Comparing occupancies
(Table 6.3) to what would be expected given the refinement (Figure 6.16) makes it possible
to assess how successful the approach is in assigning relative distributions.
Table 6.3 Theoceptor occupancies
theoceptor refinement
open intermediate closed open intermediate closed
benzene <5 <5 95 <5 <5 90
toluene 20 40 40 10 20 70
n-ethylbenzene 15 35 50 <5 50 50
n-propylbenzene <5 15 85 10 30 60
sec-butylbenzene <5 95 <5 <5 60 40
n-butylbenzene 40 60 <5 30 60 10
n-pentylbenzene 10 <5 90 65 <5 35
n-hexylbenzene 70 <5 30 65 <5 35
For benzene, the approach works very well: the benzene bound structure was refined
to occupy 90% of the density, while the remaining 10% was left unmodelled, similar to
theoceptor calculations that predict 95% of the benzene ensemble to be in the closed state.
For toluene, theoceptors predict a mixture of all three conformations, with intermediate
and closed in equal proportions ( 40%) and the remaining 20% is assigned to open.
This is in a slight disagreement with the refinement where 70% is assigned to closed,
20% to intermediate and the remainder to the open conformation. In the case of the
ethylbenzene, 50% is assigned to closed, the same as it is in the refinement. 35% is assigned
to intermediate (50% in the refinement) and the remaining 15% to open (less than 5% in
the refinement). n-propylbenzene slightly underpredicts the intermediate conformation
(15% compared to 30% in structural refinement) in favour of closed conformation (85%
compared to 60% in the refinement).
In the case of the sec-butylbenzene, calculations seem to underpredict the population
of the closed conformation. The intermediate conformation is the dominant one (95% in
2At a given temperature, the energy of a collection of molecules is distributed among the various modes
of motion (that is, translational, rotational, vibrational, electronic, ...). All distributions are equally likely;
however, the particles in the distributions are indistinguishable. Therefore, some distributions are more
probable than others. This principle is known as the equipartition of energy. As the numbers get larger, that
is 1023, the most probable distribution for a given amount of macroscopic energy among microscopic energy
states is given by the Boltzmann distribution.
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theoceptor derived populations and 60% in refinement). These discrepancies are probably
linked to the stereochemical preference that seems to exist when the protein is in a closed
conformation, but not when the ligand binds to the intermediate conformation, which
makes selecting the lowest energy ligand geometry in the binding site a challenging task.
In the n-butylbenzene, 60% is assigned to intermediate (60% in the refinement), 40%
to open (30% in the refinement), while 10% of closed conformation observed in the
refinement is not present in the significant proportions among calculated populations.
In the case of n-pentylbenzene, the open conformation seems to be underpredicted
by the calculations. This is somewhat surprising, given that the calculation results for
n-hexylbenzene are in very good agreement with the refinement (70% is assigned to open
and 30% to closed, compared to 65% and 35% in the refinement). Likely explanation
is that the suggested geometry of the ligand in the open conformation is not the optimal
one. Different ligand conformations in theoceptor were tested in this work, however, lower
energy complexes could not be found.
Fig. 6.16 Crystallographic occupancies plotted against theoceptor derived occupancies.
Theoceptor derived occupancies plotted as histograms. Crystallographic occupancies
plotted as histograms.
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6.4.6 Conclusions
The goal of the work presented in this chapter was to investigate whether quantum mechan-
ical calculations are able to correctly identify which ligands would bind preferentially to
which protein conformations. The results suggest that the method is capable of detecting
the preferred protein conformation in all cases but one (n-pentylbenzene). Furthermore, it
was possible to predict the relative populations with reasonable accuracies as well: two
cases where this was ambiguous were sec-butylbenzene and n-pentylbenzene. In case of
sec-butylbenzene this could be linked to stereochemcial preferences and it is encouraging
to see that the theoceptor approach can help elucidate stereoselectivity in this case as well.
Theoceptor calculations also suggested possible larger ligand conformations that bind to the
closed state, something that could not be inferred from crystal structures alone. In two of
the cases where the ligand conformation was guessed from the calculations (n-butylbenzene
and n-hexylbenzene), the ligand seems to fit the the density with good accuracy, whereas
in the case of n-pentylbenzene, the suggested ligand conformation presents a poor fit to
the density map. Given the success with modelling n-butylbenzene and n-hexylbenzene
structures, it is not excluded that such conformations exist for n-pentylbenzene as well.
Chapter 7
3-Phosphoglycerate dehydrogenase
(PHGDH)
7.1 Introduction
3-Phosphoglycerate dehydrogenase (PHGDH) is an enzyme that catalyses the transfor-
mation of 3-phosphoglycerate into 3-phosphohydroxypyruvate. This is the first and rate-
limiting step in the phosphorylation pathway of serine bionsynthesis, using NAD+/NADH
as a cofactor (Figure 7.1)[209].
Serine supports a number of anabolic processes, including protein, lipid, and nucleic
acid synthesis. Overexpression of the gene encoding the PHGDH has been identified in
human cancers, particularly in breast cancers and melanomas [210–212]. The identification
of a small molecule inhibitor of PHGDH would not only enable thorough preclinical
evaluation of PHGDH as a target in cancers, but would also provide a tool with which to
study serine metabolism [213].
Up until recently, no small molecule inhibitors of 3-phosphoglycerate dehydrogenase
had been reported [213].
Fig. 7.1 Reaction catalysed by 3-phosphoglycerate dehydrogenase
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Work detailed in this chapter describes the efforts in characterising thermodynamic
and kinetic signatures of some of the compounds identified in the joint project between
AstraZeneca and the Cancer Research Trust. Around 30 inhibitors for this protein target
have been tested experimentally using SPR and ITC, however, it was possible to collect
only data for a limited number of structures (Table 7.1). These examples are discussed
here.
7.2 PHGDH inhibitor selection and potency
Structures of the twelve inhibitors for which the data were collected are shown in Table
7.1, together with the inhibitor potency that was retrieved from the AstraZeneca database.
Around thirty inhibitors were initially selected for thermodynamic and kinetic charac-
terisation, however, it was only possible to collect data for the twelve structures shown
here (possible reasons will be discussed in a subsequent sections). The twelve inhibitors
were divided into three groups, based on common features. It can be noted that all twelve
structures are weak inhibitors, with pIC50 close to or below the assay threshold, even
though the starting set contained inhibitors spanning a wide pIC50 range.
Table 7.1 Structures and inhibitory potency of selected PHGDH inhibitors. Potency data
presented as pIC50 ( pIC50=-log10( IC50))
1 6 9
pIC50 = < 3 pIC50 = 3.59 pIC50 = < 3
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4 7
pIC50 = 3.6 pIC50 = 3.3
2 5 8
pIC50 = < 3 pIC50 = < 3 pIC50 = < 3
10 11 12
pIC50 = < 3 pIC50 = <3 pIC50 = < 3
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3
pIC50 = < 3
7.2.1 Structural analysis
The structures of the complexes with six inhibitors (1-4, 6, 12) were retrieved from the
AstraZeneca corporate database. The high resolution of these structures (∼ 2Å) enabled
fine details of the interactions to be seen.
Given that there is no difference in the inhibitor potency between these twelve inhibitors,
no information on structure-activity relationship (SAR) could be provided. Comparison
of the inhibitor binding modes as well as the accompanying thermodynamic and kinetic
fingerprints should provide more detailed insights into molecular determinants governing
binding of these three groups of inhibitors.
Across all the structures, the most prominent protein-ligand interaction observed is
a hydrogen bond between Asp174 and the central amide hydrogen. This interaction is
present in all three series. Interactions with water were observed in some of the crystal
structures. These water molecules are not conserved and are therefore not considered a
part of the binding site. Edge-to-face π stacking between Tyr173 and the indole ring can
also be observed in all of the available crystal structures. Members of the series with acid
substituent (2, 3, 5, 8, 10-12) form an additional salt bridge with the guanidinium moiety
of Arg235 and hydrogen bonds with two water molecules. Because representative crystal
structure from each of the three groups were available and the binding mode was well
conserved through all groups, the other six complex structures (5, 7-11) were modelled
based on their closest analogue. The same binding mode was observed in all the modelled
structures-all the inhibitors interact with the hydrophobic environment consisting of Pro175,
Ile176, Ile177, Pro207 and Leu215 (Figure 7.2). The binding site is well conserved. The
only noticeable difference is orientation of Arg235: in the presence of the COO- group, the
guanidinium moiety of Arg235 is pointing towards the binding site, forming a salt bridge
with a deprotonated acid group. Arg235 is in the same orientation in 1, which could be
explained by formation of a weak hydrogen bond between its hydroxyl group and Arg235.
In other structures, this residue is pointing away from the binding site and into the solvent.
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Fig. 7.2 x-ray structures of PHGDH in complex with inhibitors 2, 4, 6 and cofactor NAD
(PDB: 2G76). Protein backbone is show as green cartoon, inhibitors, cofactor and binding
site residues as sticks.
7.3 Docking studies
To verify and support the approach used for modelling six complex structures (5, 7-11),
ligands were docked using AutoDockVina. Available crystal structures were processed
with Schrödinger’s protein preparation wizard [197] to ensure a reasonable starting point
for docking: hydrogen atoms were added after deleting any original ones, followed by
adjustment of bond orders for amino acid residues and the ligand. The protonation and
tautomeric states of Asp, Glu, Arg, Lys and His were adjusted to match a pH of 7.4.
Docking studies were performed with AutoDock Vina 1.1.2 [196]. Ligands were extracted
from the crystal structures of the complexes and polar ligand hydrogens were added with
AutoDock Tools (ADT 1.5.4) [198]. Two types of docking experiment were performed:
redocking into the inhibitor bound conformation and docking of ligands 5, 7-11 into the
crystal structure of 2 from which the ligand has been removed.
All the ligands had comparable docking energies (±0.7 kcal/mol) with several incorrect
docking poses, therefore this approach can not be used to rank the ligands based on their
affinity. However, docking was useful in terms of determining the ligand orientation: in all
the docked cases, a hydrogen bond between Asp174 and the ligand’s amide hydrogen could
be observed, as well as aromatic π stacking between Tyr173 and the ligand’s indole ring.
AutoDock Vina did not position the acid group of the inhibitor correctly-no interactions
with Arg235 were found (Figure 7.3).
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Fig. 7.3 Redocking of the crystal structures of 6, 4, and 12. The ligand from the crystal
structure is shown in pink, the docked ligand in black
Docking results were similar for modelled structures: the acid moiety of 5, 8, 10 and
11 was placed away from the Arg235 and key interactions with Tyr173 and Asp174 were
preserved for all the structures.
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7.4 Biophysical properties
To evaluate whether the structural differences translate into different thermodynamic
and kinetic effects, the thermodynamic and kinetic profiles were analysed. Changes in
thermodynamic parameters were determined by isothermal titration calorimetry (ITC)
and binding kinetic data were obtained using surface plasmon resonance (SPR) analysis.
Despite the similarity in the pIC50 values, some distinction in the measured binding affinity
can be observed (Table 7.2).
Observed equilibrium dissociation constant (Kd) values measured by ITC and SPR
follow the same trend (Figure 7.4).
Fig. 7.4 Observed equilibrium dissociation constant (Kd) values measured by ITC and SPR
follow the same trend.
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Table 7.2 Inhibitory potency and binding affinity of PHGDH inhibitors. pIC50 values were
retrieved from the AstraZeneca database, pKd values were measured using SPR and ITC.
pIC50 pKd(SPR) pKd(ITC)
1 <3 4.54 NC
2 <3 6.07 6.57
3 <3 6.61 NC
4 3.6 5.12 NC
5 <3 6.01 6.32
6 3.59 5.27 NC
7 3.3 5.33 NC
8 <3 6.3 6.50
9 <3 NC NC
10 <3 6.5 7.02
11 <3 6.3 6.82
12 <3 6.5 6.66
* NC=not calculated
7.4.1 Thermodynamic analysis
7.4.1.1 Experimental setup
ITC experiments were carried out using an ITC200 instrument (GE Healthcare) using a
protein system that has been passed through a NAP-5 column (GE Healthcare) equilibrated
with a) 50 mM potassium phosphate, 150 mM KCl, 1 mM TCEP and 0.005 %T20, 1%
DMSO b) 20 mM TRIS, 150 mM NaCl, 1 mM TCEP, 0.005% T20, 1% DMSO c) 50 mM
HEPES, 150 mM NaCl, 1 mM TCEP, 0.005% T20, 1% DMSO, all pH 7.5.
Protein concentration was determined by measuring the absorbance at 280 nm using a
theoretical molar extinction coefficient. DMSO concentration in the protein solution was
adjusted to 1% (v/v). Concentrations of ligand stock solutions in DMSO were determined
by weight of a compound. Final ligand concentrations were achieved by diluting 1:100
(v/v) in the experimental buffer resulting in a final DMSO concentration of 1% (v/v). ITC
measurements were performed at 25 °C.
In order to check whether the observed binding enthalpy was perturbed by proton
transfer upon ligand binding, titrations in all three buffers (a, b and c) were performed.
Complete titration of 25 µM protein was carried out in the 200 µL sample cell using 2µL
injections of 0.2 mM compound every 180 s. Raw data were collected and the area under
each peak was integrated. The experimental data were fitted to a theoretical titration curve
(single site binding model) using MicroCal Origin 7 software. Thermodynamic parameters
were calculated from the equation:
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∆G = ∆H−T∆S =−RT lnKa = RT lnKd
where ∆G, ∆H and ∆S are the changes in free energy, enthalpy and entropy of binding
respectively, T is the absolute temperature and R is the gas constant: 1.986 cal mol-1K-1.
7.4.1.2 Results and discussion
Compound 1 was identified as the weakest PHGDH inhibitor, whereas other compounds
exhibited comparable affinities. All the compounds show similar half maximal inhibitory
concentrations (IC50), so no meaningful comparison with the trends in binding affinity
could be achieved. In a typical enzyme inhibition assay, the inhibitor and substrates are
serially diluted to achieve concentrations in the assay that span their respective binding
constants. The addition of cofactor is necessary to initiate the enzymatic reaction. Although
the inhibitor is necessary for enzyme activity, it is not necessary for inhibitor binding. This
suggests that all weak binding inhibitors shown here are competing with cofactor NAD for
binding in the PHGDH in vitro enzymatic assay.
To check if the observed enthalpy is perturbed by any protonation effect, titration
experiments were performed in the buffers of different ionisation enthalpies (Appendix
1). The enthalpies were essentially the same in two of the buffer systems (HEPES and
TRIS), which have significantly different heats of ionisation. There were some differences
in enthalpies measured in phosphate buffer: however, superimposing 5, 8, 10-12 to a
cofactor bound structure (PDB code 2G76) revealed that the phosphate moiety of NAD and
inhibitors occupy the same space, suggesting that inhibitors and phosphate are competing
for binding (Figure 7.5). Therefore, enthalpies measured in phosphate buffer were excluded
from further analysis. Corrected values (geometric means of the values obtained from the
experiments performed in HEPES and TRIS buffer) are summarised in table 7.3.
Table 7.3 Thermodynamic data for inhibitors binding to PHGDHa
∆H (kcal/mol) -T∆S
(kcal/mol)
∆G (kcal/mol) Kd (µM)
2 -9.22 ± 0.25 0.29 ± 0.25 -8.92 ± 0.35 0.26 ± 0.00
5 -8.01 ± 0.15 -0.66 ± 0.16 -8.58 ± 0.22 0.47 ± 0.05
8 -8.23 ± 0.10 -0.63 ± 0.12 -8.87 ± 0.15 0.29 ± 0.03
10 -10.09 ± 0.18 0.39 ± 0.25 -9.61 ± 0.31 0.08 ± 0.02
11 -10.48 ± 0.12 1.05 ± 0.15 -9.43 ± 0.19 0.11 ± 0.01
12 -8.94 ± 0.15 -0.11 ±0.14 -9.04 ± 0.18 0.21 ± 0.02
a ITC titrations were performed at 298.15 K. Data represent geometric mean ± SE from at least two
independent experiments
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Fig. 7.5 Cofactor bound structure superimposed to 1. NAD is shown as ball and sticks and
inhibitor 1 as pink sticks.
∆G values of all inhibitors are within ±1 kcal/mol, which translates to a 1 fold change
pKd, which is insufficient for structure-activity relationship analysis. There is a small
variation in observed thermodynamic signatures. All tested inhibitors exhibited strongly
enthalpically driven binding. Three of the inhibitors tested, 2, 10 and 11, have unfavourable
entropic component (Figure 7.6).
Fig. 7.6 Thermodynamic profile of the binding of 2, 5, 8, 10-12 to human PHGDH based
on ITC measurements
This entropic penalty is compensated by an increased enthalpic contribution: 2, 10 and
11 have the highest binding enthalpies in the series. Enthalpy-entropy compensation [52]
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resulted in these slightly different thermodynamic signatures giving essentially the same
∆G values (Figure 7.7).
Fig. 7.7 Compensation behaviour between enthalpic (∆H ) and entropic (T∆S) components
of free energy of binding.
Although the molecular origin of this small difference in entropic contribution has
remained elusive, it is tempting to speculate about the possible causes. The crystal structure
of 2 and models of 10 and 11 provide insights in this regard. These structures show the
methoxy group projecting into solution (Figure 7.8). The first hydration shell around
proteins is usually ordered, showing coherent hydrogen-bond patterns [214]. The methoxy
group is pointing towards the solvent environment, which might have caused orientational
reordering of the hydration shell water molecules, disrupting the hydrogen bonding network
and resulting in the observed entropic penalty. The entropic penalty could also be incurred
by restriction of rotational and translational degrees of freedom of the methoxy group upon
binding [215].
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Fig. 7.8 Structure of 2 in complex with PHGDH. The methoxy group is pointing towards
the solvent environment, which might have enhanced the water hydrogen bonding network
and resulted in an entropic penalty.
Even though thirty inhibitors were analysed using ITC and following the same protocol,
data could only be collected for six structures. These six structures share a carboxylic
group as a common motif, carrying negative charge at physiological pH.
If the observed enthalpies were caused by the proton exchange, it would be reasonable
to expect to see the difference in the observed enthalpies in different buffers, given the
ionisation enthalpies of HEPES and TRIS buffers. However, there is no significant
difference between these values, so buffer effects are considered to be unimportant. In
the case of compound 1 TRIS buffer titration (Figure 7.9, left) and compound 3 HEPES
buffer titration (Figure 7.10, right), the integrated binding isotherms do not seem to have
sufficient curvature as required to confidently determine thermodynamic parameters.
The critical parameter which determines the shape of the binding isotherm is the
unitless constant c [216]:
c =
Mtot
Kd
or, more generally, for receptors with several identical noninteracting binding sites,
c = nKaMtot
where Mtot is the total macromolecule concentration in the cell at the start of the
experiment, and n is the number of binding sites per receptor M.
c values of 10-500 [216, 217] or even 20-100 [218] are most often recommended.
However, easily modelled curves can also be obtained using a low c-value protocol [219].
Even though c values for this experimental setup were within the recommended range
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Fig. 7.9 Representative ITC titrations for compound 1 in TRIS and phosphate buffer.
(Mtot=25 µM and Kd < 1 µM), experiments at higher c values (Mtot=250 µM) were
performed, but no meaningful data could be extracted. Between every measurement, cell
and syringe were cleaned thoroughly.
Some of the compounds (such as compound 4, Figure 7.11 ) showed no binding in the
ITC experiment. When this was the case, the experiment was repeated to ensure no error in
sample handling occurred, however, binding could still not be observed. Given that (at least
in the case of compound 4) the crystal structure of the protein-ligand complex is available,
the fact that the binding was confirmed in several independent SPR experiments, and that
the IC50 values were available, it could be hypothesised that the binding is not observed due
to low protein concentration in the mixture. However, due to limited amounts of sample,
no additional attempts at measuring thermodynamic properties of these compounds were
made.
In all the experiments, the measured stoichiometry, n, was lower than what would
be expected for a 1:1 binding mode, and varies throughout the experiments from 0.3 to
1. To obtain accurate values for stoichiometry, binding affinity, and normalised heats
or the enthalpy of binding, the concentration of each species must be known. Error
in the concentration of macromolecule in the cell will directly affect the stoichiometry
while error in the concentration of ligand will affect all three fitted parameters of the
binding experiment. Ligand samples were prepared by diluting a stock solution of known
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Fig. 7.10 Representative ITC titrations for compound 3 in TRIS and HEPES buffer.
concentration. Some of the ligands had poor solubility, which might have affected n values
(although, this would be expected to cause higher n values, rather than lower). A more
likely explanation is that low n values are linked to the fraction of active protein in the
sample. The experiments were performed with different batches of protein and there were
some concerns about the state of the protein in older batches. Another possible explanation
is that the proposed 1:1 binding mode is not correct. This is unlikely given that the value
of n varies so much across the titrations (if the binding mode was indeed 0.5:1, the value
would not be expected to deviate more than 20%). No attempts were made at adjusting the
concentrations before fitting the isotherm to the data.
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Fig. 7.11 Representative ITC titrations for compound 4 HEPES buffer shows no ligand
binding.
7.4.2 Kinetic analysis
7.4.2.1 Experimental setup
Surface plasmon resonance (SPR) experiments were performed using a Biacore T2000
(GE Healthcare) equipped with a CM7 sensor chip. Protein was immobilised using
amine-coupling chemistry. All the experiments were carried out using 50 mM potassium
phosphate, pH 7.5, 150 mM NaCl, 0.005% T20, 1 mM TCEP, 1% DMSO. The surfaces of
flow cells 2 and 3 were first activated with a 7 min injection of a 1:1 ratio of 0.2 M EDC
and 0.5 M NHS at a flow rate of 5 µl/min.
Protein at a concentration of 10 and 20 µg/ml in 10 mM HEPES, pH 7.5 was immo-
bilised at a density of 8000 RU on flow cells 2 and 3, and flow cell 1 was left blank to
serve as a reference surface. Any remaining activated groups were blocked with a 7 min
injection of a 0.1 M TRIS, pH 8.0. To collect kinetic binding data, multi cycle kinetic
analysis was carried out at a constant flow rate of 30 µL/min and at a temperature of 25 °C.
Compounds were diluted in the running buffer to yield 9 point concentration responses
with a top concentration of 20 µM and 3 fold dilutions. Control (NADH 20µM prepared as
test compound) and buffer injections were interspersed throughout the run every 25 cycles
respectively.
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Individual concentrations were injected from lowest to highest, with 90 s association
and 300 s dissociation time.
Kd is determined from a Langmuir (1:1) binding isotherm. There is a very rapid
interaction between the inhibitors and the protein, and it was impossible to extract kon
values confidently from the sensorgram; therefore only ko f f rate constants were determined,
by fitting the following equation:
R = R0× e(−kd(t−t0)+o f f set)
kon was calculated from the Kd = ko f f /kon relationship.
7.4.2.2 Results and discussion
Binding kinetic data was obtained using surface plasmon resonance (SPR) and demon-
strated binding affinities comparable to those measured by ITC (Figure 7.4 and Table 7.2).
Because of a rapid association and dissociation, it is necessary to interpret the individual
data with caution. However, it is clear that the strongest binders (Kd < 1 µM) have the
fastest observed kon rates, while the ko f f rates are essentially the same for all the inhibitors
(Table 7.4).
Table 7.4 Kinetic data for inhibitors binding to PHGDHa,b
pKd log(kon) (M-1 s-1) log(koff) (s-1)
1 4.54 2.97 -1.58
2 6.07 4.65 -1.43
3 6.61 5.18 -1.44
4 5.12 3.51 -1.62
5 6.01 4.71 -1.30
6 5.27 NC NC
7 5.33 3.82 -1.52
8 6.3 5.1 -1.21
9 NC NC NC
10 6.5 5.06 -1.44
11 6.3 5.12 -1.27
12 6.5 5.43 -1.09
a SPR experiments were performed at 298.15 K.
b Equilibrium dissociation constants (kon/koff). Data represent geometric mean ± SE
from at least three independent experiments.
Kinetic analysis shows that, despite essentially the same dissociation rates, association
rates vary, and cause slight differences in the overall binding affinity (Figure 7.12).
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Fig. 7.12 Association rate constant kon plotted against dissociation rate constant ko f f
based on SPR measurements. Diagonal lines in the plot represent equilibrium dissociation
constant (Kd) values.
The association event is often expected to be rate-limited by diffusion [220]. If there
was no underlying rate-limiting mechanism other than diffusion that is affecting binding,
smaller compounds would be expected to bind quicker. A simple approach allowing an
estimate of diffusion coefficient from the molecular weight of the solute and the identity
of the solvent has been reported [221]. The calculator that implements this calculation
[222] has been used to obtain the estimates of the diffusion coefficients of the inhibitors
1-12 (Table 7.5). Estimated diffusion coefficients plotted against association rates show
no correlation between the two (R2=0.26, Figure 7.13), or, in other words, that there are
additional mechanisms affecting binding.
It can be noted that inhibitors with an acid moiety (2, 3, 5, 8, 10-12) are the quicker
binders, despite the fact that they are not the smallest inhibitors tested. This is linked
to the shape and nature of the binding site: a very shallow binding cleft and positive
surface potential promotes faster association of negatively charged inhibitors that overrides
the diffusion effects (Figure 7.14) [223]. Looking at the electrostatic surface of the
protein, it is reasonable to assume faster complex recognition is governed by the charge
complementarity and long range electrostatic interactions [224].
Even though SPR experiments were performed for around thirty compounds, it was
possible to collect data for only twelve of them. When data could not be collected, it was
either because no binding could be observed, observed signal was negative, or because
of the poor fit of the curve to the sensorgram. In an attempt to overcome these issues,
different immobilisation densities and sensor chips were tried, varying flow rates, as well
as different compound concentrations, yielding no improvements.
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Table 7.5 Molecular weight and diffusion coefficient* of the inhibitors
log(kon) (M-1 s-1)
molecular
weight
diffusion
coefficient x 10-10
1 2.97 344 8.19
2 4.65 388 7.76
3 5.18 457 7.09
4 3.51 344 8.19
5 4.71 352 8.1
7 3.82 328 8.36
8 5.1 358 8.04
10 5.06 368 7.94
11 5.12 372 7.9
12 5.43 356 8.06
* Diffusion coefficient was estimated given the molecular weight and the viscosity of
methanol [221, 222]
Fig. 7.13 Diffusion coefficients plotted against log(kon) values.
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Fig. 7.14 Electrostatic surface of PHGDH. Inhibitor 2 is shown in sticks. Surface is
coloured by calculated charge from red (–10 kbT/ec) to blue (+10 kbT/ec) using a dielectric
constant of 78. The surfaces were generated using APBS plugin for PyMol [225].
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7.5 Conclusions
Work detailed in this chapter describes the efforts in characterising thermodynamic and
kinetic signatures of some of the compounds identified in the joint project to investigate
PHGDH between AstraZeneca and the Cancer Research Trust. Although 30 inhibitors for
this protein target were tested experimentally using SPR and ITC, the data were collected
only for a limited number of structures. Both ITC and SPR are often considered to be “gold
standard” methods for the determination of affinities as both measure the direct interaction
of a compound with the target protein without any modification. This chapter shows that
great care has to be taken during the establishment of conditions for the experiment, as these
can dramatically affect the observed results and lead to an erroneous SAR interpretation.
Even though binding affinities could be confidently determined over a large number of
experiments, thermodynamic and kinetic fingerprints had to be carefully interpreted by
combining available crystal structures, molecular modelling and chemical intuition.
Chapter 8
Mycobacterium tuberculosis Enoyl-ACP
reductase (InhA)
8.1 Introduction
Tuberculosis is a major global cause of morbidity and mortality, due to the infectious
pathogen Mycobacterium tuberculosis (Mtb). After dramatic outbreaks of multidrug-
resistant tuberculosis in the early 1990s, resistance became recognised as a global problem
[226].
Fatty acids are essential for bacterial growth. They cannot be scavenged from the host
and must be synthesised de novo [227]. Enoyl-ACP reductases participate in fatty acid
biosynthesis by utilising NADH to reduce the trans double bond between positions C2
and C3 of a fatty acyl chain linked to the acyl carrier protein (Figure 8.1). The enoyl-ACP
reductase from Mycobacterium tuberculosis, known as InhA, is a member of an unusual
FAS-II system that prefers longer chain fatty acyl substrates for the purpose of synthesising
mycolic acids, a major component of mycobacterial cell walls [228]. This protein presents
an attractive target for the development of novel drugs against tuberculosis, as it is essential
in Mtb as well as sufficiently different from human enzymes [229].
The structures discussed in this chapter were selected from the AstraZeneca corporate
database, based on their potency and clogP values, calculated by the in-house tool. The
initial set contained 30 inhibitors with clogP values between 0 and 5 and pIC50 values up
to 9.5.
Work detailed in this chapter describes the efforts in characterising thermodynamic
and kinetic signatures of some of these compounds.
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Fig. 8.1 Reaction catalysed by Enoyl-ACP reductase
8.2 InhA inhibitor selection and potency
Even though thirty inhibitors were analysed using ITC following the same protocol,
data could only be collected for a limited number of structures. Data for six fragments
binding to Mtb Enoyl-ACP reductase was collected using ITC, and eight fragments using
SPR. Inhibitory potency measured in a Fluorescence based assay as retrieved from the
AstraZeneca database and binding affinity measured by SPR and ITC of all the inhibitors
is summarised in table 8.1.
Table 8.1 Inhibitory potency and binding affinity of InhA inhibitors. pIC50 values were
retrieved from the AstraZeneca database.
pIC50
pKd
(SPR)
pKd
(ITC)
1 6.44 NC 6.28
2 7.57 NC 5.62
3 7.20 NC 6.29
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4 5.54 NC 5.55
5 5.28 4.78 5.56
6 7.40 5.79 5.91
7 5.94 6.43 NC
8 6.73 6.06 NC
9 8.15 6.68 NC
10 7.07 5.96 NC
11 8.48 5.44 NC
12 8.52 6.94 NC
* NC=not calculated
All compounds belong to the di-methyl pyrimidine fragment series. Crystal structures
for the complexes 1, 3, 4, 6, 8, 11, 12 were available in the AstraZeneca database. The
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binding mode is conserved throughout the series: a H-bond donor-acceptor pair is formed
between an isoxazole ring nitrogen (oxadiazole 5, thiadiazole in 12) and the backbone
amide in Met98, and the amide or amine of the inhibitor and the backbone carbonyl
in Met98 (Figure 8.2). Compound 8 has a thiazole ring with nitrogen pointing away
from Met98 and does not form this interaction. The pyrimidine group engages with
the nicotinamide and ribose groups of the NAD1 cofactor (Figure 8.2). These specific
interactions with the cofactor are in common with known substrate competitive InhA
inhibitors [230]. The active site loop of InhA (residues 198-206), a helix which may be
disordered or ordered in crystal structures of InhA dependent on interactions with ligand,
makes nonpolar contacts with the ligand.
Fig. 8.2 Compound 1 binding mode. All the compounds (apart from 8) form hydrogen
bonds with Met98. Electrostatic surface of Inha. Inhibitor 1 is shown in white sticks, and
cofactor in yellow. Surface is coloured by calculated charge from red (–10 kbT/ec) to blue
(+10 kbT/ec) using a dielectric constant of 78. The surfaces were generated using APBS
plugin for PyMol [225].
8.2.1 Kinetic analysis
Surface plasmon resonance (SPR) experiments were performed using a Biacore T2000
(GE Healthcare) equipped with a CM7 sensor chip. Untagged InhA was immobilised
at a density of 3000 RU on flow cells 2 and 3, and flow cell 1 was left blank to serve
as a reference surface. Protein was immobilised using amine-coupling chemistry, 50
mM HEPES buffer, pH 7.5, 150 mM NaCl, 0.005% T20 (v/v), 1 mM TCEP was used
as immobilization buffer. All the experiments were carried out using 50 mM HEPES
buffer, pH 7.5, 150 mM NaCl, 0.005% T20, 1 mM TCEP, 1% DMSO and 100µM NADH
1resolution is not sufficient to determine whether the cofactor is present in a reduced or oxidized state.
NAD is used to denote cofactor when either the actual redox state is not confirmed or the statement refers
equally to NAD+ or NADH. However, based on the experimental settings [230], it can be assumed that the
cofactor is in the reduced (NADH) form
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as running buffer. The surfaces of flow cells 2 and 3 were first activated with a 10 min
injection of a 1:1 ratio of 0.2 M EDC and 0.5 M NHS. Remaining activated groups were
blocked with an injection of 0.1 M Tris, pH 8.0.
To collect kinetic binding data, multi-cycle kinetic analysis was carried out at a constant
flow rate of 30 µL/min and at a temperature of 25 °C. Compounds were diluted in DMSO
to yield 8 point concentration responses with a maximum concentration of 2 µM and 2 fold
dilutions. Control (compound 7) and buffer injections were interspersed with injections
of compound to allow monitoring of the functionality of the immobilised protein surface.
Individual concentrations were injected from lowest to highest, with 60 s association and
60 s dissociation time. Kd is determined from Langmuir (1:1) binding isotherms.
It was not possible to accurately collect kinetic data for this protein system. Many
compounds did not show binding at all, binding only at high concentrations, signal below
zero or higher than the theoretical binding maximum, or the signal was too weak for
the model to be confidently fitted. Different buffer compositions were tested (such as
20 mM potassium phosphate, 150 mM NaCl, 1 mM DTT and 0.00 5%T20, 1% DMSO,
100µM NADH), compound concentrations (500, 250, 125 , 62.5, 31.25, 15.6, 7.8, 3.9
µM) as well as different flow rates, but no improvement was observed. Some compounds
have previously been observed to give refractive index problems or to aggregate, so when
the signal was considered unreliable these measurements were discarded. Both multi-
cycle and single-cycle kinetics approaches were tested, and, while multi-cycle approach
provided better results, only Kd values were determined. Kinetic rate constants could not
be determined. This could be for several reasons: compounds may interact quickly with
the protein (large kon rate constants) and/or dissociate quickly (large ko f f rate constants),
such that the changes are outside the detection range of the instrument. There were also
ambiguities about the state of the protein: an older batch had to be used which might have
caused poor performance. All the compounds bind in the presence of the NADH, and,
although care was taken to minimise the possibility of the cofactor degrading, it can not be
excluded that the cofactor stability might have affected the performance.
Fragments 9 and 12 were the strongest binders in the SPR experiment (pKd values of
6.68 and 6.94). However, compound 11 had pKd of 5.44, significantly lower than what
would be expected given the high pIC50 value of 8.52.
8.2.2 Thermodynamic analysis
The ITC experimental setup was the same as it was for PHGDH. Briefly, ITC measurements
were performed at 25 °C in a) 50 mM potassium phosphate, 150 mM KCl, 1 mM TCEP
and 0.00 5%T20, 1% DMSO, 100µM NADH b) 20 mM TRIS, 150 mM NaCl, 1 mM
TCEP, 0.005% T20, 1% DMSO, 100µM NADH c) 50 mM HEPES, 150 mM NaCl, 1 mM
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TCEP, 0.005% T20, 1% DMSO 100µM NADH all pH 7.5. The titrations were performed
on 25 µM INHA in the 200 µL sample cell using 2 µL injections of 0.2 mM ligand solution
every 180 s.
Even thought the titration experiments were performed in three buffers of different
ionisation enthalpies, it was possible to collect data only for some of the compounds: for
four of the compounds the data was collected in all three buffers, and for two compounds
this was achieved only in TRIS buffer, buffer of the highest ionisation enthalpy. Proton
transfer could not be confidently determined either: despite the structural similarity between
the compounds, the slope n indicating the number of exchanged protons and the direction
is negative (-0.44 net deprotonation of groups in the protein and/or the ligand) in compound
3, and positive (0.66 net protonation of groups in the protein and/or the ligand) in the case
of compound 1 (Figure 8.3), while compound 4 shows no such effects. Compound 2 shows
the biggest difference in binding enthalpy (-14.66 kcal/mol in phosphate, -6.07 kcal/mol
in TRIS and -0.66 in HEPES), and the direction of possible proton exchange can not be
determined. Therefore, it is not possible to draw any conclusions about the thermodynamic
signatures of these compounds.
Fig. 8.3 ∆Hobs plotted against ∆Hion for compounds 1, 3 and 4.
However, Kd values in different buffers were similar, so where possible, the geometric
mean across all the Kd values was calculated. The measured data with representative
titration curves is shown in Figures 8.4-8.9.
The measured stoichiometry, n varied between 0.5 and 1.5 throughout titrations. Ligand
samples were prepared by diluting a stock solution of known concentration. In titration
of compound 6, stoichiometry was determined to be 1.5. Higher n values can be linked
to lower than expected ligand concentrations. Given that the clogP of this compound is
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2.4, no solubility issues would be expected. A more likely explanation is that the observed
discrepancy in n values is linked to the concentration of active protein in the sample.
The experiments were performed with different batches of protein and there were some
concerns about the state of the protein in older batches. Additional protein binding sites
or alternative binding models are also unlikely given that the value of n varies so much
across the titrations in both directions, and no additional binding modes were observed
in the available crystal structures. No attempts were made at adjusting the concentrations
before fitting the isotherm to the data.
Table 8.2 InhA thermodynamic data for compound 1
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 0.79 ± 0.00 5.61 ± 0.76 -12.65 ± 0.13 -3.48 ± 0.15 0.17 ± 0.02
phosphate 0.60 ± 0.00 0.73 ± 0.17 -15.72 ± 0.75 -7.75 ± 0.76 1.36 ± 0.31
TRIS 1.19 ± 0.00 4.15 ± 0.54 -8.81 ± 0.08 0.17 ± 0.11 0.24± 0.03
Fig. 8.4 Representative ITC titrations for compound 1 in HEPES, phosphate and TRIS
buffer.
In cases where it was not possible to obtain thermodynamic parameters, it was either
because no binding could be detected (surprising as crystal structures of some of these
complexes were available), or the experiments did not yield a sigmoidal binding isotherm
(Figure 8.10).
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Table 8.3 InhA thermodynamic data for compound 2
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 1.27 ± 0.08 0.48 ± 0.26 -0.66 ± 0.25 7.05 ± 0.33 2.07 ± 1.14
phosphate 0.59 ± 0.05 0.28 ± 0.09 -14.64 ± 1.83 -7.23 ± 1.84 3.57 ± 1.22
TRIS 0.98 ± 0.02 0.65 ± 0.12 -6.07 ± 0.18 1.83 ± 0.21 1.51± 0.27
Fig. 8.5 Representative ITC titrations for compound 2 in HEPES, phosphate and TRIS
buffer.
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Table 8.4 InhA thermodynamic data for compound 3
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 0.61 ± 0.00 5.23 ± 1.39 -9.96 ± 0.23 -0.83 ± 0.27 0.19 ± 0.05
phosphate 0.75 ± 0.02 0.80 ± 0.23 -9.61 ± 0.50 -1.60 ± 0.53 1.25 ± 0.37
TRIS 0.51 ± 0.00 10.3 ± 2.17 -13.93 ± 0.21 4.35 ± 0.25 0.09 ± 0.02
Fig. 8.6 Representative ITC titration for compound 3 in HEPES, phosphate and TRIS
buffer.
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Table 8.5 InhA thermodynamic data for compound 4
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 1.21 ± 0.04 0.50 ± 0.15 -2.74 ± 0.13 4.99 ± 0.22 2.0 ± 0.06
phosphate 1.09 ± 0.05 0.81 ± 0.37 -4.75 ± 0.35 3.28 ± 0.44 1.22 ± 0.55
TRIS 1.02 ± 0.08 0.18 ± 0.7 -3.99 ± 0.48 3.17 ± 0.53 5.34 ± 2.08
Fig. 8.7 Representative ITC titration for compound 4 in HEPES, phosphate and TRIS
buffer.
Table 8.6 InhA thermodynamic data for compound 5
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
TRIS 0.86 ± 0.03 0.35 ± 0.28 -3.17 ± 0.18 4.37 ± 0.23 2.78 ± 0.67
Fig. 8.8 Representative ITC titration for compound 5 in TRIS buffer.
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Table 8.7 InhA thermodynamic data for compound 6
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
TRIS 1.49 ± 0.03 0.80 ± 0.24 -2.66 ± 0.09 5.36 ± 0.20 1.23 ± 0.37
Fig. 8.9 Representative ITC titration for compound 6 in TRIS buffer.
Fig. 8.10 Binding isotherms of some of the titrations that were considered unsuccessful.
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8.3 Conclusions
Work detailed in this chapter describes the efforts in characterising thermodynamic and
kinetic signatures of some of the compounds identified in AstraZeneca’s Mtb Enoyl-
ACP reductase project. Although 30 inhibitors for this protein target have been tested
experimentally using SPR and ITC, the data were collected only for a limited number
of structures. Like the previous chapter (Chapter 7, 3-Phosphoglycerate dehydrogenase
(PHGDH)), this chapter highlights some of the difficulties encountered when using the
two techniques.
Again, affinity values could confidently be determined across a number of experimental
repeats, while thermodynamic and kinetic fingerprints could not be determined. Kinetic
rates seem to be outside the range of what can confidently be determined by the instrument
and thermodynamic signatures seem to be buffer dependent. However, without additional
experiments, these signatures can not be interpreted conclusively.
Summary and future work
Proteins have numerous functions: as enzymes they accelerate vital chemical reactions, they
act as regulatory molecules, signaling molecules, selective channels, and many more. To
have any of these functions, proteins bind small molecules, nucleic acids or other partners
by forming networks of noncovalent interactions between the two binding partners.
In hit selection or ligand optimisation, success is usually measured by evaluating
changes in binding affinity. Affinity is usually determined by measuring a binding constant
or IC50 value.
At equilibrium and under standard conditions, affinity can be understood as Gibbs
free free energy, logarithmically related to the dissociation constant. Free energy can be
factorised into enthalpy and entropy contributions and these two thermodynamic properties
potentially provide further insights into the forces that drive formation of the complex.
Considering binding kinetics of protein–ligand complex formation, the binding constant
can be understood as the quotient of the kinetically determined rate constants ko f f and kon.
Different combinations of enthalpic and entropic contributions or ko f f and kon can result
in the same binding affinity. However, compounds with equal affinities are not equivalent
because the interactions they make with the target give rise to different thermodynamic or
kinetic signatures. How to exploit and modify the forces contributing to ligand binding is
still not clear.
Structure-based drug design relies on knowledge of the three dimensional structure of
the biological target to generate high-affinity small molecules that, when bound to the target,
elicit the desired functional response. For any small molecule to be considered a likely
drug candidate, it must satisfy a number of important properties such as bioavailability,
lack of toxicity, lipophilicity, selectivity and stability. However, a small molecule must
above all be active, which means that it must bind tightly and selectively to a specific
location in the protein target.
Predicting the potency of a compound remains an unsolved problem. Many compounds
are synthesised and their potency is tested, most of which turn out to be inactive against
the desired target, failing thus at the very first hurdle.
The reliable prediction of affinity is difficult because it is not simply a summation
of individual contributions. An interaction involving one part of a molecule perturbs
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every other interaction that molecule makes. Furthermore, ligands and targets associate in
aqueous media and significant contributions arise from the solvent. Most computational
efforts in this area have been structurally “inclusive”, employing extensive sampling of
orientations and conformations of the full system. However, accuracy is compromised be-
cause a poor physical description of the protein and the ligand has to be used because these
are computationally cheap and quick and hence amenable for the full system. Although
many significant advances in understanding how to rank molecules for their biochemical
activity have been made, a robust and general process does not yet exist.
An alternative structurally “exclusive” approach that includes only the parts of the pro-
tein that are involved in ligand recognition and neglects the remainder has been introduced
in chapter 5. With the example of LDHA inhibitors it has been demonstrated that QM
calculations can provide useful insights into interactions between the binding partners, and
a deeper understanding of the nature of the interactions can be exploited to generate new
ideas: the outcome of modelling different LDHA inhibitors is a new fragment series with
high predicted affinity and the potential for fragment growth.
In chapter 6, a similar approach was applied to study if QM can be used to select
preferred protein conformations and ligand positions where there is some movement of the
protein backbone. The results demonstrate that the method is not only capable of detecting
the preferred protein conformation (in all cases but one), but also of predicting the relative
populations with reasonable accuracies as well.
It was shown in both chapters 5 and 6 how QM calculations can be used for deter-
mining conformational, tautomeric and stereochemical preferences and to help elucidate
uncertainties caused by poor crystallographical models or, equally impressive, add an
additional level of detail to highly accurate models (as was shown in the theoceptor guided
refinement of lysozyme).
Chapters 7 and 8 detailed the efforts in characterising the thermodynamic and kinetic
signatures of PHGDH and InhA inhibitors. Although more than 30 inhibitors of both
protein systems were tested experimentally using SPR and ITC, it was possible to collect
data only for a limited number of structures. Binding affinities could be confidently
determined over a large number of experiments, but thermodynamic signatures varied
with experimental conditions, while rate constants could be determined only for a limited
number of PHGDH inhibitors. In both of these chapters the importance of evaluating the
experimental setup and conditions at which the data were measured is discussed in greater
detail.
Although the quality of the experimental results does not permit conclusive interpreta-
tion, they do provoke appreciation for how much measured parameters can deviate from
ideal, error-free values. This is especially important for anyone attempting any compu-
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tational modelling, as it highlights the importance of assessing accuracy, reliability and
relevance of the experimental data, which is often overlooked by modellers.
Both kinetic and thermodynamic behaviour of a ligand binding to a protein can be
viewed as a combination of interactions between the binding partners, paired with con-
formational effects caused by restricting degrees of freedom of the ligand upon binding
and reordering the protein. A lot of work in this area is still retrospective in nature;
optimising thermodynamics and kinetics as a part of medicinal chemistry programmes
is still not routine, although such efforts are becoming more frequent. The individual
contributions of intermolecular interactions like the formation of hydrogen bonds or ionic
interactions are not direct experimental observables, which makes correct interpretation of
the ITC data very difficult. Due to these complications, raw thermodynamic data as well
as thermodynamically derived metrics like enthalpic efficiency should be used with great
care. Although appealing, the potential for using thermodynamic or kinetic signatures as
end points appears to be limited. It is more likely that the combination of computational
approaches, crystallography, and experimental data can contribute to the understanding
of the forces that govern protein-ligand binding. Comparison of experimental thermody-
namic data with LLE, combined with the QM calculations shown in this work enables the
identification of compounds that do not behave as expected. Identifying and analysing
those outliers has a great potential of maximising the use of thermodynamic profiling.
The ability to manipulate kinetic signatures is likely to improve with advances in the
technologies used for studying binding events and the increase of available experimental
data. Despite the increase in computer power and the design of specific hardware, accurate
predictions of any of the kinetic determinants is still very difficult. Most of the efforts
in this area are centred around molecular mechanics and the main reasons for limited
success in computing binding kinetics seems to be linked to the known limitations of
the method: inability to accurately and adequately sample protein and ligand conforma-
tions and reproduce association or dissociation pathways, solvent sampling and force
field parametrisation. Still, this area seems to be provoking interest, and it is possible
that we will soon begin to rationally design kinetically optimised drugs. QM approaches
such as theoceptors could be used to post-process molecular dynamics snapshots, or to
evaluate ligand poses from ligand binding/unbinding trajectories. Another application
would be to develop and optimise faster methodologies, such as force-field parametrisation
of bonded and nonbonded (e.g. partial atomic charges, Lennard-Jones parameters) terms
for molecular mechanics, molecular dynamics, crystallographic refinement and docking
calculations. It is likely that the use of QM approaches in all phases of in-silico structure
based and ligand based drug design will experience growth in the coming years. The high
accuracy with which QM describes the interactions between receptor and ligand and the
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ability to generate novel descriptor classes should attract even more attention to the use of
these methods.
Part III
Matched molecular pairs
Chapter 9
Quantifying the effect that chemical
environment exerts upon changes in
matched molecular pair analysis
9.1 Introduction
Since the beginning of rational drug design, compound designers have been facing the
same question: “What to make next?” With the increased availability and applicability of
high throughput techniques from around the mid 1990s, the amount of data available and
the diversity of compounds for which data exists has increased incredibly. Despite this,
an estimated 90% of compounds entering clinical trials fail to reach the market [231]. It
is therefore imperative that drug discoverers find ways to use the vast repository of data
already available to improve their chances of success in the future.
One of the ways to decide what to make next is to analyse all of the molecules that
differ only by a well-defined structural transformation and use the effect of these structural
changes in the past to estimate their likely effect if applied again. This is matched molecular
pair analysis, MMPA. One of the hypotheses that underpin this approach is that the effect
on pharmaceutical properties of a small structural change between molecules is more
easily predicted than the absolute value of those properties for each molecule alone [232–
235]. MMPA has been successfully applied in a range of ways: suggesting what to make
next, predicting the properties of a new compound, identifying cases where a structural
change has a minimal effect on key properties (like bioisosteres), or simply to increase our
understanding of the links between biology and chemistry.
MMPA has recently been applied to the ADMET databases of Roche, AstraZeneca and
Genentech and the output combined to create what could be the world’s largest repository
of medicinal chemistry knowledge, akin to a textbook. A by-product of this merging is that
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a large set of MMPA data are available that can answer fundamental questions about the
technique: i) how many pairs are needed in order to be confident that a particular change
in structure actually causes an increase (or decrease) in property? ii) for small sets of
molecules, how large must the change in property be in order to be reasonably confident
that a particular change in structure actually causes an increase (or decrease) in property?
iii) is there an upper limit to the number of pairs needed? This chapter details the initial
findings from this work that will help others to maximise the value arising from measuring
physical and biological properties of compounds.
9.2 Context definition
The analysis used WizePairZ [236], which identifies matched molecular pairs in an un-
supervised fashion and encodes the chemical environment (the context) adjacent to any
structural changes. The simplest environment is the first atom at the attachment point
of the changing structure (context level 1), and the largest environment encompasses
up to 4 atoms (level 4) from the attachment point (Figure 9.1). Others have shown that
the chemical environment can be used to split groups of pairs into subsets that reveal
interesting details about the link between structures and properties [237]. This work aims
to investigate whether better chemical definition reduces the number of data required to
achieve a given level of accuracy.
Fig. 9.1 The definition of chemical context for a matched molecular pair
Initial investigations have focused on one endpoint: inhibition of the hERG ion channel,
which is linked to a cardiac toxicity risk [238]. hERG is a typical dataset and is used to
illustrate the general case. Application of the WizePairZ algorithm found more than 1.1
million pairs of measured values representing more than 700k unique changes in structure.
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9.3 MMPs as coin flip experiment
A positive mean change for a set of matched pairs has previously been found for a set that,
when expanded, actually has a negative mean change [233]. Hence, a strict approach to
selecting pairs was adopted, in which each pair is viewed as a coin flip experiment where
the property increasing corresponds to “heads” and the property decreasing corresponds to
“tails”. This reduces the challenge to detecting biased coins, a well-understood problem
[239].
When matched pairs are considered as coin flips, knowing the probability of any
outcome due to random chance, the number of actual successes (coin landing heads) can
be evaluated for signs of bias. If the coin consistently lands higher or lower than would be
expected due to chance, then after a large number of coin flips, there will come a point
where the chance probability of an observed outcome is sufficiently small that the observed
results are evidence for bias. In the matched pairs analogy, a bias corresponds to a real
effect caused by the structural change: a mechanism exists linking the structural change to
a property change (Figure 9.2).
Fig. 9.2 Matched pairs viewed as coins
9.3.1 Detecting biased coins
When is it reasonable to suspect that an observed event is caused by some underlying
mechanism? All possible outcomes for flipping a coin up to 60 times were examined
(Figure 9.3). For each possible outcome the 95% confidence interval (CI) was calculated.
If the CI contained 0.5, which would be a true mean for a fair, unbiased coin, the case was
evaluated as ‘true’, or else, if 0.5 was outside the 95% CI, the case was evaluated as ‘false’.
The 95% CI defines a range of values that we can be 95% certain contains the population
mean: if the interval contains 0.5, which is the mean for a fair coin, there is not evidence
to suggest that the coin is biased.
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Fig. 9.3 Evaluation of all possible outcomes for flipping a coin up to 60 times. The inset
highlights the case of 10 coin flips.
Considering the case of 10 coin flips, heads can appear 0 to 10 times. There are 4 cases
when the 0.5 value is outside the 95% CI: 0 or 1 head (equivalent to 10 or 9 tails) or 9 or 10
heads (1 or 0 tails). It is only in these 4 cases that we can be 95% confident 0.5 is outside
the CI, which suggests that the coin is biased, or, in other words, that that structural change
causes an effect (Table 9.1). If there are 10 matched pairs in a set, only if the measured
property changes in the same direction for a least 9 cases it is possible to be 95% confident
that this is caused by the structural change.
The first time that a biased coin can be identified with 95% confidence is for 6 coins
all landing the same way. This means that in order to make confident assumptions about
whether a structural change is indeed changing a property of interest, at least 6 MMPs are
required and in all 6 pairs the value of the measured property has to change in the same
direction.
Although the coin flip analogy reduces the likelihood of misassigning the direction of
change, it analyses only the direction of change in a property and reduces the number of
structural transformations that are identified as having a significant effect. Having access
to a very large database of matched pairs permits the link between the coin flip approach
and the mean changes to be probed. The encoding of the chemical environment permits
analysis of its impact.
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Table 9.1 All possible outcomes for flipping a coin 10 times, together with 95% CI
boundaries.
Number of
heads
Fraction of
heads
Lower 95%
confidence
bound
Upper 95%
confidence
bound
Is the coin biased?
0 0.0 0 0.308 Biased
1 0.1 0.003 0.445 Biased
2 0.2 0.025 0.556 No bias detected
3 0.3 0.067 0.652 No bias detected
4 0.4 0.122 0.738 No bias detected
5 0.5 0.187 0.813 No bias detected
6 0.6 0.262 0.878 No bias detected
7 0.7 0.348 0.933 No bias detected
8 0.8 0.444 0.975 No bias detected
9 0.9 0.555 0.997 Biased
10 1.0 0.692 1 Biased
9.4 Analysis of the hERG dataset
The matched pairs from the hERG dataset were analysed using the coin flip approach.
For sets with more than 5 members, the fraction of cases corresponding to increases in
inhibition and the 95% confidence interval range for this fraction are computed. If this
range does not include 50%, a biased coin has been detected. Those sets causing an
increase or decrease in inhibition are styled INC or DEC respectively. The remaining sets
were assigned to the class No Effect Determined (NED); this includes structural changes
that cause no change in hERG inhibition and those that do change the property but for
which there is not yet enough data. Having assigned each set with more than 5 pairs to one
of three classes (INC, DEC, NED), the measured difference ∆ for each pair of molecules
was examined. The variation in the average of ∆, as pairs are added to each set, tracks
how sets of matched pairs evolve. If the sequence is ∆1, ∆2, ∆3. . .∆N , then the mean of
∆1 and ∆2 is µ2, the mean of ∆1, ∆2 and ∆3 is µ3. The ordering of pairs in this database is
arbitrary (in real datasets it is governed by the order in which compounds are made and
tested). Hence, in each set the order of ∆s was scrambled and µ1 to µN recomputed. The
scrambling is repeated 50 times and the average for each µ computed to give µ2, µ3...µN .
For each set of pairs, this tracks how the mean value evolves as more pairs are added.
These are then averaged over all sets of pairs to give µ2 µ3...µN . The evolution along this
series corresponds to what happens (on average) for sets of pairs in each class (INC, DEC
and NED) as more pairs are added. All analysis was performed in R [240–243].
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9.4.1 Predicting the transformation outcome
Logistical regression analysis links µ with the likelihood of that set ultimately becoming
INC, DEC or NED as more pairs are added. These probabilities are plotted against values
of µ2 to µ20 in Figure 9.4. This shows that high values of µi are most likely to correspond
to INC, low values to DEC and intermediate values to one of the three classes depending
upon the exact value. In the following, we focus upon mean changes that are positive
but symmetrical arguments concerning negative mean values would hold. There are three
distinct zones highlighted:
• the ‘Comfort Zone’, where the probability of INC is more than 95%
• the ‘Twilight Zone’ where both INC and NED are equally probable
• the ‘Danger Zone’ in which there remains a likelihood above 1% that the set of pairs
will ultimately be in the DEC class.
Fig. 9.4 The probability that a set of N pairs with mean value µ will evolve into a set of
pairs classified as INC (blue), DEC (green) or NED (red). The colouring starts dark for
N=2 and becomes progressively lighter as N increases to 20.
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When the number of pairs is low, the comfort zone is only reached for sets of pairs in
which the mean change is very high – it is effectively never reached when there are only
two pairs in the set. As the number of pairs in the set increases, the comfort zone expands
such that sets with lower mean values are increasingly likely to fall into it. However, this
converges such that by the time there are 20 pairs, adding more pairs does not provide
a marked benefit; a mean change above 0.31 for a set of 20 or more pairs indicates a
structural change that is highly likely to increase the property. The twilight zone varies in a
similar fashion: a large mean change is required for sets with few pairs before they become
most likely to belong to the INC class. For sets with two pairs, the mean change in pIC50
has to be above 0.5 before INC is the most likely class for the set to belong to. Again there
is convergence as the set size increases to 20 pairs, such that mean values of ∆ above 0.15
correspond to INC being the most likely class. Finally, the danger zone extends out to 0.40
when there are two pairs in the set and contracts to 0.08 by the time there are 20 pairs.
9.4.2 The effect of chemical environment
Turning to the importance of chemistry, the sets can be subdivided according to the different
levels of description of their chemical environment. When there are low numbers of pairs,
chemical environment has a strong influence on the size of the three zones. For instance,
with 5 pairs, the comfort zone starts at 0.83 for context level 1, 0.76 for level 2, 0.68 for
level 3 and 0.63 for level 4. Meanwhile, the twilight zone is at 0.39, 0.36, 0.32 and 0.31 for
context levels 1-4 respectively and the danger zone at 0.25, 0.21, 0.17 and 0.16 (Figure 9.5).
Increasing the chemical specificity of small sets of pairs increases the likelihood that they
provide correct guidance about the impact of a structural change. A set of 4 pairs with a
4-atom chemical environment specification is as likely to suggest the correct effect as a set
of 7-8 pairs with a 1-atom chemical environment specification. This suggests that chemical
specificity allows reliable knowledge to be extracted from smaller sets of pairs than would
be possible with the 6 pair lower limit required by the strict biased coin detection approach.
The power of this reduction is that there are over 12k groups of pairs with 4 in the set but
only 2.1 k groups of 7 pairs and 1.6 k groups with 8 pairs. Indeed, there are only 12 k
sets with 7 or more pairs in the set. As more pairs are added, however, context becomes
less important, suggesting that there is a critical point after which ‘statistics overrides
chemistry’, and more certain outcomes are achieved although they are for less chemically
specific sets.
Medicinal chemists often have a value in mind above which changes measured in any
given assay might be considered “real”. This is typically about two- to three-fold (0.3 –
0.5 log units). Figure 9.6 shows that substantial numbers of pairs would be required before
average changes of this size could be considered as providing a useful guide to the effect of
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Fig. 9.5 The probability that a set of 5 pairs with mean value µ will evolve into a set of
pairs classified as INC (blue), DEC (green) or NED (red). The colouring starts dark for
context level 1 and becomes lighter as it increases to 4.
a structural change (9 pairs on average for context level 1 and 6 pairs for context level 4).
The requirements for an assay to correctly rank order compounds are different to providing
a clear guidance about the effect of changes in structure in a predictive fashion.
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Fig. 9.6 The evolution of the edge of the twilight zone as more pairs are added. When the
mean is above the value shown, the set is most likely to become INC.
9.5 ChEMBL hERG IC50 case study
In order to bring this analysis to life, the ChEMBL public domain data for hERG IC50
values was analysed. Plots similar to those shown in Figures 9.4 and 9.5 were generated
from a set comprising 7347 compounds forming 733 matched pairs that could be grouped
into sets of size 259, 241, 161 and 72 with context levels 1-4 respectively (Figure 9.7).
Fig. 9.7 The probability that a set of N pairs (left) and set of 5 pairs (right) with mean value
µ will evolve into a set of pairs classified as INC (blue), DEC (green) or NED (red). The
colouring starts dark for N=2 or context level 1 and becomes progressively lighter as N
increases to 20 or context level 4.
An illustrative set with context level 4 is provided in figure 9.8 wherein exchanging the
highlighted fluorine atom with a methyl group increases the hERG binding in all seven
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cases, when the set is defined at context level 3 or 4: molecules bearing a p-fluorophenyl
group.
Fig. 9.8 A set of 7 compounds grouped at context level 4 where exchanging the highlighted
F for Me increases hERG potency.
When the set is structurally less well-defined, larger sets of pairs are obtained (18 at
context level 2 and 51 at level 1) which do not statistically support an underlying bias
suggesting that the general effect of exchanging fluorine and methyl is too small to measure
easily. Furthermore, the sets of pairs with µ5 in the range 0.45 to 0.55 include 3, 5, 3 and 3
sets of the 108 in the INC group; 9, 5, 4 and 1 of the 516 in the NED group with context
levels 1-4 respectively in each case and none of the DEC sets. This distribution is in line
with what would be expected given the plot in Figure 9.5.
9.6 Conclusions
In the coin toss analogy, every coin is identical and the outcome is random. For molecules,
each is unique and the effect of a structural transformation will usually be dependent on
the molecule. The purpose of MMPA is to identify transformations that are highly likely
to engender the same effect if applied again.
By using a combination of statistics and chemistry, a progress has been made towards
answering the dilemma ‘is MMPA more about chemistry or statistics?’- it is both! Having
access to a very large dataset enabled monitoring of how the mean change in property
evolves as more pairs are added. This led to the conclusion that, when predicting the effect
of a structural transformation with only a few examples in the dataset, the uncertainty in
the outcome heavily depends on the structural environment in which the transformation is
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made. As more and more pairs are added, chemical context becomes less influential, and
decisions can be driven by statistics.
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Appendix A
A.1 Representative ITC titrations for PHGDH
A.1 Representative ITC titrations for PHGDH 160
Table A.1 PHGDH raw ITC data for compound 2
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 0.34 ± 0.00 3.45 ± 0.92 -8.26 ± 0.28 0.62 ± 0.32 0.28 ± 0.07
HEPES 0.30 ± 0.00 4.03 ± 1.33 -10.30 ± 0.43 -1.32 ± 0.47 0.24 ± 0.08
phosphate 0.45 ± 0.00 4.99 ± 1.04 -10.36 ± 0.21 -1.25 ± 1.24 0.2 ± 0.41
Fig. A.1 Representative ITC titration for compound 2 in HEPES (upper row) and phosphate
buffer (bottom row).
A.1 Representative ITC titrations for PHGDH 161
Table A.2 PHGDH raw ITC data for compound 5
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 0.41 ± 0.01 1.33 ± 0.36 -9.24 ± 0.47 0.91 ± 0.50 0.75 ± 0.20
HEPES 0.50 ± 0.00 3.33 ± 0.51 -7.98 ± 0.16 0.88 ± 0.18 0.30 ± 0.04
phosphate 0.5 ± 0.00 2.36 ± 0.30 -12.84 ± 0.21 -4.18 ± 0.22 0.42 ± 0.05
TRIS 0.69 ± 0.00 0.08± 0.16 -7.50 ± 0.07 1.08 ± 0.09 0.48 ± 0.03
Fig. A.2 Representative ITC titrations for compound 5 in HEPES (upper row), phosphate
and TRIS buffer (bottom row).
A.1 Representative ITC titrations for PHGDH 162
Table A.3 PHGDH raw ITC data for compound 8
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 0.59 ± 0.00 1.99 ± 0.21 -8.79 ± 0.10 -0.23 ± 0.12 0.50 ± 0.05
HEPES 0.33 ± 0.00 2.85 ± 0.40 -8.22 ± 0.16 0.55 ± 0.18 0.35 ± 0.05
phosphate 0.54 ± 0.00 4.29 ± 0.84 -7.98 ± 0.15 1.03 ± 0.19 0.04 ± 0.05
TRIS 0.38 ± 0.00 4.80± 0.80 -8.58 ± 0.15 0.49 ± 0.18 0.20 ± 0.03
Fig. A.3 Representative ITC titrations for compound 8 in HEPES (upper row), phosphate
and TRIS buffer (bottom row).
A.1 Representative ITC titrations for PHGDH 163
Table A.4 PHGDH raw ITC data for compound 10
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 0.31 ± 0.00 6.88 ± 1.63 -10.60 ± 0.25 -1.30 ± 0.29 0.14 ± 0.03
HEPES 0.33 ± 0.00 9.12 ± 4.49 -10.20 ± 0.40 -0.74 ± 0.49 0.10 ± 0.05
phosphate 0.35 ± 0.00 22.1 ± 6.15 -13.44 ± 0.16 -3.45 ± 0.23 0.04 ± 0.01
TRIS 0.55 ± 0.00 17.6 ± 9.77 -9.64 ± 0.27 0.20 ± 0.42 0.05± 0.03
Fig. A.4 Representative ITC titrations for compound 10 in in HEPES (upper row), phos-
phate and TRIS buffer (bottom row).
A.1 Representative ITC titrations for PHGDH 164
Table A.5 PHGDH raw ITC data for compound 11
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 0.40 ± 0.00 6.39 ± 1.37 -11.5 ± 0.24 -1.90 ± 0.27 0.15 ± 0.03
HEPES 0.50 ± 0.00 3.99 ± 0.39 -11.06 ± 0.14 -2.09 ± 0.15 0.25 ± 0.02
phosphate 0.48 ± 0.00 14.8 ± 3.74 -12.31 ± 0.18 -2.56 ± 0.23 0.06 ± 0.01
TRIS 0.49 ± 0.00 9.13 ± 2.12 -9.91 ± 0.27 -0.45 ± 0.21 0.10 ± 0.02
Fig. A.5 Representative ITC titrations for compound 11 in HEPES (upper row), phosphate
and TRIS buffer (bottom row).
A.1 Representative ITC titrations for PHGDH 165
Table A.6 PHGDH raw ITC data for compound 12
Buffer N Ka (µM-1)
∆H
(kcal/mol)
T∆S
(kcal/mol)
Kd (µM)
HEPES 0.35 ± 0.00 3.06 ± 0.51 -8.58 ± 0.19 0.23 ± 0.21 0.32 ± 0.05
HEPES 0.42 ± 0.00 5.63 ± 0.78 -10.17 ± 0.17 -0.99 ± 0.18 0.17 ± 0.02
phosphate 0.66 ± 0.00 2.82 ± 0.49 -10.02 ± 0.49 -1.25 ± 0.50 0.35 ± 0.04
TRIS 0.61 ± 0.00 5.01 ± 1.07 -8.55 ± 0.16 0.55 ± 0.20 0.19 ± 0.04
Fig. A.6 Representative ITC titration for compound 12 in HEPES (upper row), phosphate
and TRIS buffer (bottom row).
A.1 Representative ITC titrations for PHGDH 166
The observed enthalpies were plotted against the buffer ionisation enthalpies (Figure
A.7). The enthalpies were essentially the same in two of the buffer systems (HEPES and
TRIS), which have significantly different heats of ionisation. There were some differences
in enthalpies measured in phosphate buffer: however, superimposing 5, 8, 10-12 to a
cofactor bound structure (PDB code 2G76) revealed that the phosphate moiety of NAD and
inhibitors occupy the same space, suggesting that inhibitors and phosphate are competing
for binding (Figure 7.5).
Fig. A.7 ∆Hobs plotted against ∆Hion. The data measure in HEPS buffer are geometric
means ± SE.
Values measured in phosphate buffer were excluded from further analysis (Figure A.8).
The observed enthalpies from the titration experiments were then plotted against buffer
ionisation enthalpies of the two buffers.
Fig. A.8 The observed enthalpies were essentially the same in HEPES and TRIS buffer.
The slope of the line does not indicate proton release or uptake.
The slope of the line (which gives the number of protons released by the buffers) does
not indicate proton release or uptake. There is some ambiguity when looking at compound
A.2 Representative SPR sensorgrams for PHGDH 167
5. Data suggest other members of the series do not undergo proton exchange, hence, it is
reasonable to infer that compound 5 behaves the same.
HEPES and TRIS buffer were therefore treated as an equivalents, and geometric mean
from these independent experiments was taken to give values reported in the main text
(Table 7.3).
A.2 Representative SPR sensorgrams for PHGDH
Table A.16 PHGDH raw data for compound 4
measurement
number
Kd (µM) koff(s-1)× 10-4
1 8.43 ± 1.2 0.0225 ± 1.2
2 6.71 ± 0.48 0.0305 ± 1.8
3 NC 0.0206 ± 0.9
4 NC 0.0248 ± 1.6
5 NC 0.0238 ± 0.6
* NC=not calculated
Table A.17 PHGDH raw data for compound 6
measurement
number
Kd (µM) koff(s-1)× 10-4
1 3.74 ± 0.95 NC
2 3.84 ± 2.5 NC
3 5.77 ± 5.8 NC
4 2.99 ± 2.8 NC
5 0.93 ± 0.59 NC
* NC=not calculated
A.2 Representative SPR sensorgrams for PHGDH 168
Fig. A.9 Top: Representative equilibrium analysis. Bottom: representative sensorgram for
compound 1 (dissociation part of the curve) Kd=25.31 ± 11 µM, koff=0.0533 ± 2.1 × 10-4
s-1.
Table A.7 PHGDH raw data for compound 1
measurement
number
Kd (µM) koff(s-1)× 10-4
1 28.87 ± 12 0.0229 ± 1.0
2 23.02 ± 8.6 0.0234 ± 0.9
3 25.31 ± 11 0.0533 ± 2.1
4 25.09 ± 9.7 0.0264 ± 1.3
5 44.2 ± 18 0.0178 ± 0.9
A.2 Representative SPR sensorgrams for PHGDH 169
Fig. A.10 Top: Representative equilibrium analysis. Bottom: representative sensorgram
for compound 2 (dissociation part of the curve) Kd=0.767 ± 0.29 µM, koff=0.0476 ± 1.8
× 10-4 s-1.
Table A.8 PHGDH raw data for 2
measurement
number
Kd (µM) koff(s-1)× 10-4
1 1.44 ± 0.99 0.0289 ± 1.8
2 0.84 ± 0.53 0.0302 ± 1.5
3 0.83 ± 0.32 0.0336 ± 1.0
4 1.05 ± 0.36 0.0344 ± 1.1
5 0.76 ± 0.29 0.0476 ± 1.8
6 0.41 ± 0.18 0.0521 ± 1.5
A.2 Representative SPR sensorgrams for PHGDH 170
Fig. A.11 Top: Representative equilibrium analysis. Bottom: representative sensorgram
for compound 3 (dissociation part of the curve) Kd=0.240 ± 0.009 µM, koff=0.0478 ± 1.3
× 10-4 s-1.
Table A.9 PHGDH raw data for compound 3
measurement
number
Kd (µM) koff(s-1)× 10-4
1 0.15 ± 0.07 0.0367 ± 1.4
2 0.62 ± 0.12 0.0373 ± 1.2
3 0.34 ± 0.09 0.0375 ± 0.7
4 0.30 ± 0.11 0.0478 ± 1.3
5 0.29 ± 0.04 0.0325 ± 0.9
6 0.89 ± 0.68 0.0361 ± 1.2
7 0.30 ± 0.06 0.0290 ± 1.6
8 0.23 ± 0.08 NC
9 0.01 ± 0.01 NC
* NC=not calculated
A.2 Representative SPR sensorgrams for PHGDH 171
Fig. A.12 Top: Representative equilibrium analysis. Bottom: representative sensorgram
for compound 5 (dissociation part of the curve) Kd=0.223 ± 0.03 µM, koff=0.0502 ± 1.4
× 10-4 s-1.
Table A.10 PHGDH raw data for compound 5
measurement
number
Kd (µM) koff(s-1)× 10-4
1 2.73 ± 2.0 0.0320 ± 1.4
2 2.09 ± 1.5 0.0502 ± 1.2
3 0.40 ± 0.13 0.0604 ± 2.6
4 0.22 ± 0.03 0.0626 ± 2.0
5 0.97 ± 0.19 0.0496 ± 0.9
6 0.62 ± 0.19 NC
7 0.95 ± 0.06 NC
* NC=not calculated
A.2 Representative SPR sensorgrams for PHGDH 172
Fig. A.13 Top: Representative equilibrium analysis. Bottom: representative sensorgram
for compound 7 (dissociation part of the curve) Kd=7.660 ± 1.0 µM, koff=0.0426 ± 2.3 ×
10-4 s-1.
Table A.11 PHGDH raw data for compound 7
measurement
number
Kd (µM) koff(s-1)× 10-4
1 4.44 ± 1.8 0.0335 ± 3.1
2 4.67 ± 3.2 0.0201 ± 2.4
3 5.02 ± 7.2 0.0426 ± 2.3
4 4.29 ± 1.4 0.0287 ± 2.6
5 7.66 ± 1.0 0.0301 ± 1.3
6 5.45 ± 4.4 NC
7 4.39 ± 3.4 NC
8 5.82 ± 4.1 NC
9 3.14 ± 2.4 NC
10 4.59 ± 1.0 NC
11 2.78 ± 0.8 NC
* NC=not calculated
A.2 Representative SPR sensorgrams for PHGDH 173
Fig. A.14 Top: Representative equilibrium analysis. Bottom: representative sensorgram
for compound 8 (dissociation part of the curve) Kd=0.7811 ± 0.033 µM, koff=0.0993 ±
2.4 × 10-4 s-1.
Table A.12 PHGDH raw data for compound 8
measurement
number
Kd (µM) koff(s-1)× 10-4
1 0.860 ± 0.28 0.4574 ± 3.6
2 0.953 ± 0.44 0.0480 ± 3.0
3 0.505 ± 0.23 0.0332 ± 1.9
4 0.607 ± 0.23 0.0324 ± 2.2
5 0.781 ± 0.33 0.0629 ± 2.5
6 0.643 ± 0.26 0.0993 ± 2.4
7 0.677 ± 0.14 0.0472 ± 1.7
8 0.124 ± 0.13 0.0420 ± 2.2
9 0.155 ± 0.17 0.0439 ± 3.5
A.2 Representative SPR sensorgrams for PHGDH 174
Fig. A.15 Top: Representative equilibrium analysis. Bottom: representative sensorgram
for compound 10 (dissociation part of the curve) Kd=0.678 ± 0.49 µM, koff=0.0405 ± 8.3
× 10-5 s-1.
Table A.13 PHGDH raw data for compound 10
measurement
number
Kd (µM) koff(s-1)× 10-4
1 0.435 ± 0.19 0.0378 ± 0.4
2 0.285 ± 0.13 0.0448 ± 0.8
3 0.678 ± 0.49 0.0405 ± 0.8
4 0.162 ± 0.09 0.0389 ± 2.2
5 0.352 ± 0.11 0.0243 ± 1.6
6 0.207 ± 0.04 NC
* NC=not calculated
A.2 Representative SPR sensorgrams for PHGDH 175
Fig. A.16 Top: Representative equilibrium analysis. Bottom: representative sensorgram
for compound 11 (dissociation part of the curve) Kd=0.398 ± 0.39 µM, koff=0.0416 ± 1.0
× 10-4 s-1.
Table A.14 PHGDH raw data for compound 11
measurement
number
Kd (µM) koff(s-1)× 10-4
1 0.286 ± 0.2 0.0333 ± 0.7
2 0.620 ± 0.24 0.0360 ± 0.6
3 0.079 ± 0.02 0.0416 ± 1.2
4 0.466 ± 0.37 0.0355 ± 1.2
5 0.855 ± 0.66 0.0299 ± 1.6
6 0.398 ± 0.39 0.0308 ± 2.7
7 0.271 ± 0.01 0.0315 ± 2.0
8 0.950 ± 0.39 NC
9 0.823 ± 0.38 NC
10 0.258 ± 0.03 NC
11 0.424 ± 0.24 NC
* NC=not calculated
A.2 Representative SPR sensorgrams for PHGDH 176
Fig. A.17 Top: Representative equilibrium analysis. Bottom: representative sensorgram
for compound 12 (dissociation part of the curve) Kd=0.628 ± 0.9 µM, koff=0.052 ± 2.5 ×
10-4 s-1.
Table A.15 PHGDH raw data for compound 12
measurement
number
Kd (µM) koff(s-1)× 10-4
1 0.628 ± 0.9 0.0483 ± 1.5
2 0.720 ± 0.77 0.0377 ± 1.4
3 0.197 ± 0.03 0.0393 ± 0.9
4 0.160 ± 0.09 0.0525 ± 2.5
5 0.176 ± NC
* NC=not calculated
Appendix B
B.1 LDHA single point energies
Table B.1 LDHA theoceptor complexation energies with different functionals. Energies
are in units kcal/mol.
M06 M06-L M06-2X B3LYP
1 -23.2 -25.2 -25.8 -1.7
2 -13.6 -16.2 -13.1 2.7
3 -13.8 -15.9 -12.5 5.8
4 -15.0 -2.7 0.8 28.6
5 -17.7 -19.6 -19.4 6.6
6 -10.3 -11.2 -11.6 -1.0
7 -24.9 -24.4 -24.0 -3.9
8 -15.6 -17.9 -18.2 1.0
9 -18.9 -20.7 -18.7 -20.9
10 -19.7 -22.7 -20.9 -0.7
11 -10.4 -13.1 -12.5 2.9
malonate -39.5 57.7 -50.3 468.3
oxamate -62.6 27.4 -31.4 577.5
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B.2 Lysozyme single point energies
Table B.2 The calculated complexation energies (B3LYP/6-31+G*), relative to the benzene
closed conformation. Energies are in units kcal/mol.
closed intermediate open
benzene 0.0 4 4.7
toluene 1.3 2.7 3.3
n-ethylbenzene 3.6 8.7 6.1
n-propylbenzene 7.9 8.3 8.1
sec-butylbenzene 7.4 8.9 11.8
n-butylbenzene 14.1 9.3 9.7
n-pentylbenzene 19.7 13 12.5
n-hexylbenzene 19.2 13 11.4
0.0	  
5.0	  
10.0	  
15.0	  
20.0	  
25.0	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Fig. B.1 Relative complexation energies (B3LYP/6-31+G*).
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Table B.3 The calculated complexation energies (M06-L/6-31+G*), relative to the benzene
closed conformation. Energies are in units kcal/mol.
closed intermediate open
benzene 0.0 0.6 1.8
toluene -5.0 -5.0 -4.6
n-ethylbenzene -5.3 -4.3 -5.1
n-propylbenzene -8.5 -7.5 -6.6
sec-butylbenzene -7.9 -9.9 -7.0
n-butylbenzene -6.5 -8.6 -8.8
n-pentylbenzene -8.9 -10.1 -11.9
n-hexylbenzene -9.4 -11.4 -14.8
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Fig. B.2 Relative complexation energies (M06-L/6-31+G*).
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Table B.4 The calculated complexation energies (M06-2X/6-31+G*), relative to the ben-
zene closed conformation. Energies are in units kcal/mol.
closed intermediate open
benzene 0.0 1.5 3.9
toluene -3.9 -5.6 -2.0
n-ethylbenzene -3.6 -1.9 -2.0
n-propylbenzene -6.2 -3.6 -2.9
sec-butylbenzene -5.5 -5.5 -2.6
n-butylbenzene -2.9 -4.3 -3.8
n-pentylbenzene -4.0 -5.2 -6.1
n-hexylbenzene -4.1 -6.5 -7.9
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Fig. B.3 Relative complexation energies (M06-2X/6-31+G*).
